<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106308</article-id><article-id pub-id-type="doi">10.7554/eLife.106308</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The role of co-infection in the pathogenesis of acute SARS-CoV-2 infection and development of post-acute sequelae: A perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Henrich</surname><given-names>Timothy J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6684-0622</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Montgomery</surname><given-names>Christopher P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Graf</surname><given-names>Joerg</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Ismali</surname><given-names>Nahed</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Mohandas</surname><given-names>Sindhu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8397-6249</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Suthar</surname><given-names>Mehul S</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author"><name><surname>Brim</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Coffin</surname><given-names>John M</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author"><name><surname>Pagaria</surname><given-names>Aayush</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-9972-9608</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Guzmán Rivera</surname><given-names>Jeisac</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8799-6629</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Vudali</surname><given-names>Urmila</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Keim</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Guangming</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>McGrath</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>Belinda</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>García-Sastre</surname><given-names>Adolfo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6551-1827</contrib-id><email>adolfo.garcia-sastre@mssm.edu</email><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gennaro</surname><given-names>Maria Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4801-3567</contrib-id><email>gennarma@njms.rutgers.edu</email><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Division of Experimental Medicine, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/003rfsp33</institution-id><institution>Center for Microbial Pathogenesis, Abigail Wexner Research Institute; Division of Critical Care Medicine, Nationwide Children’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Columbus</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rs6vg23</institution-id><institution>Department of Pediatrics, The Ohio State University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Columbus</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01wspgy28</institution-id><institution>Pacific Biosciences Research Center, University of Hawaiʻi at Mānoa</institution></institution-wrap><addr-line><named-content content-type="city">Honolulu</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02mpq6x41</institution-id><institution>Department of Pathology, University of Illinois at Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03taz7m60</institution-id><institution>Division of Infectious Diseases, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03czfpz43</institution-id><institution>Emory Vaccine Center, Department of Pediatrics, Emory University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Atlanta</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gt1vc06</institution-id><institution>Howard University Pathology Department</institution></institution-wrap><addr-line><named-content content-type="city">Washington DC</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wvpxv85</institution-id><institution>Department of Molecular Biology and Microbiology, Tufts University</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/014ye1258</institution-id><institution>PHRI, Rutgers New Jersey Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0272j5188</institution-id><institution>Pathogen and Microbiome Institute, Northern Arizona University</institution></institution-wrap><addr-line><named-content content-type="city">Flagstaff</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kd65564</institution-id><institution>Department of Microbiology, Immunology and Molecular Genetics, University Texas Health</institution></institution-wrap><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>NIH RECOVER Research Initiative: Patient representative</institution><addr-line><named-content content-type="city">Attleboro</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>NIH RECOVER Research Initiative: Patient representative</institution><addr-line><named-content content-type="city">Odenton</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0317dzj93</institution-id><institution>Department of Microbiology, Global Health and Emerging Pathogens Institute, Department of Medicine, The Tisch Cancer Institute, The Icahn Genomics Institute, and Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/014ye1258</institution-id><institution>Department of Medicine, Rutgers New Jersey Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>11</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e106308</elocation-id><history><date date-type="received" iso-8601-date="2025-02-13"><day>13</day><month>02</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-14"><day>14</day><month>10</month><year>2025</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106308-v1.pdf"/><abstract><p>A major health challenge resulting from the COVID-19 pandemic is the manifestation of post-acute sequelae of SARS-CoV-2 (PASC). PASC (or long COVID) is a collective term used for clinical symptoms, various pathologies, and life-quality-changing functional impairment that persist for months to years after the initial SARS-CoV-2 infection. The mechanisms underlying PASC are not understood, although advances have been made in identifying factors that may contribute to long-term pathology. Recent data have emerged, showing an association between SARS-CoV-2 viral persistence and non-SARS-CoV-2 infections (pre-existing, viral reactivation, or new infections) in facilitating or mediating PASC. However, the heterogeneous nature and timing of co-infections have made it challenging to understand, interpret, and contextualize their contribution to PASC. Here, we summarize the impact of potential viral, bacterial, and fungal infections on SARS-CoV-2 pathogenesis, with a focus on their possible roles in the development of PASC. We also provide a framework to understand the mechanisms of PASC and inform basic, translational, and clinical research initiatives, including RECOVER, a large and ongoing research initiative to understand, treat, and prevent long COVID.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PASC</kwd><kwd>SARS-CoV-2</kwd><kwd>co-infection</kwd><kwd>long COVID</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or infection with other microorganisms, which may be pre-existing, concurrent, or subsequent to acute COVID-19.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to persistent symptoms and sequelae that range from mild impairment of daily activities to severe long-term disability or death (<xref ref-type="bibr" rid="bib184">Seeßle et al., 2022</xref>; <xref ref-type="bibr" rid="bib155">Peluso et al., 2022c</xref>; <xref ref-type="bibr" rid="bib222">Yang et al., 2022</xref>; <xref ref-type="bibr" rid="bib153">Peluso and Deeks, 2022a</xref>; <xref ref-type="bibr" rid="bib131">Mehandru and Merad, 2022</xref>). These symptoms, which relate to one or more organ systems and may be ongoing, relapsing, or new, define a multi-syndromic entity referred to as post-acute sequelae of SARS-CoV-2 infection (PASC). The World Health Organization describes PASC (or ‘long COVID’ or ‘post-COVID-19’) as a condition occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, 3 months from the onset of COVID-19, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition">https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</ext-link>). The US National Academies (<xref ref-type="bibr" rid="bib142">National Academies of Sciences E, and Medicine et al., 2024</xref>) describe long COVID as a set of signs, symptoms, and conditions that continue or develop after initial infection, are present for 4 weeks or more, may be multisystemic, and present with relapsing-remitting patterns. Sequelae associated with other viral infections include the induction by infection of antibodies that enhance disease after subsequent reinfections, as is the case with dengue virus infections (<xref ref-type="bibr" rid="bib103">Katzelnick et al., 2017</xref>). During the first months of the COVID-19 pandemic, the possibility of antibody-dependent enhancement (ADE) of disease associated with SARS-CoV-2 antibodies was a major concern for vaccine development. In fact, ADE has been documented for SARS-CoV-1 infections in laboratory and animal studies (<xref ref-type="bibr" rid="bib102">Karthik et al., 2020</xref>). Nevertheless, there have been no documented cases of ADE in humans infected with SARS-CoV-2. The possibility that ADE might be involved in some of the PASC symptoms is therefore quite remote.</p><p>The worldwide burden of PASC is staggering: estimates of its incidence have ranged between 65 and 400 million by the end of 2023 (<xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>). Although they incorporate risk reductions associated with roll-out of COVID-19 vaccines and reduced virulence of infection with newer SARS-CoV-2 strains (<xref ref-type="bibr" rid="bib3">Al-Aly et al., 2022</xref>; <xref ref-type="bibr" rid="bib8">Antonelli et al., 2022</xref>; <xref ref-type="bibr" rid="bib44">Cortellini et al., 2023</xref>), these estimates may be conservative as they only represent cases arising from symptomatic infection (<xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>). Given the burden, the potential effects of PASC on health, quality of life, and life expectancy are of concern worldwide. Finding causative or exacerbating mechanisms of PASC should be a public health priority.</p><p>PASC is of unknown etiology, presents heterogeneous clinical phenotypes, potentially impacts multiple organs, and is likely multifactorial. Affected organ systems include the neurological system, the gastrointestinal system, heart, lung, pancreas, and the reproductive system (<xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>). Other organs, as well as blood vessels and the immune system, may also be affected (<xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>; <xref ref-type="bibr" rid="bib7">Altmann et al., 2023</xref>). While emerging data point to various major potential drivers of PASC (<xref ref-type="bibr" rid="bib153">Peluso and Deeks, 2022a</xref>; <xref ref-type="bibr" rid="bib131">Mehandru and Merad, 2022</xref>; <xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>; <xref ref-type="bibr" rid="bib33">Castanares-Zapatero et al., 2022</xref>), several causative hypotheses of PASC involve microbes or microbial products. For example, SARS-CoV-2 itself may persist in tissues after extrapulmonary viral dissemination during acute infection, resulting in lasting antigenic stimulus, inflammation, aberrant immune responses, and tissue damage (<xref ref-type="bibr" rid="bib7">Altmann et al., 2023</xref>; <xref ref-type="bibr" rid="bib196">Swank et al., 2023</xref>; <xref ref-type="bibr" rid="bib141">Natarajan et al., 2022</xref>; <xref ref-type="bibr" rid="bib154">Peluso et al., 2022b</xref>; <xref ref-type="bibr" rid="bib38">Cheung et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Acosta-Ampudia et al., 2022</xref>; <xref ref-type="bibr" rid="bib152">Peluso et al., 2021b</xref>; <xref ref-type="bibr" rid="bib164">Phetsouphanh et al., 2022</xref>). In addition to SARS-CoV-2, reactivation of latent viruses such as Epstein-Barr virus (EBV) and herpes simplex or herpes zoster viruses may be associated with PASC. Additionally, gut microbial dysbiosis and subsequent bacterial translocation to liver or other organs can lead to sustained inflammation, immune dysregulation, and tissue damage (<xref ref-type="bibr" rid="bib48">Davis et al., 2023</xref>; <xref ref-type="bibr" rid="bib7">Altmann et al., 2023</xref>; <xref ref-type="bibr" rid="bib158">Peluso et al., 2023</xref>; <xref ref-type="bibr" rid="bib69">Giron et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Gold et al., 2021</xref>; <xref ref-type="bibr" rid="bib109">Klein et al., 2023</xref>; <xref ref-type="bibr" rid="bib195">Su et al., 2022</xref>; <xref ref-type="bibr" rid="bib73">Grobbelaar et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">De Michele et al., 2022</xref>; <xref ref-type="bibr" rid="bib227">Zuo et al., 2020</xref>). Moreover, it is well documented that co-infections exacerbate the severity of acute SARS-CoV-2 infection and worsen its outcome (<xref ref-type="bibr" rid="bib137">Musuuza et al., 2021</xref>; <xref ref-type="bibr" rid="bib150">Patton et al., 2023</xref>; <xref ref-type="bibr" rid="bib61">Feldman and Anderson, 2021</xref>; <xref ref-type="bibr" rid="bib193">Sreenath et al., 2021</xref>). Thus, it is tempting to consider the possibility that acute and chronic infectious diseases occurring prior to, during, or after acute SARS-CoV-2 infection may contribute to PASC development and phenotypic presentation. Understanding microbial contribution to PASC might dramatically improve our capabilities to diagnose and treat PASC, and to prevent it.</p><p>In this review, we outline how various viral, bacterial, and fungal co-infections may induce or facilitate the development of PASC. To do so, we use the current, limited evidence on the association between PASC and certain co-infections (mostly viral), the current knowledge on the impact of viral, bacterial, and fungal infections on the severity of acute SARS-CoV-2, and biological plausibility criteria derived from our collective understanding of the pathogenesis of various infectious diseases. While, as of this writing, all possible associations we discuss are within the realm of biological plausibility, they are, of necessity, speculative, and compelling evidence for a causal association of PASC with any microbial infection remains to be obtained. Here, our goal is to present the current state of understanding of the candidate microorganisms in the context of SARS-CoV-2 infection in the hope of stimulating and informing future research into this still mysterious and often debilitating condition. While changes in the composition of commensal microbiota may also be related to PASC, the potential role of dysbiosis in PASC has already been discussed in many reviews (e.g. <xref ref-type="bibr" rid="bib168">Raj et al., 2024</xref>; <xref ref-type="bibr" rid="bib77">Guo et al., 2023</xref>; <xref ref-type="bibr" rid="bib148">Norouzi Masir and Shirvaliloo, 2022</xref>), requires specific considerations and is not included in the present review.</p></sec><sec id="s2"><title>Pandemic-associated surge of non-SARS-CoV-2 infections</title><p>Although some forms of PASC were first reported in the very early stages of the pandemic (<xref ref-type="bibr" rid="bib31">Callard and Perego, 2021</xref>), the changing epidemiology of infectious diseases throughout the world during and after the COVID-19 pandemic suggests that other pathogens may have contributed to the pathophysiology of PASC. For example, 44 countries have experienced a 10-fold increase in the incidence of at least 13 infectious diseases relative to the pre-pandemic baseline (<ext-link ext-link-type="uri" xlink:href="http://www.airfinity.com/articles/global-surge-in-infectious-diseases-as-over-40-countries-report-outbreaks-10">http://www.airfinity.com/articles/global-surge-in-infectious-diseases-as-over-40-countries-report-outbreaks-10</ext-link>). Several non-mutually exclusive explanations have been proposed for this phenomenon (<xref ref-type="fig" rid="fig1">Figure 1</xref>). First, interruptions of public health measures may explain the emergence of some infections. For example, declining vaccine rates during the pandemic due to disrupted supply chains and limited immunization are likely to be major factors for increases in measles, polio, and whooping cough. Similarly, increases in tuberculosis cases may be related to the collapse of public health infrastructure, resulting in delayed diagnosis and treatment and failure of infection control measures (reviewed in <xref ref-type="bibr" rid="bib125">Marco et al., 2024</xref>). Second, immune mechanisms may have contributed to a dramatic increase in respiratory viral infections, particularly in children (<xref ref-type="bibr" rid="bib179">Rubin, 2024</xref>). One mechanism, popularized as ‘immunity theft’, describes a period of increased vulnerability to other infections following acute SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib179">Rubin, 2024</xref>). This mechanism is not only possible but probable, given that hyperinflammation of various microbial or viral origin is often followed by a period of immune suppression (<xref ref-type="bibr" rid="bib19">Biswas and Lopez-Collazo, 2009</xref>; <xref ref-type="bibr" rid="bib119">Libbey and Fujinami, 2002</xref>) and that PASC in children has been reported to give rise to prolonged periods of innate immune hyporesponsiveness (<xref ref-type="bibr" rid="bib105">Khan et al., 2025</xref>). An alternative mechanism, known as ‘immunity debt’, which postulates a rebound of infections following a period of reduced exposure during lockdowns, widespread masking, and social distancing, has lost scientific support in favor of immune dysfunction hypotheses (<xref ref-type="bibr" rid="bib143">Needle and Russell, 2023</xref>). Third, changes in temperature and rainfall patterns due to climate change may enable the spread of water- and mosquito-borne diseases such as cholera and dengue (<xref ref-type="bibr" rid="bib60">Feinmann, 2024</xref>). A link between climate change and COVID-19 itself has been proposed (<xref ref-type="bibr" rid="bib64">Ford et al., 2022</xref>), the implications of which are beyond the scope of the present article.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Potential mechanisms implicated in post-COVID-19 surge of non-SARS-CoV-2 infections.</title><p>Some of the mechanisms and underlying causes that can explain the increased incidence of various non-SARS-CoV-2-driven infectious diseases following the COVID-19 pandemic are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106308-fig1-v1.tif"/></fig><p>While causal links between the emergence of other viral and bacterial infections and the development of PASC have yet to be established, it is possible that the interactions of SARS-CoV-2 and other pathogens lead to PASC either directly or indirectly. For example (and as discussed below in more detail), SARS-CoV-2-induced immune dysregulation may increase susceptibility to other infections. Conversely, increased incidence of other infections may directly induce organ dysfunction or elicit immune dysregulation, leading to persistence of SARS-CoV-2 in the tissues. Regardless of the responsible mechanisms, further study of the interactions of SARS-CoV-2 and other pathogens, and their role in the development of PASC, is warranted.</p></sec><sec id="s3"><title>General considerations on co-infections and PASC</title><p>Below, we briefly review current evidence on the role of SARS-CoV-2 persistence in tissues as a driver of PASC (<xref ref-type="fig" rid="fig2">Figure 2</xref>, top row). In the following sections, we discuss how, in the presence or absence of persistent SARS-CoV-2, other microorganisms may favor the development of PASC or exacerbate its severity. The discussion of causative relationships between PASC and co- or secondary infections requires considering multiple and intertwined elements. These include: (i) the type of co-infection (e.g. acute vs chronic, de novo infection vs reactivation of latent infection); (ii) mechanisms of pathogenesis, i.e., how infection with other agents may favor PASC development or worsen its severity and duration; (iii) temporal relationships, i.e., when co- or secondary infections have occurred relative to the acute SARS-CoV-2 infection, and (iv) the anatomical location of the infection.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Potential temporal relationships between SARS-CoV-2 and co-infections.</title><p>Various co-infections occurring at various times relative to the acute SARS-CoV-2 infection may predispose to post-acute sequelae of SARS-CoV-2 infection (PASC) or modulate the course of PASC.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106308-fig2-v1.tif"/></fig></sec><sec id="s4"><title>Does SARS-CoV-2 persist?</title><p>SARS-CoV-2 is transmitted through respiratory droplets and targets ciliated epithelial cells in the nasal cavity, trachea, and lungs by utilizing the cellular receptor angiotensin-converting enzyme 2 (ACE2) (<xref ref-type="bibr" rid="bib2">Ahn et al., 2021</xref>; <xref ref-type="bibr" rid="bib95">Jayaweera et al., 2020</xref>; <xref ref-type="bibr" rid="bib115">Lamers and Haagmans, 2022</xref>; <xref ref-type="bibr" rid="bib92">Jackson et al., 2022</xref>; <xref ref-type="bibr" rid="bib65">Fraser et al., 2023</xref>). Infection limited to the upper respiratory tract is generally associated with milder disease outcomes, whereas dissemination to the lungs, in particular infection of the bronchi, bronchioles, and alveoli, can cause pneumonia, severe disease, acute respiratory distress syndrome, and death (<xref ref-type="bibr" rid="bib115">Lamers and Haagmans, 2022</xref>). In addition, infected cells can be found in many other tissues throughout the body, particularly in vascular tissues. Studies in humans have described roles for type I and III interferons (IFNs), inflammatory cytokines (IL-6, TNF-α, IL-1β), innate immune cells (monocytes, pDCs, cDCs, natural killer cells), antibodies (IgG, sIgA, neutralizing antibodies), and adaptive immune cells (B cells, CD8<sup>+</sup> and CD4<sup>+</sup> T cells) in both pathogenesis and clearance of SARS-CoV-2 infection within the respiratory tract (<xref ref-type="bibr" rid="bib191">Sievers et al., 2024</xref>; <xref ref-type="bibr" rid="bib82">Harne et al., 2023</xref>).</p><p>The term <italic>infection</italic> can have a wide-ranging definition when referring to cells or tissues that harbor SARS-CoV-2 virus. This ambiguity often leads to varying interpretations of whether persistent SARS-CoV-2 infection is the cause of PASC symptoms. The definition of infection is rooted in the concept of tropism, which refers to the ability of a virus to infect a particular cell type or tissue. SARS-CoV-2 infection itself requires that a cell type expresses the ACE2 receptor, which can be ubiquitously expressed on cells within the respiratory tract and extrapulmonary tissues (<xref ref-type="bibr" rid="bib79">Hamming et al., 2004</xref>; <xref ref-type="bibr" rid="bib149">Ortiz et al., 2020</xref>). Historically, scientists relied on a rigorous definition of infection, which involved demonstrating the production of a virus in a cell type either by measurement of infectious virus (e.g. plaque assay, focus forming assay, outgrowth assay) or electron microscopy to visualize virions. These techniques are often difficult to perform or require specialized facilities/equipment. Alternatively, infection is defined in the literature by the presence of viral antigen, viral RNA using in situ hybridization or highly sensitive quantitative reverse transcription PCR (qRT-PCR), or viral sequencing. With these now routine, but less rigorous definitions, caution must be taken to avoid over-interpreting the impact that infection can have on PASC symptoms. For instance, viral antigen can persist for several weeks to months without any active virus replication in cells. Similarly, qRT-PCR or viral sequencing data can be from residual RNA in a particular cell type or tissue that has yet to be cleared following infection. In this section, we will look at findings within the respiratory tract in the context of acute and persistent SARS-CoV-2 infection.</p><p>To better understand SARS-CoV-2 persistence, it is important to consider the known cellular targets of SARS-CoV-2 during acute infection. Extensive studies using in vitro and in vivo (e.g. mice, hamsters, and nonhuman primates) infection models and specimens from infected humans have identified key cellular targets of SARS-CoV-2 infection. In the upper respiratory tract, SARS-CoV-2 infects the olfactory epithelium, mainly sustentacular cells, which can result in its rapid and gross desquamation (<xref ref-type="bibr" rid="bib104">Khan et al., 2021</xref>; <xref ref-type="bibr" rid="bib212">Verma et al., 2022</xref>). The resulting anosmia, defined by the loss of the senses of smell and taste, was described early in the pandemic and recognized as a profound neurological manifestation of COVID-19 (<xref ref-type="bibr" rid="bib207">Tsukahara et al., 2023</xref>). A recent study suggests that a transition from the olfactory to the respiratory epithelium from the ancestral variants (e.g. WA1 and Delta) to the Omicron variants may account for the reduced incidence of anosmia in the Omicron era (<xref ref-type="bibr" rid="bib36">Chen et al., 2024</xref>). Within the trachea, SARS-CoV-2 can infect epithelial cells of the mucosa, including goblet, ciliated, and basal cells. In the lungs, SARS-CoV-2 infects epithelial cells of the bronchi/bronchioles, including basal, ciliated, type II pneumocytes (ATII), and club cells (<xref ref-type="bibr" rid="bib89">Hou et al., 2020</xref>). Other studies have identified macrophage subsets, including interstitial macrophages and alveolar macrophages, as potential targets of infection based on the presence of viral antigen or viral RNA (<xref ref-type="bibr" rid="bib91">Huot et al., 2023</xref>; <xref ref-type="bibr" rid="bib220">Wu et al., 2024</xref>). However, this observation may be a result of either phagocytosed infected cell debris or abortive infection, defined by a likely block in virus replication. The impact of SARS-CoV-2 infection of macrophages is not yet clear but may lead to dysregulated airway repair mechanisms (<xref ref-type="bibr" rid="bib218">Wendisch et al., 2021</xref>). Macrophages have also been identified as potential targets of persisting SARS-CoV-2 (<xref ref-type="bibr" rid="bib91">Huot et al., 2023</xref>).</p><p>The persistence of SARS-CoV-2 spike protein several months after a PCR-confirmed test has become a central tenet in the pathology of PASC. In a RECOVER-led multi-cohort study, SARS-CoV-2 spike can be detected in the blood for up to 14 months with around 50% of those experiencing persistent cardiopulmonary, musculoskeletal, and neurological symptoms also showing spike in the blood (<xref ref-type="bibr" rid="bib197">Swank et al., 2024</xref>). It is also important to note that around 20% of asymptomatic individuals also showed circulating spike for up to 7 months post-recovery. It is not clear from this study whether a delay in viral clearance within the lungs or viral persistence in extrapulmonary tissues is the cause of persistent spike antigen in the blood. Autopsy studies have observed SARS-CoV-2 antigen and viral RNA in several extrapulmonary tissues, central nervous system, and the brain (<xref ref-type="bibr" rid="bib194">Stein et al., 2022</xref>; <xref ref-type="bibr" rid="bib49">Deinhardt-Emmer et al., 2021</xref>; <xref ref-type="bibr" rid="bib124">Maffia-Bizzozero et al., 2023</xref>; <xref ref-type="bibr" rid="bib161">Pesti et al., 2023</xref>). A longitudinal cohort study found that persistent inflammation characterized by type II interferon signaling and neutrophil activation was observed in individuals experiencing SARS-CoV-2 symptoms for more than 2 months (<xref ref-type="bibr" rid="bib199">Talla et al., 2023</xref>).</p></sec><sec id="s5"><title>Types of co-infection</title><p>Various types of co-infection (i.e. those coincident with active SARS-CoV-2) may be implicated in the development or exacerbation of PASC. These include:</p><list list-type="bullet" id="list1"><list-item><p>acute infections by respiratory or other pathogens (e.g. influenza virus, respiratory syncytial virus [RSV], measles virus, adenovirus, <italic>Staphylococcus aureus</italic>, streptococci, <italic>Hemophilus</italic> spp., <italic>Moraxella</italic> spp., <italic>Klebsiella pneumoniae, Acinetobacter, Pseudomonas, Aspergillus</italic>).</p></list-item><list-item><p>chronic infections (e.g. human immunodeficiency virus [HIV], cytomegalovirus [CMV], tuberculosis) and reactivation of latent infections (e.g. EBV, varicella zoster virus [VZV], or latent tuberculosis).</p></list-item></list></sec><sec id="s6"><title>Mechanisms of pathogenesis</title><p>Our in-depth understanding of the pathogenesis of many infectious diseases points to the biological plausibility of various direct pathophysiological mechanisms such as PASC drivers. For example, co-infections may predispose to PASC development by inducing altered organ function, immune dysregulation, autoimmunity, and organ damage (<xref ref-type="box" rid="box1">Box 1</xref>). Of note, noxious effects may be reciprocal, with pre-existing and concurrent co-infections worsening SARS-CoV-2 infection outcome and post-acute sequelae, and SARS-CoV-2 infection increasing the risk of superinfections during acute COVID-19 and post-acute secondary infections. While this is a burgeoning area of research, few studies have been able to make causal links between co-infections and PASC pathology. The following section is speculative, but we highlight how temporal and anatomical locations, as well as chronic infections, may influence the development of PASC.</p><boxed-text id="box1"><label>Box 1.</label><caption><title>How co-infections may induce post-acute sequelae of SARS-CoV-2 (PASC).</title></caption><list list-type="bullet" id="list2"><list-item><p>By presenting the incoming SARS-CoV-2 with a microenvironment that is already immunologically or functionally altered.</p></list-item><list-item><p>By reactivating from latent reservoirs during acute or convalescent COVID-19.</p></list-item><list-item><p>By taking advantage of perturbed immune responses during acute or early convalescent COVID-19.</p></list-item><list-item><p>By triggering autoreactive adaptive immune responses via molecular mimicry or by reducing regulatory immune functions.</p></list-item><list-item><p>By inducing immunosuppressive mechanisms (e.g. measles virus).</p></list-item><list-item><p>By reducing mucosal (e.g. lung and/or gut) barrier functions.</p></list-item><list-item><p>By altering the composition of microbiota.</p></list-item><list-item><p>By potentiating noninfectious drivers of PASC through immune activation and systemic inflammation.</p></list-item></list></boxed-text></sec><sec id="s7"><title>Temporal relationships</title><p>Infection with any pathogen – may it be viruses, bacteria, and/or fungi – may precede, occur concurrently with (or soon after), or follow the onset of acute SARS-CoV-2 infection (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Development of PASC may be induced or facilitated by pre-existing and/or latent infections, via dysregulated immune responses and/or dysfunctional organ systems. New infections and reactivation of latent infections that develop during (or soon after) acute SARS-CoV-2 infection may potentiate PASC by worsening histopathology and/or immune dysregulation. Furthermore, new or reactivated secondary infections may occur in the weeks or months following SARS-CoV-2 infection. In this case, it may be envisioned that SARS-CoV-2-induced immune dysregulation increases susceptibility to secondary infections or that, conversely, the effects of SARS-CoV-2 infection are exacerbated by immune dysregulation by ensuing infections, or both.</p></sec><sec id="s8"><title>Anatomical location: respiratory infections</title><p>An additional set of considerations relates to anatomical location. As mentioned above, PASC may target various end organs such as the lungs, heart, and brain (<xref ref-type="bibr" rid="bib7">Altmann et al., 2023</xref>). The lungs are a primary target organ during SARS-CoV-2 infection, and respiratory symptoms are important sequelae of PASC. It stands to reason, therefore, that respiratory infections due to other pathogens, including viruses, bacteria, and fungi, may modify risk factors for the development of PASC (<xref ref-type="fig" rid="fig3">Figure 3</xref>). For example, pre-existing acute or chronic inflammation, tissue damage, or impaired lung function may predate SARS-CoV-2 infection. Similarly, concurrent or post-acute co-infection with other pathogens may result in worsened inflammation, immunosuppression, immune dysregulation, or exacerbated tissue damage. In turn, these co-infections may then predispose to the development of respiratory PASC and associate dyspnea, fatigue, and cough. Below, we discuss some of the respiratory pathogens that may most conceivably contribute to PASC development.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>How co-infections may result in post-acute sequelae of SARS-CoV-2 (PASC) development in an organ system: the example of the lung.</title><p>Pre-existing fungal, bacterial, and viral infections may result in acute and chronic inflammation, parenchymal damage, immune activation, and impaired lung function. For example, latent <italic>Mycobacterium tuberculosis</italic> infection may be reactivated during acute COVID-19, worsen COVID-19 clinical outcome, and/or lead to the development of PASC. Other pathogens such as those causing bacterial or fungal pneumonia during acute SARS-CoV-2 infection or early convalescence may also exacerbate lung tissue damage, cardiopulmonary function, systemic inflammation, and immune dysregulation, and favor development of PASC.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106308-fig3-v1.tif"/></fig><sec id="s8-1"><title>Respiratory viruses</title><p>The onset of the COVID-19 pandemic led to dramatic changes in the landscape of seasonal respiratory viral infections, due to social/physical distancing, lockdowns, dramatic decrease in attendance to restaurants, movie theatres, , shifting to at-home schooling, and the widespread use of masks in some geographic locations (reviewed in <xref ref-type="bibr" rid="bib39">Chow et al., 2023</xref>). The role of seasonal and endemic respiratory viruses (e.g<italic>.</italic> influenza virus, RSV, rhinovirus, etc.) in the development or the clinical course of PASC remains unclear. Overall, rates of infection with enveloped respiratory viruses, such as influenza, RSV, common cold, human coronaviruses, and para-influenza viruses, were lower than usual during stricter pandemic non-pharmacological interventions (NPIs), e.g., masks, social distancing, reduced travel, school closings (<xref ref-type="bibr" rid="bib18">Binns et al., 2022</xref>; <xref ref-type="bibr" rid="bib140">Nasrullah et al., 2023</xref>). Resurgence has been identified following easing of NPIs. Infections with non-enveloped respiratory viruses, such as respiratory adenoviruses and especially rhinovirus, were less affected by NPIs during the pandemic (<xref ref-type="bibr" rid="bib39">Chow et al., 2023</xref>). This may be associated with their greater environmental persistence, which might promote a more prevalent fomite-associated vs direct respiratory droplets and aerosol transmission. Acute or early convalescent SARS-CoV-2 infection may reduce the risk of acquiring a second viral infection through boosted innate immune responses (e.g<italic>.</italic> increased interferon production). Conversely, prior infection with a respiratory virus, as well as prior immunization against other agents (<xref ref-type="bibr" rid="bib144">Netea et al., 2023</xref>), might also reduce the ability of SARS-CoV-2 to infect, likely due to increased innate immunity.</p><sec id="s8-1-1"><title>Influenza and RSV</title><p>Rates of influenza were quite low during the initial 2 years of the COVID-19 pandemic, likely due to NPI across the globe (<xref ref-type="bibr" rid="bib123">Lu et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Doroshenko et al., 2021</xref>). With the easing of COVID-19 restrictions, influenza re-emerged with an early surge in cases in the fall of 2022. Interestingly, hospital emergency visits showed an increase in RSV and influenza infections, peaking in December 2022 (<xref ref-type="bibr" rid="bib22">Boehm et al., 2023</xref>; <xref ref-type="bibr" rid="bib169">Rao et al., 2023</xref>), following an earlier peak of COVID-19 caused by the Omicron variant in August 2022. For example, emergency room visits for RSV dramatically increased during the fall of 2022, predominantly involving children aged 4 years and under (<xref ref-type="bibr" rid="bib22">Boehm et al., 2023</xref>; <xref ref-type="bibr" rid="bib169">Rao et al., 2023</xref>). This combined respiratory viral surge placed an elevated level of stress on pediatric healthcare systems. A major outstanding question is whether infection with influenza or RSV in subjects with pre-existing PASC would lead to PASC exacerbation. It is also unknown whether recent non-COVID-19 respiratory infections impact the course of subsequent SARS-CoV-2 infection or the development of PASC. Vaccination for influenza is a major intervention to reduce influenza burden, and combination influenza/COVID-19 vaccines are now available to simultaneously tackle both infections. However, the usefulness of these vaccines on PASC is yet to be evaluated.</p></sec><sec id="s8-1-2"><title>Non-COVID-19 beta-coronaviruses</title><p>Other endemic coronaviruses such as alpha- and beta-coronaviruses are less pathogenic compared to SARS-CoVs. The human beta-coronaviruses OC43 and HKU-1 are more closely related to SARS-CoV-2 than are human alpha-coronaviruses 229E and NL63 (<xref ref-type="bibr" rid="bib45">Cui et al., 2019</xref>). Human coronavirus OC43 and HKU-1 are responsible mostly for mild respiratory symptoms in the general population, although they can cause severe diseases in vulnerable individuals (<xref ref-type="bibr" rid="bib45">Cui et al., 2019</xref>). There was early evidence of cross-immunity of SARS-CoV-2 with other human beta-coronaviruses that may have played a role in mediating severity of acute infection, thereby hypothetically reducing the risk of PASC. For instance, SARS-CoV-2 infection may boost memory B cells producing antibodies that bind to the most conserved S2 region and that are present in people with pre-existing immunity to seasonal human beta-coronaviruses (<xref ref-type="bibr" rid="bib13">Aydillo et al., 2021</xref>). There is also evidence of cross-reactive T cell responses among human coronaviruses and SARS-CoV-2 (<xref ref-type="bibr" rid="bib129">Mateus et al., 2020</xref>). Interestingly, people with PASC were found more likely to have SARS-CoV-2 antibody responses that cross-react with the less pathogenic OC43 strain (<xref ref-type="bibr" rid="bib85">Herman et al., 2023</xref>; <xref ref-type="bibr" rid="bib192">Spatola et al., 2023</xref>). However, it is not yet clear how cross-reactive antibody or T cell responses between OC43 and HKU-1 could lead to dysregulated immune responses that participate in the development of PASC.</p></sec><sec id="s8-1-3"><title>Adenovirus</title><p>Infection with these viruses has an unclear role in PASC, but adenovirus infections have been recently associated with severe and fatal hepatitis outbreaks in children (<xref ref-type="bibr" rid="bib187">Servellita et al., 2023</xref>). Many of these children had co-infection with SARS-CoV-2 and human herpesvirus (HHVs) (<xref ref-type="bibr" rid="bib86">Ho et al., 2023</xref>), suggesting the possibility that these viruses may potentiate the pathogenicity of co-infecting viruses. However, no experimental evidence has demonstrated a link between adenovirus and the development of PASC. Future efforts to routinely conduct diagnostics for the most common viruses, including respiratory viruses, might improve our understanding of the impact of viral co-infections on health.</p></sec><sec id="s8-1-4"><title>Rhinovirus</title><p>The circulation of these viruses was less affected by the COVID-19 pandemic compared to other respiratory viruses (<xref ref-type="bibr" rid="bib202">Teo et al., 2022</xref>). It cannot be excluded that, as with other respiratory viruses, rhinovirus may enhance or reduce acute or post-acute effects of SARS-CoV-2 infection by driving inflammation or by promoting increased innate antiviral responses, respectively. However, given the co-circulation of rhinovirus and SARS-CoV-2, there is no direct evidence that rhinovirus infection is associated with PASC, and additional studies are warranted .</p></sec><sec id="s8-1-5"><title>Measles virus</title><p>Co-infections with both measles virus and SARS-CoV-2 have been documented, though they appear to be rare (<xref ref-type="bibr" rid="bib139">Nascimento et al., 2020</xref>). It is known that measles virus infections are associated with loss of B cell memory (<xref ref-type="bibr" rid="bib162">Petrova et al., 2019</xref>; <xref ref-type="bibr" rid="bib133">Mina et al., 2019</xref>). As some PASC symptoms appear to be associated with immune dysregulation resulting in reactivation of chronic infections, measles infection in PASC patients might further exacerbate PASC symptoms by decreasing memory B cells specific for chronic viruses. However, there is currently no evidence suggesting that co-infection necessarily leads to more severe disease or sequelae. In any case, measles vaccination is the best way to prevent this possibility.</p></sec></sec><sec id="s8-2"><title>Respiratory bacteria</title><p>Bacterial infections occurring during acute COVID-19 (i.e. detected within the first 48 hr) are relatively rare. Although early reports suggested a high rate of bacterial co-infection at presentation (<xref ref-type="bibr" rid="bib116">Langford et al., 2020</xref>), most studies report rates between 3% and 9% (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib211">Vaughn et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Cong et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Cheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib99">Karaba et al., 2021</xref>; <xref ref-type="bibr" rid="bib135">Moreno-García et al., 2022</xref>). Of these, about half occur in the respiratory tract and are caused by common, community-associated pathogens, including <italic>Staphylococcus aureus</italic>, <italic>Moraxella catarrhalis</italic>, <italic>Hemophilus influenzae</italic>, <italic>Streptococcus</italic> spp., and <italic>Escherichia coli</italic> (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Cheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Calcagno et al., 2021</xref>). It remains difficult to discriminate benign colonization, which may occur in more than half of individuals (<xref ref-type="bibr" rid="bib111">Kolenda et al., 2020</xref>; <xref ref-type="bibr" rid="bib188">Sharifipour et al., 2020</xref>), from symptomatic bacterial respiratory co-infections, which have been reported in less than 5% of the population (<xref ref-type="bibr" rid="bib211">Vaughn et al., 2021</xref>; <xref ref-type="bibr" rid="bib180">Russell et al., 2021</xref>; <xref ref-type="bibr" rid="bib100">Karami et al., 2021</xref>). Bloodstream infections comprise approximately the other half of acute co-infections and are most commonly caused by <italic>S. aureus</italic>, coagulase-negative staphylococci, <italic>E. coli</italic>, <italic>Enterococcus faecalis</italic>, <italic>Acinetobacter</italic> spp., and <italic>Pseudomonas aeruginosa</italic> (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib211">Vaughn et al., 2021</xref>; <xref ref-type="bibr" rid="bib99">Karaba et al., 2021</xref>; <xref ref-type="bibr" rid="bib185">Sepulveda et al., 2020</xref>; <xref ref-type="bibr" rid="bib106">Khatri et al., 2021</xref>). Differences in case definitions, isolation methods, geographic variability, and time periods make interpretation of the myriads of studies difficult, but the consensus in the field is that bacterial co-infections during acute COVID-19 are relatively rare.</p><p>In contrast, secondary bacterial infections during or following treatment of COVID-19 are more common, with estimates ranging between 10% and 40% depending on the clinical setting (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Cong et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Cheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib175">Ripa et al., 2022</xref>; <xref ref-type="bibr" rid="bib174">Ripa et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Grasselli et al., 2021b</xref>; <xref ref-type="bibr" rid="bib84">Hedberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib136">Murgia et al., 2023</xref>; <xref ref-type="bibr" rid="bib27">Budhiraja et al., 2022</xref>). Not surprisingly, rates of secondary pneumonia (frequently ventilator-associated) and bacteremia (frequently catheter-associated) are more common in critically ill patients (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Cong et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Cheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib175">Ripa et al., 2022</xref>; <xref ref-type="bibr" rid="bib174">Ripa et al., 2021</xref>; <xref ref-type="bibr" rid="bib84">Hedberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib136">Murgia et al., 2023</xref>; <xref ref-type="bibr" rid="bib27">Budhiraja et al., 2022</xref>; <xref ref-type="bibr" rid="bib71">Grasselli et al., 2021a</xref>). The bacterial species most commonly isolated in these patients include <italic>S. aureus</italic>, <italic>K. pneumoniae</italic>, <italic>Enterobacter</italic> spp., <italic>P. aeruginosa</italic>, <italic>Serratia</italic> spp., <italic>Acinetobacter baumannii,</italic> and <italic>E. coli</italic> (<xref ref-type="bibr" rid="bib30">Calcagno et al., 2021</xref>; <xref ref-type="bibr" rid="bib84">Hedberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib136">Murgia et al., 2023</xref>; <xref ref-type="bibr" rid="bib28">Buehler et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Ceballos et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Chen et al., 2023</xref>; <xref ref-type="bibr" rid="bib17">Bartoszewicz et al., 2023</xref>), reflecting the healthcare-associated nature of these infections. In some locations, secondary infections with multidrug-resistant gram-negative bacteria have also been reported (<xref ref-type="bibr" rid="bib174">Ripa et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Budhiraja et al., 2022</xref>; <xref ref-type="bibr" rid="bib25">Bork et al., 2021</xref>). Moreover, bacterial bloodstream infections were more common in hospitalized COVID-19 patients (3–4%) (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib106">Khatri et al., 2021</xref>; <xref ref-type="bibr" rid="bib174">Ripa et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Grasselli et al., 2021b</xref>; <xref ref-type="bibr" rid="bib136">Murgia et al., 2023</xref>) than during mild acute infection, likely due to a combination of prolonged hospitalization and immunosuppressive therapy to treat COVID-19 (<xref ref-type="bibr" rid="bib106">Khatri et al., 2021</xref>; <xref ref-type="bibr" rid="bib178">Rothe et al., 2021</xref>). There are conflicting reports of whether secondary bacterial infection is more common among COVID-19 patients compared with those infected with other respiratory pathogens (<xref ref-type="bibr" rid="bib84">Hedberg et al., 2022</xref>; <xref ref-type="bibr" rid="bib205">Thelen et al., 2021</xref>; <xref ref-type="bibr" rid="bib223">Youngs et al., 2020</xref>). It remains unclear whether SARS-CoV-2 itself specifically increased the susceptibility to bacterial superinfection, or the high rates reflect instead the severity of infection, use of ventilators, and prolonged hospital course, which are also known to be associated with increased risk of secondary infection.</p><p>While initial studies suggested that co-infections do not exacerbate COVID-19 symptoms (<xref ref-type="bibr" rid="bib37">Cheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Grasselli et al., 2021b</xref>), most reports demonstrate higher mortality, longer hospital length of stay, and longer duration of ventilatory support in patients with bacterial co-infection (<xref ref-type="bibr" rid="bib163">Petty et al., 2022</xref>; <xref ref-type="bibr" rid="bib174">Ripa et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Grasselli et al., 2021b</xref>; <xref ref-type="bibr" rid="bib136">Murgia et al., 2023</xref>; <xref ref-type="bibr" rid="bib27">Budhiraja et al., 2022</xref>; <xref ref-type="bibr" rid="bib28">Buehler et al., 2021</xref>). This raises the possibility that bacterial co-infection may predispose to PASC. For example, one would anticipate that longer duration of ventilatory support might increase long-term pulmonary inflammation and subsequent fibrosis, a proposed mechanism for PASC. Indeed, pulmonary infection following recovery from acute COVID-19 is common in survivors (<xref ref-type="bibr" rid="bib93">Jakubec and Genzor, 2022</xref>) and could reflect either heightened susceptibility to secondary consequences of COVID-19 or a causative role for late-onset infections in mediating PASC. While there is no direct evidence at this time that bacterial infections contribute to the development of PASC, these studies together highlight the need for additional investigations. Specific questions that should be addressed include: (1) Does bacterial co-infection, either at presentation or developing during COVID-19, contribute to the development of PASC? (2) Is secondary bacterial infection a marker for PASC? (3) Can undiagnosed co-infections be found in patients with relatively mild COVID-19 disease who developed PASC? (4) Are secondary infections merely a marker for severe COVID-19 or do they affect the severity of COVID-19? (5) How can we discriminate severe COVID-19 and the postinfection course from post-ICU syndrome sequelae?</p><sec id="s8-2-1"><title><italic>M. tuberculosis</italic></title><p>Given the global burden of tuberculosis (TB) (over 10 million cases and 1.6 million deaths worldwide in 2021; <ext-link ext-link-type="uri" xlink:href="http://www.who.int/publications/i/item/9789240061729">http://www.who.int/publications/i/item/9789240061729</ext-link>) and the large reservoir of people latently infected with <italic>M. tuberculosis</italic> (estimated as one-quarter of the world population; <xref ref-type="bibr" rid="bib41">Cohen et al., 2019</xref>), the question has arisen of whether pre-existing <italic>M. tuberculosis</italic> infections increase the risk of PASC or other severe manifestations of COVID-19 and, vice versa, whether infection with SARS-CoV-2 may trigger TB reactivation in latently infected individuals. Some evidence exists, mostly based on meta-analyses, that TB (with or without concurrent HIV infection) increases COVID-19 severity and mortality (<xref ref-type="bibr" rid="bib26">Boulle et al., 2021</xref>; <xref ref-type="bibr" rid="bib200">Tamuzi et al., 2020</xref>). A recent, multi-site register-based cohort study further supports a deleterious interaction between COVID-19 and TB, as co-infection was found associated with increased mortality, particularly in high-risk subjects, such as elderly males (<xref ref-type="bibr" rid="bib74">Group, 2022</xref>), who are also highly susceptible to COVID-19 or TB alone (<xref ref-type="bibr" rid="bib225">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib145">Nhamoyebonde and Leslie, 2014</xref>).</p><p>The observed harmful interactions between these two infections may have a biological basis. For example, immunological measurements have shown that (1) HIV-induced lymphopenia in HIV-TB patients was associated with reduced anti-viral antibody levels and frequencies of SARS-CoV-2-specific CD4<sup>+</sup> T cells; (2) active TB was associated with reduced polyfunctionality of SARS-CoV-2-specific CD4<sup>+</sup> T cell responses; and (3) acute SARS-CoV-2 infection diminished the pool of <italic>M. tuberculosis</italic>-specific memory T cell responses (<xref ref-type="bibr" rid="bib173">Riou et al., 2021</xref>), possibly due to SARS-CoV-2-induced lymphopenia (<xref ref-type="bibr" rid="bib189">Shariq et al., 2022</xref>). Thus, concurrent <italic>M. tuberculosis</italic> and SARS-CoV-2 infection can reciprocally reduce the magnitude and possibly the effectiveness of the CD4<sup>+</sup> T cell response to the co-infecting pathogen. Other biological mechanisms have been invoked, including the <italic>M. tuberculosis</italic>-induced upregulation of ACE2 (<xref ref-type="bibr" rid="bib189">Shariq et al., 2022</xref>), which is a critical SARS-CoV-2 receptor on host cells (<xref ref-type="bibr" rid="bib88">Hoffmann et al., 2020</xref>). When interpreting epidemiological data, however, it is important to consider that potential bias may be introduced by unmeasured confounding factors (<xref ref-type="bibr" rid="bib26">Boulle et al., 2021</xref>), particularly because the populations concurrently exposed to these infections may be highly vulnerable due to socioeconomic and geographic factors (<xref ref-type="bibr" rid="bib57">Duarte et al., 2021</xref>). Moreover, it is widely recognized that the COVID-19 pandemic has had a devastating impact on essential tuberculosis control worldwide (<xref ref-type="bibr" rid="bib52">Dheda et al., 2022</xref>), resulting in increased tuberculosis morbidity and mortality in 2021, following decades of decline (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/publications/i/item/9789240061729">http://www.who.int/publications/i/item/9789240061729</ext-link>).</p><p>Given the clinical spectrum of <italic>M. tuberculosis</italic> infection (<xref ref-type="bibr" rid="bib15">Barry et al., 2009</xref>) and the abovementioned enormous burden of asymptomatic infection (latent <italic>M. tuberculosis</italic> infection [LTBI]), concerns exist that SARS-CoV-2 infection in patients with LTBI may increase the risk of progression to active TB (<xref ref-type="bibr" rid="bib74">Group, 2022</xref>; <xref ref-type="bibr" rid="bib189">Shariq et al., 2022</xref>). These concerns are justified, since SARS-CoV-2 infection may induce lymphopenia (<xref ref-type="bibr" rid="bib189">Shariq et al., 2022</xref>) and, in particular, as mentioned above , reduce the pool of <italic>M. tuberculosis</italic>-specific CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib173">Riou et al., 2021</xref>), which are central to immune control of <italic>M. tuberculosis</italic> infection (<xref ref-type="bibr" rid="bib63">Flynn and Chan, 2022</xref>). Moreover, the use of corticosteroids in COVID-19 treatment may increase the risk of TB reactivation in latently infected patients (<xref ref-type="bibr" rid="bib66">Friedman and DeGeorge, 2022</xref>). Assessing the association between history of SARS-CoV-2 infection and TB reactivation – at a large scale, and beyond occasional case reports (<xref ref-type="bibr" rid="bib107">Khayat et al., 2021</xref>; <xref ref-type="bibr" rid="bib118">Leonso et al., 2022</xref>) – will prove challenging due to the sources of bias mentioned above and the need for large-scale prospective studies.</p><p>Whether and how TB might contribute to PASC is even less understood. TB may give rise to chronic lung abnormalities in subjects who have completed therapy, referred to as post-TB lung disease (PTLD) (<xref ref-type="bibr" rid="bib5">Allwood et al., 2020</xref>). PTLD is poorly recognized and insufficiently studied, despite its relatively high prevalence (lung impairment following pulmonary TB is found in 18–87% of cases, depending on the setting; <xref ref-type="bibr" rid="bib5">Allwood et al., 2020</xref>) and its association with reduced quality of life. PTLD is highly heterogeneous, as it may include airflow obstruction, restrictive ventilatory defects, and/or impairment in gas exchange, which are in turn associated with various lung immunopathological processes, such as tissue necrosis, cavitation, and aberrant tissue repair leading to fibrosis (<xref ref-type="bibr" rid="bib172">Ravimohan et al., 2018</xref>). These processes are mediated mostly by proinflammatory and fibrogenic cytokines and chemokines, and tissue-degrading enzymes such as matrix metalloproteinases (<xref ref-type="bibr" rid="bib172">Ravimohan et al., 2018</xref>). While still speculative, it is quite possible that the TB-induced chronic lung damage may not only increase the risk of severe acute COVID-19 but also favor additional chronic lung damage following SARS-CoV-2 infection. Indeed, precedents exist for respiratory infections, such as aspergillosis, to become chronic due to underlying lung damage by preceding infectious (TB, nontuberculous mycobacterioses) or noninfectious diseases (sarcoidosis, chronic obstructive pulmonary disease) (<xref ref-type="bibr" rid="bib113">Kosmidis and Denning, 2015</xref>).</p></sec><sec id="s8-2-2"><title>Non-tuberculous mycobacteria</title><p>Non-tuberculous mycobacteria (NTM) comprise approximately 200 bacterial saprophytic species that are found in the environment, particularly soil and water, and can cause opportunistic infections in the presence of host risk factors, such as old age, immunosuppression, and underlying chronic lung disease (in particular cystic fibrosis or bronchiectasis) (<xref ref-type="bibr" rid="bib97">Johansen et al., 2020</xref>). Little is known about the association between NTM and COVID-19. Isolated cases of co-infection have been reported (e.g. <xref ref-type="bibr" rid="bib176">Rodriguez et al., 2021</xref>; <xref ref-type="bibr" rid="bib128">Masoumi et al., 2021</xref>), and a single-center study in Korea including almost 4000 subjects reported an excess of COVID-19 incidence in subjects treated for NTM (<xref ref-type="bibr" rid="bib108">Kim et al., 2022</xref>) relative to the general population. However, a National COVID Collaborative Cohort (N3C) study including &gt;6 million subjects failed to observe increased COVID-19 morbidity and mortality associated with pulmonary NTM disease (<xref ref-type="bibr" rid="bib62">Figueroa Castro and Hersh, 2021</xref>). Even less is known about NTM infection and increased risk of PASC. However, it is plausible that lung damage resulting from severe COVID-19 might increase the risk of subsequent NTM infection.</p></sec></sec><sec id="s8-3"><title>Respiratory fungi</title><p>Individuals with SARS-CoV-2 infection have increased susceptibility to invasive fungal infections caused by three major fungal pathogens: <italic>Aspergillus</italic>, <italic>Zygomycetes</italic>, and <italic>Candida</italic>. Since the first reported co-infection with <italic>Aspergillus</italic> in China in 2020, many cases of severe COVID-associated pulmonary aspergillosis have been described (<xref ref-type="bibr" rid="bib11">Arastehfar et al., 2020b</xref>; <xref ref-type="bibr" rid="bib110">Koehler et al., 2020</xref>; <xref ref-type="bibr" rid="bib165">Prattes et al., 2022</xref>; <xref ref-type="bibr" rid="bib160">Permpalung et al., 2022</xref>; <xref ref-type="bibr" rid="bib181">Salmanton-García et al., 2021</xref>; <xref ref-type="bibr" rid="bib94">Janssen et al., 2021</xref>). In 2021, COVID-19-associated mucormycosis emerged in India and was associated with high mortality rates (<xref ref-type="bibr" rid="bib171">Ravani et al., 2021</xref>; <xref ref-type="bibr" rid="bib170">Raut and Huy, 2021</xref>; <xref ref-type="bibr" rid="bib87">Hoenigl et al., 2022</xref>). Invasive <italic>Candida</italic> infections in patients with COVID-19 are thought to represent opportunistic infections. Causative agents are <italic>Candida albicans,</italic> which is the most reported cause of candidiasis in critically ill patients (44% of candidemia cases in one US multicenter study), followed by <italic>Candida auris</italic> (<xref ref-type="bibr" rid="bib183">Seagle et al., 2022</xref>; <xref ref-type="bibr" rid="bib10">Arastehfar et al., 2020a</xref>; <xref ref-type="bibr" rid="bib96">Jeffery-Smith et al., 2018</xref>). Risk factors associated with fungal co-infection include acute respiratory distress syndrome (ARDS) secondary to COVID-19, immunosuppressive therapies such as corticosteroids, and uncontrolled diabetes. Although frequently restricted to the lungs, fungal co-infection may often be disseminated with associated angioinvasion and severe tissue necrosis; such dissemination is associated with high mortality (up to 80%).</p><p>The potential mechanisms by which COVID-19 may predispose to severe fungal superinfection include epithelial damage, impaired ciliary clearance, pathologic immune activation and inflammation, and tissue necrosis. Conversely, fungal infection may exacerbate the severity of COVID-19 by inducing tissue necrosis and thrombosis, which may promote endothelial dysfunction and hypercoagulability, two cardinal features of severe COVID-19. As discussed above for viral and bacterial infections, the relationship between immune activation, endothelial dysfunction, and thrombosis associated with COVID-19 and fungal co-infection and the development of PASC remains unknown, indicating a need for future studies. Similarly, diagnostic challenges may have caused underestimation of the actual incidence and prevalence of fungal co-infections in patients with COVID-19. Future studies are needed to understand the pathophysiological mechanisms by which fungal co-infections may exacerbate the severity of COVID-19 and potentially contribute to the development of PASC.</p></sec></sec><sec id="s9"><title>Anatomical location: extrapulmonary or systemic infections</title><p>PASC may also be characterized by systemic symptomatology and/or the involvement of multiple organs. This is particularly relevant, since the ACE2 receptor, which is the cellular receptor by which SARS-CoV-2 enters cells, is widely distributed throughout the body. Systemic co-infections may play a causative/facilitating role in at least two different ways. One is by damaging mucosal barriers, with consequent microbial translocation and subepithelial immune activation, leading to systemic inflammation, endothelial damage, and compromised organ systems. The example of intestinal co-infections (or changes in gut microbiota) and gut lining damage as PASC drivers is depicted in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, but systemic disease caused by bacterial and angioinvasive fungal infections (discussed above) could drive similar changes.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>How co-infections may result in post-acute sequelae of SARS-CoV-2 (PASC) development systemically.</title><p>The etiology of PASC is heterogeneous and involves multiple pathophysiological mechanisms. (<bold>A</bold>) shows how SARS-CoV-2 along with other viral and bacterial infections may compromise mucosal barriers (in this example, the intestinal lining) or change microbiome homeostasis leading to dysregulation of tight junctions, microbial translocation, immune activation, and systemic inflammation. (<bold>B</bold>) shows the potential impact of Epstein-Barr virus (EBV) reactivation during or following acute COVID-19. Viral shedding from lytic EBV-infected epithelial or B cells may lead to direct tissue damage, molecular mimicry, autoreactivity from host-cell expression of viral proteins, or pathogenic transformation of B cells that may traffic to various anatomical regions outside the areas of initial viral reactivation. All these mechanisms may lead to immune dysregulation and systemic tissue damage (<bold>C</bold>). LMP = latent membrane protein; EBNA = EBV nuclear antigen.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106308-fig4-v1.tif"/></fig><p>Another mechanism of pathogenesis of systemic PASC relates to the reactivation of latent viruses, such as EBV. It can be envisioned that SARS-CoV-2 infection may facilitate EBV reactivation in the Peyer’s patches in the gut (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) or in lymphoid tissue elsewhere (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), resulting in either viral shedding and direct tissue damage, systemic damage secondary to EBV-induced immune dysregulation or pathogenic transformation of B cells that may traffic to anatomical regions outside the areas of initial viral reactivation (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Thus, co-infections may be drivers of PASC, either at the site of infection or systemically, and induce a wide range of clinical phenotypes.</p></sec><sec id="s10"><title>Chronic (pre-existing) viral pathogens</title><sec id="s10-1"><title>Epstein-Barr virus</title><p>Latent EBV is an HHV harbored by 95% of the world population usually defined by the presence of detectable, long-lived EBV viral capsid antigen IgG levels (<xref ref-type="bibr" rid="bib58">Dunmire et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Damania et al., 2022</xref>). EBV can infect B cells and epithelial cells (in addition to many other cell types) and fluctuate between latent and lytic infection (<xref ref-type="bibr" rid="bib47">Damania et al., 2022</xref>). As a result, EBV can reactivate in the setting of various physiological stressors or dysregulated immune responses. In some cases, reactivated EBV in tissues may not manifest with detectable circulating DNA in blood (<xref ref-type="bibr" rid="bib76">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib132">Middeldorp, 2015</xref>). While reactivation of EBV can lead to end-organ damage, most commonly in immunocompromised hosts, EBV infection can also lead to various malignancies such as Burkitt lymphoma, gastric carcinoma, Hodgkin lymphoma, nasopharyngeal carcinoma, B cell lymphomas, and posttransplant lymphoproliferative disease in which EBV viral gene expression has been detected (e.g<italic>.</italic> EBER, BART, EBNA, LMP) (<xref ref-type="bibr" rid="bib47">Damania et al., 2022</xref>). Recent data suggest that EBV infection may drive multiple sclerosis (MS) (<xref ref-type="bibr" rid="bib21">Bjornevik et al., 2022</xref>), perhaps due to aberrant autoreactive immune responses (<xref ref-type="bibr" rid="bib6">Aloisi and Salvetti, 2022</xref>). EBV nuclear antigens 1 and 2 (EBNA1 and 2) are expressed during the latent and lytic phases of infection and have been demonstrated to exhibit molecular mimicry with human proteins involved in various autoimmune conditions (e.g. rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, celiac disease, and MS) (<xref ref-type="bibr" rid="bib90">Houen and Trier, 2020</xref>; <xref ref-type="bibr" rid="bib81">Harley et al., 2018</xref>).</p><p>Whereas the precise causative relationship between EBV infection or reactivation and various rheumatological diseases is lacking, associations between EBV reactivation during acute SARS-CoV-2 infection and the development of various PASC symptom clusters have been reported. For example, a study published early during the COVID-19 pandemic identified EBV early antigen-diffuse (EA-D) IgG positivity, a marker that may indicate recent viral activity or reactivation, in two-thirds of individuals experiencing PASC; in particular, EBV EA-D IgG levels were higher in those with more PASC symptoms (<xref ref-type="bibr" rid="bib70">Gold et al., 2021</xref>). A subsequent study found that detectable EBV DNA during acute SARS-CoV-2 infection predicted the presence of symptoms at 30–60 days post-COVID-19 (<xref ref-type="bibr" rid="bib195">Su et al., 2022</xref>), although the long-term impact on persistent symptoms was not studied. Another recent study of 280 participants showed that PASC symptoms such as fatigue and neurocognitive dysfunction 4 months following acute COVID-19 were independently associated with serological evidence of recent EBV reactivation (EBV EA-D positivity) or high EBNA1 IgG levels, but not with ongoing circulating EBV DNA (<xref ref-type="bibr" rid="bib158">Peluso et al., 2023</xref>). EBV reactivation was also independently associated with fatigue, a hallmark feature of acute EBV infection/mononucleosis that can persist for weeks to months (<xref ref-type="bibr" rid="bib158">Peluso et al., 2023</xref>). Another study showed that, in addition to EBV EA-D antibody responses, seropositivity to EBV envelope glycoproteins gp42 and gp350, which are essential for EBV lytic infection of B cells, was higher in participants with long COVID (<xref ref-type="bibr" rid="bib109">Klein et al., 2023</xref>), also suggesting recent viral activity associated with the development of PASC (<xref ref-type="bibr" rid="bib101">Karsten et al., 2022</xref>).</p><p>It is also of interest that oligoclonal bands, which represent immunoglobulins that are classically associated with MS, have been identified in the cerebrospinal fluid in approximately 70% of individuals with PASC compared with none in controls without PASC (<xref ref-type="bibr" rid="bib9">Apple et al., 2022</xref>). Notably, of patients with MS, ~40% had oligoclonal bands in the cerebrospinal fluid that are reactive to HHVs, including human herpesvirus 6 (HHV-6), and EBV, compared to none in patients with other inflammatory neurological disorders (<xref ref-type="bibr" rid="bib213">Virtanen et al., 2014</xref>). Additionally, these herpes-reactive oligoclonal bands in MS patients were also associated with the presence of viral DNA in the cerebrospinal fluid (<xref ref-type="bibr" rid="bib171">Ravani et al., 2021</xref>). Therefore, it is possible that EBV reactivation in B cell-rich areas, such as lymph node follicles or bone marrow, may lead to autoreactive antibody responses. Indeed, EBV-infected, pathogenic B cells have been shown to migrate to the brain in MS patients (<xref ref-type="bibr" rid="bib47">Damania et al., 2022</xref>). Further investigation is urgently needed to determine whether a similar autoimmune process may be involved in the development of PASC neuronal symptoms.</p></sec><sec id="s10-2"><title>Cytomegalovirus</title><p>CMV is another HHV that infects and persists in greater than 80% of the global population (<xref ref-type="bibr" rid="bib226">Zuhair et al., 2019</xref>). Some groups, such as those living with HIV, exhibit a much higher prevalence of IgG positivity (&gt;95%). Like other HHVs, CMV persists indefinitely in a predominantly quiescent state and can reactivate during physiological stress and dysfunctional immunity, leading to detectable circulating DNA and end-organ damage. CMV reactivation is relatively common in critically ill patients requiring intensive care, and treatment of CMV in these patients may reduce time on mechanical ventilation and improve oxygenation (<xref ref-type="bibr" rid="bib122">Limaye et al., 2017</xref>). COVID-19 patients infected earlier during the pandemic who were CMV IgG+ experienced higher rates of hospitalization and overall morbidity during acute infection (<xref ref-type="bibr" rid="bib4">Alanio et al., 2022</xref>; <xref ref-type="bibr" rid="bib217">Weber et al., 2022</xref>). CMV can reactivate in anatomical locations similar to SARS-CoV-2, including the lungs and endovasculature, and may play a role in exacerbating the severity of COVID-19 progression.</p><p>The impact of underlying CMV infection (i.e. IgG positivity) was independently associated with a lower odds ratio of developing neurocognitive PASC, an association that was not observed with reports of fatigue (<xref ref-type="bibr" rid="bib158">Peluso et al., 2023</xref>). Thus, CMV clearly plays a multifactorial role in modulating acute COVID-19 and PASC. One hypothesis is that CMV-seropositive individuals may mount more robust and durable adaptive immune responses to SARS-CoV-2 over time, perhaps due to higher basal levels of IFNγ (<xref ref-type="bibr" rid="bib16">Barton et al., 2007</xref>). In support of this idea, CMV seropositivity in younger adults has been linked with more robust adaptive immune responses to influenza vaccination (<xref ref-type="bibr" rid="bib67">Furman et al., 2015</xref>). Other studies have linked CMV infection to immunosenescent phenotypes (<xref ref-type="bibr" rid="bib146">Nicoli et al., 2022</xref>). Furthermore, CMV-induced immunoregulatory pathways may reduce local inflammation or decrease autoantibody formation. While speculative, these mechanisms need further study.</p></sec><sec id="s10-3"><title>Other HHVs</title><p>HHV-1, HHV-6, and HHV-7 can reactivate in the setting of acute SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib221">Xu et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Drago et al., 2021</xref>), but there is a paucity of data on reactivation or underlying seropositivity of other HHVs as potential drivers of PASC. However, given the complex interactions between EBV, CMV, and PASC, tissue and blood studies should include more detailed investigation into the potential role of these chronic viral infections in modulating PASC. Indeed, VZV glycoprotein E was found increased in PASC patients (<xref ref-type="bibr" rid="bib109">Klein et al., 2023</xref>), providing further evidence that other HHVs may play a role in PASC pathogenesis.</p></sec><sec id="s10-4"><title>HIV-1</title><p>Emerging data suggest that people with HIV-1, especially those with underlying HIV-1-associated immune dysfunction, are more susceptible to acute SARS-CoV-2 infection or have worse clinical outcomes (<xref ref-type="bibr" rid="bib12">Augello et al., 2023</xref>). Importantly, chronic HIV infection leads to detrimental chronic immune activation and inflammation (e.g. elevated IL-6, scCD14, sCD163, C-reactive protein [CRP], etc.), even after decades of suppressive antiretroviral therapy (ART), and people with HIV continue to have elevated risks of various cardiopulmonary, metabolic, and oncological diseases over time due to ongoing persistent inflammation (<xref ref-type="bibr" rid="bib24">Borges et al., 2013</xref>; <xref ref-type="bibr" rid="bib186">Sereti et al., 2017</xref>; <xref ref-type="bibr" rid="bib147">Nordell et al., 2014</xref>; <xref ref-type="bibr" rid="bib201">Tenorio et al., 2014</xref>; <xref ref-type="bibr" rid="bib114">Kuller et al., 2008</xref>). Similar markers of aberrant immune activation and inflammation have been observed in the setting of various manifestations of PASC (e.g. IL-6, CRP) (<xref ref-type="bibr" rid="bib152">Peluso et al., 2021b</xref>; <xref ref-type="bibr" rid="bib59">Durstenfeld et al., 2022</xref>; <xref ref-type="bibr" rid="bib156">Peluso et al., 2022d</xref>). Thus, the question arises whether pre-existing HIV infection can potentiate PASC (<xref ref-type="bibr" rid="bib12">Augello et al., 2023</xref>). In at least some HIV-infected or otherwise immunodeficient individuals, inability to clear SARS-CoV-2 may lead to long-lasting, persistent infection, which is characterized by a much greater level of evolution and immune escape. It has been speculated that such coinfected individuals may be the source of the sudden appearance of new SARS variants, such as the Omicron variant in southern Africa in late 2021 (<xref ref-type="bibr" rid="bib51">Dhama et al., 2023</xref>).</p><p>While the association between HIV and SARS-CoV-2 is understudied, several studies suggest that people with HIV, many on suppressive ART, have a 1.4- to 4-fold increase in PASC risk (<xref ref-type="bibr" rid="bib157">Peluso et al., 2022e</xref>). IL-6 levels were also observed to be higher in PASC participants with HIV relative to those without HIV (<xref ref-type="bibr" rid="bib157">Peluso et al., 2022e</xref>). Another investigation showed that pre-existing HIV infection was independently associated with higher odds (&gt;2) of developing neurocognitive symptoms when controlled for demographic factors, initial disease severity, other underlying medical conditions, and CMV and EBV serological status (<xref ref-type="bibr" rid="bib158">Peluso et al., 2023</xref>).</p><p>It is plausible that COVID-19 is essentially an insult added to an existing ‘injury’, exacerbating an already dysregulated and inflammatory environment, including increased gut microbial translocation and disruption of mucosal barriers observed in both HIV-1 and SARS-CoV-2 infections (<xref ref-type="bibr" rid="bib69">Giron et al., 2022</xref>; <xref ref-type="bibr" rid="bib190">Sheth et al., 2008</xref>; <xref ref-type="bibr" rid="bib78">Haase, 2005</xref>; <xref ref-type="bibr" rid="bib182">Schuetz et al., 2014</xref>). An increased frequency of HIV ‘blips’ or low-level, transient detectable HIV RNA copies in the blood has been reported in people with HIV on ART months following initial COVID-19 (<xref ref-type="bibr" rid="bib151">Peluso et al., 2021a</xref>), suggesting that SARS-CoV-2 infection may also exacerbate smoldering, persistent HIV-1 activity, leading to a synergistic spiral of virus-induced inflammation.</p></sec><sec id="s10-5"><title>Hepatitis B and C viruses</title><p>Hepatitis C virus (HCV) infects up to 2% of the global population despite the availability in well-resourced settings of direct antivirals with high efficacy. Data are sparse, but some studies have suggested that people with HCV may have higher rates of hospitalization for COVID-19 and higher degrees of liver inflammation/damage, although ICU admission and mortality were not affected (<xref ref-type="bibr" rid="bib29">Butt et al., 2021</xref>). Experimental data have also emerged that HCV may increase ACE2 expression on hepatocytes, potentially facilitating SARS-CoV-2 entry in liver tissue (<xref ref-type="bibr" rid="bib54">Domovitz et al., 2022</xref>). However, the evidence of SARS-CoV-2 infection of the liver in humans is limited, and further tissue-based studies are warranted. Acute SARS-CoV-2 infection can also lead to HCV reactivation, but there is a paucity of data suggesting that HCV predisposes or plays a direct pathogenic role in the development of PASC. Reactivation of chronic hepatitis B virus (HBV) infection during acute COVID-19 is low, and individuals with cirrhosis may be at higher risk of severe disease (<xref ref-type="bibr" rid="bib126">Marjot et al., 2021</xref>). As with HCV, however, there is no evidence supporting chronic HBV infection or reactivation with PASC.</p></sec></sec><sec id="s11"><title>Non-respiratory bacterial infection</title><sec id="s11-1"><title>Lyme disease</title><p>Concerns exist regarding <italic>Borrelia burgdorferi</italic> infection potentially predisposing patients to more severe symptoms of COVID-19, especially given the propensity for many individuals to develop postinfectious syndromes following acute borreliosis (<xref ref-type="bibr" rid="bib127">Marques, 2022</xref>). The term chronic Lyme disease is used to describe distinct clinical manifestations of late Lyme disease, including progressive encephalomyelitis, chronic polyneuropathy, and chronic fatigue syndrome (CFS) (<xref ref-type="bibr" rid="bib14">Bai and Richardson, 2023</xref>). The latter has been used frequently to refer to patients with chronic subjective complaints, such as fatigue, musculoskeletal pain, and cognitive dysfunction without a documented history of Lyme disease or evidence of an active infection with <italic>B. burgdorferi</italic> (<xref ref-type="bibr" rid="bib121">Lim and Torpy, 2000</xref>). However, in some cases, evidence for infection based on serology or clinical presentations of Lyme has been documented (<xref ref-type="bibr" rid="bib14">Bai and Richardson, 2023</xref>). In addition to serology, diagnosis of CFS associated with chronic Lyme disease is based on two assumptions: first, that chronic Lyme disease is caused by persistent infection with <italic>B. burgdorferi</italic>; and second, that this chronic infection form is unresponsive to conventional antimicrobial treatment.</p><p>Fatigue is a frequently documented component of PASC and persistent Lyme disease, as well as other viral infections such as EBV and influenza (<xref ref-type="bibr" rid="bib204">Thaweethai et al., 2023</xref>; <xref ref-type="bibr" rid="bib215">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib130">McCall et al., 2008</xref>). Interestingly, the presence of fatigue is consistent with later stages of these infectious conditions that share symptoms with noninfectious neurodegenerative states such as post‐traumatic brain injury and post-stroke (<xref ref-type="bibr" rid="bib203">Thapa Magar et al., 2022</xref>; <xref ref-type="bibr" rid="bib134">Mollayeva et al., 2014</xref>). In addition to fatigue, chronic Lyme disease and PASC are characterized by persistent or chronic neurological manifestations, including cognitive dysfunction, suggesting similar pathophysiological mechanisms (<xref ref-type="bibr" rid="bib127">Marques, 2022</xref>; <xref ref-type="bibr" rid="bib204">Thaweethai et al., 2023</xref>).</p><p>A recent study that combined serological and clinical data found that Borrelia-specific IgG antibodies correlated with COVID-19 severity (<xref ref-type="bibr" rid="bib198">Szewczyk-Dąbrowska et al., 2022</xref>), with 31 out of 31 hospitalized COVID-19 patients, 19 out of 28 mild/asymptomatic, and only 8 out of 28 healthy controls positive for Borrelia-specific IgGs. A lower positivity was reported for Borrelia-specific IgM. While the authors evaluated cross-reactive antibodies against other bacterial and spirochetal species, such as <italic>Anaplasma</italic> and <italic>Treponem</italic>a, respectively, there remains a concern about the specificity of IgG antibodies against <italic>Borrelia</italic>. Serological diagnosis of Lyme disease, as well as tick-borne diseases, is challenging due to antibody cross-reactivity among several tick-borne pathogens, which causes false-positive results. Thus, serology-based diagnosis of co-infection with Borrelia and SARS-CoV-2 is questionable and requires further confirmation by other immunoassays or molecular nucleic acid amplification testing (<xref ref-type="bibr" rid="bib210">van Gorkom et al., 2017</xref>; <xref ref-type="bibr" rid="bib117">Lantos et al., 2015</xref>; <xref ref-type="bibr" rid="bib216">Webber et al., 2019</xref>). Further studies combining multiple diagnostic approaches and larger cohorts of patients are needed to confirm these intriguing findings.</p><p>The mechanisms by which neurophysiological changes occur following recovery from acute infections with <italic>Borrelia</italic> or SARS-CoV-2 and the disappearance of acute systemic cytokine storm remain elusive. Murine studies demonstrated that systemic injection of lipopolysaccharide, a pathogen-associated molecular pattern (PAMP) constitutively expressed in Gram-negative bacteria including <italic>Borrelia</italic>, is followed by prolonged systemic TNF-α production and persistence in the cerebrospinal fluid (<xref ref-type="bibr" rid="bib167">Qin et al., 2007</xref>). Whether similar PAMPs exist in SARS-CoV-2 and persist in the CSF following resolution of acute infection remains unknown. Nevertheless, access of these PAMPS to the CNS through the blood-brain barrier can activate microglia (resident macrophage-like cells) via TLR4, leading to local production of TNF and other inflammatory cytokines (<xref ref-type="bibr" rid="bib20">Biswas, 2023</xref>). Understanding the shared pathophysiological mechanisms of chronic Lyme disease and PASC might have therapeutic and diagnostic implications.</p></sec></sec><sec id="s12"><title>Animal models of PASC</title><p>Animal models, including mice, hamsters, and nonhuman primates (NHPs), have been used to study the pathogenesis, immunity, transmission, and protection against SARS-CoV-2 infection. These models have been essential for preclinical development and testing of countermeasures, which include vaccines, monoclonal antibodies, and direct-acting antivirals (<xref ref-type="bibr" rid="bib23">Boras et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Corbett et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Guebre-Xabier et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Hansen et al., 2020</xref>; <xref ref-type="bibr" rid="bib83">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib166">Pruijssers et al., 2020</xref>; <xref ref-type="bibr" rid="bib206">Tian et al., 2021</xref>; <xref ref-type="bibr" rid="bib209">van Doremalen et al., 2020</xref>; <xref ref-type="bibr" rid="bib214">Vogel et al., 2021</xref>).</p><p>Mice, hamsters, and NHPs have been used to define the contributions of the innate immune response, including type I IFNs, pro-inflammatory and anti-inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-10, IL-2), and innate cell-mediated responses (macrophages, monocytes, neutrophils, eosinophils, natural killer cells), and the adaptive immune response (humoral, B cells, and T cells) in modulating protection against SARS-CoV-2 (<xref ref-type="bibr" rid="bib32">Case et al., 2025</xref>). These animal models are now being leveraged to replicate facets of long COVID and serve as platforms for mechanistic studies and therapeutic development. Several review articles have been published describing animal models of gastrointestinal, neurological, and cardiovascular PASC and will not be discussed in this review (<xref ref-type="bibr" rid="bib208">Vanderheiden and Diamond, 2025</xref>; <xref ref-type="bibr" rid="bib40">Chung et al., 2025</xref>; <xref ref-type="bibr" rid="bib46">Dai et al., 2025</xref>). We highlight how animal models are being used to study pulmonary sequelae and viral persistence.</p><p>Pulmonary sequelae, such as lung fibrosis and chronic inflammation, have been prominently observed during the recovery phase following SARS-CoV-2 infection of mice. For instance, infection of standard laboratory strains with a mouse-adapted SARS-CoV-2 strain (MA10) has been shown to cause chronic pulmonary epithelial and immune cell dysfunction with fibrosis, as well as sustained lung inflammation, injury, and airway wall thickening (<xref ref-type="bibr" rid="bib53">Dinnon et al., 2022</xref>). Sustained neutrophil activation and extracellular trap formation (<xref ref-type="bibr" rid="bib68">Giannakopoulos et al., 2024</xref>), complement (<xref ref-type="bibr" rid="bib159">Perico et al., 2023</xref>), dysregulated macrophage-CD8<sup>+</sup> T cell signaling axis (<xref ref-type="bibr" rid="bib138">Narasimhan et al., 2024</xref>), and fibroblast-intrinsic CD147 (<xref ref-type="bibr" rid="bib219">Wu et al., 2022</xref>) have been shown to contribute to SARS-CoV-2-induced progressive pulmonary fibrosis. Further, therapeutics including antivirals and monoclonal antibodies have been shown to reduce lung fibrosis and disease severity (<xref ref-type="bibr" rid="bib53">Dinnon et al., 2022</xref>; <xref ref-type="bibr" rid="bib219">Wu et al., 2022</xref>; <xref ref-type="bibr" rid="bib112">Kolloli et al., 2023</xref>; <xref ref-type="bibr" rid="bib224">Zhang et al., 2024</xref>).</p><p>Persistent SARS-CoV-2 reservoirs that remain hidden in various tissues have been postulated to drive chronic inflammation and symptoms long after acute infection. One of the challenges with animal models is that SARS-CoV-2 is rapidly cleared following acute infection, which has made it difficult to study viral persistence. CD4<sup>+</sup> and CD8<sup>+</sup> T cells have been shown to be recruited to the upper and lower respiratory tract following SARS-CoV-2 infection in mice (<xref ref-type="bibr" rid="bib98">Kar et al., 2024</xref>). Antibody-based depletion of T cells resulted in persistent infectious virus in the upper respiratory tract, but not lungs, for more than a month. This finding demonstrates that T cells are required for preventing viral persistence in the respiratory tract. Treatment with antivirals cleared viral persistence in the upper respiratory tract (<xref ref-type="bibr" rid="bib120">Lieber et al., 2024</xref>). In a reductionist model, intravenous delivery of the SARS-CoV-2 spike protein led to neuroinflammation within the skull-meninges-brain axis and induced anxiety-like behavior in mice (<xref ref-type="bibr" rid="bib177">Rong et al., 2024</xref>).</p><p>Animal models should continue to be used to develop deeper mechanistic insight to the pathophysiology of PASC. There are many factors that should be considered, including age, sex, host genetics, immunological status (e.g. pre-existing vaccine or infection-induced immunity), metabolic state, sequential and/or co-infections with other heterologous pathogens, obesity, and diabetes. We should attempt to use models that appropriately recapitulate acute infection, pathogenesis, immune responses, and recovery observed in humans.</p></sec><sec id="s13"><title>Summary and implications for future research and clinical care</title><p>Here, we reviewed data regarding the interactions of pathogenic microorganisms with SARS-CoV-2 infection and the possibility that co-infections are associated with the development of PASC. Co-infections important to PASC can be pre-existing, reactivated during or after acute infection, or infect de novo along a wide time range. The relationship between SARS-CoV-2 and other co-infecting microorganisms may be multifaceted. On one hand, SARS-CoV-2 infection might exacerbate immunological dysfunctions caused by previous infections with other pathogens. On the other hand, immune dysregulation and tissue damage during SARS-CoV-2 infection might trigger reactivation of latent infections or predispose to severe disease from the subsequent encounter with other pathogens. In addition, co-infections might trigger severe manifestations and sequelae of SARS-CoV-2 infection that may not occur in the absence of co-infection. Moreover, various co-infections might have different consequences for PASC manifestations. Depending on the pathogen, the time between infections, and the presence of other predisposing host and environmental factors, co-infection-related effects may be organ-specific and/or have systemic implications, giving rise to a wide spectrum of sequelae of SARS-CoV-2 infection and diverse PASC symptoms. Given the multitude of clinical phenotypes and potential mechanistic drivers, small epidemiological and tissue or blood-based mechanistic studies are insufficient to demonstrate the causal roles of any given co-infection in PASC development. As a result, these studies should be complemented with large longitudinal studies, such as the RECOVER initiative, which have the potential to assess the association of various co-infections with PASC or specific PASC phenotypes across a wide cross-section of the population. A better understanding of pathogen-specific associations of co-infections with PASC will be critical in the development of appropriate diagnosis of long COVID patients. This, in turn, will help find PASC therapies tailored according to the specific underlying mechanism.</p></sec><sec id="s14"><title>Limitations</title><p>Due to the large heterogeneity of PASC phenotypes and the various co-variates that might drive them, including co-morbidities, genetic predisposition, previous exposure to various agents, and, as discussed in this manuscript, co-infections, we propose a framework to best conduct PASC research, which allows for informed comparisons among studies, so that advances can be achieved leading to specific therapies for the affected patients (<xref ref-type="box" rid="box2">Box 2</xref>). This framework involves the participation of clinicians, microbiologists, immunologists, pathologists, statisticians, bioinformaticians, machine learning and AI experts, patient advocates, regulators, and funders to ensure not only that samples are collected from large longitudinal studies, such as the RECOVER initiative, but also that the appropriate information is collected to address the multiple variables that can drive PASC symptoms, and that samples are analyzed in a comprehensive and comparative way to best establish correlates of disease and to generate hypotheses to further investigate possible therapies. With this framework, clinical trials targeting specific mechanisms identified in subsets of PASC patients, related or not related to co-infections, are likely to be more informative than clinical trials in PASC patients without a clear hypothesis on the underlying causes of their symptoms. In this respect, the development of animal models of PASC that investigate the impact of co-infections will also be of significant help for the discovery of preventive measures and therapies to mitigate the sequelae associated with SARS-CoV-2 infection. The implementation of adequate clinical strategies based on a better understanding of the factors associated with PASC, including the impact of co-infections, will pave the way for finding treatments that mitigate the development of PASC.</p><boxed-text id="box2"><label>Box 2.</label><caption><title>A framework to study the role of co-infections in post-acute sequelae of SARS-CoV-2 (PASC).</title></caption><list list-type="bullet" id="list3"><list-item><p>Establish a network of investigators, clinicians, patient advocates, regulators, and funders to continue large longitudinal studies that generate samples and clinical information from PASC patients, including those ascertaining the presence of co-infections.</p></list-item><list-item><p>Analyze samples from large cohorts in ways, including machine learning and AI, that allow for correlations between data generated and clinical information.</p></list-item><list-item><p>Generate hypotheses on drivers of PASC symptoms.</p></list-item><list-item><p>Establish animal models, ex vivo systems, and human studies to investigate hypotheses and test therapies.</p></list-item><list-item><p>Conduct informed clinical trials based on the inhibition of the mechanisms found to be involved in PASC phenotypes, including those driven by co-infections.</p></list-item></list></boxed-text></sec></body><back><sec sec-type="additional-information" id="s15"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Receives grant support from Merck and has received consulting fees from Regeneron and Roche</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Provides Intus Biosciences (formerly Shoreline Biome) with scientific advice regarding microbiome applications and holds equity interest in this non-publicly traded company</p></fn><fn fn-type="COI-statement" id="conf4"><p>Serves in an advisory role for Occugen, Inc</p></fn><fn fn-type="COI-statement" id="conf5"><p>A member of the Scientific advisory Boards and owns shares in ROME Therapeutics, Inc and Generate Biomedicine, Inc</p></fn><fn fn-type="COI-statement" id="conf6"><p>The AG-S laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson &amp; Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. AG-S has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta. AG-S has been an invited speaker at meeting events organized by Seqirus, Janssen, Abbott and AstraZeneca. AG-S is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York</p></fn><fn fn-type="COI-statement" id="conf7"><p>Inventor on patent applications on diagnostic markers of SARS-CoV-2-related disease and has received consulting fees from Diasorin and Biomerieux</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization</p></fn><fn fn-type="con" id="con13"><p>Conceptualization</p></fn><fn fn-type="con" id="con14"><p>Conceptualization</p></fn><fn fn-type="con" id="con15"><p>Conceptualization</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><ack id="ack"><title>Acknowledgements</title><p>The authors were all members of the Microbiology task force of the NIH-funded RECOVER initiative. We would like to thank the National Community Engagement Group (NCEG), all patient, caregiver, and community representatives, and all the participants enrolled in the RECOVER initiative. We also thank Diana Berrent Gûthe for her contribution to this manuscript during her service in RECOVER as patient representative from October 2021 to May 2023.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Ampudia</surname><given-names>Y</given-names></name><name><surname>Monsalve</surname><given-names>DM</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Rodríguez</surname><given-names>Y</given-names></name><name><surname>Zapata</surname><given-names>E</given-names></name><name><surname>Ramírez-Santana</surname><given-names>C</given-names></name><name><surname>Anaya</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome</article-title><source>The Journal of Infectious Diseases</source><volume>225</volume><fpage>2155</fpage><lpage>2162</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac017</pub-id><pub-id pub-id-type="pmid">35079804</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>SP</given-names></name><name><surname>Choi</surname><given-names>SY</given-names></name><name><surname>Yang</surname><given-names>MJ</given-names></name><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Rahman</surname><given-names>MDT</given-names></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>Hong</surname><given-names>SD</given-names></name><name><surname>Bae</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e148517</elocation-id><pub-id pub-id-type="doi">10.1172/JCI148517</pub-id><pub-id pub-id-type="pmid">34003804</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Aly</surname><given-names>Z</given-names></name><name><surname>Bowe</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Long COVID after breakthrough SARS-CoV-2 infection</article-title><source>Nature Medicine</source><volume>28</volume><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01840-0</pub-id><pub-id pub-id-type="pmid">35614233</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Dunn</surname><given-names>T</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Collman</surname><given-names>RG</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Rader</surname><given-names>D</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>D’Andrea</surname><given-names>K</given-names></name><name><surname>Adamski</surname><given-names>S</given-names></name><name><surname>Alam</surname><given-names>Z</given-names></name><name><surname>Addison</surname><given-names>MM</given-names></name><name><surname>Byrne</surname><given-names>KT</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Descamps</surname><given-names>HC</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Kaminskiy</surname><given-names>Y</given-names></name><name><surname>Kammerman</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Greenplate</surname><given-names>AR</given-names></name><name><surname>Hamilton</surname><given-names>JT</given-names></name><name><surname>Markosyan</surname><given-names>N</given-names></name><name><surname>Noll</surname><given-names>JH</given-names></name><name><surname>Omran</surname><given-names>DK</given-names></name><name><surname>Pattekar</surname><given-names>A</given-names></name><name><surname>Perkey</surname><given-names>E</given-names></name><name><surname>Prager</surname><given-names>EM</given-names></name><name><surname>Pueschl</surname><given-names>D</given-names></name><name><surname>Rennels</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>JB</given-names></name><name><surname>Shilan</surname><given-names>JS</given-names></name><name><surname>Wilhausen</surname><given-names>N</given-names></name><name><surname>Vanderbeck</surname><given-names>AN</given-names></name><collab>The UPenn COVID Processing Unit</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization</article-title><source>The Journal of Infectious Diseases</source><volume>226</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac020</pub-id><pub-id pub-id-type="pmid">35134186</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allwood</surname><given-names>BW</given-names></name><name><surname>van der Zalm</surname><given-names>MM</given-names></name><name><surname>Amaral</surname><given-names>AFS</given-names></name><name><surname>Byrne</surname><given-names>A</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Egere</surname><given-names>U</given-names></name><name><surname>Evans</surname><given-names>CA</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>Gray</surname><given-names>DM</given-names></name><name><surname>Hoddinott</surname><given-names>G</given-names></name><name><surname>Ivanova</surname><given-names>O</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Makanda</surname><given-names>G</given-names></name><name><surname>Marx</surname><given-names>FM</given-names></name><name><surname>Meghji</surname><given-names>J</given-names></name><name><surname>Mpagama</surname><given-names>S</given-names></name><name><surname>Pasipanodya</surname><given-names>JG</given-names></name><name><surname>Rachow</surname><given-names>A</given-names></name><name><surname>Schoeman</surname><given-names>I</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Stek</surname><given-names>C</given-names></name><name><surname>van Kampen</surname><given-names>S</given-names></name><name><surname>von Delft</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>NF</given-names></name><name><surname>Wallis</surname><given-names>RS</given-names></name><name><surname>Mortimer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Post-tuberculosis lung health: perspectives from the first international symposium</article-title><source>The International Journal of Tuberculosis and Lung Disease</source><volume>24</volume><fpage>820</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.5588/ijtld.20.0067</pub-id><pub-id pub-id-type="pmid">32912387</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloisi</surname><given-names>F</given-names></name><name><surname>Salvetti</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Epstein-Barr virus and multiple sclerosis: supporting causality</article-title><source>The Lancet. Neurology</source><volume>21</volume><fpage>300</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00086-2</pub-id><pub-id pub-id-type="pmid">35305331</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altmann</surname><given-names>DM</given-names></name><name><surname>Whettlock</surname><given-names>EM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Arachchillage</surname><given-names>DJ</given-names></name><name><surname>Boyton</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The immunology of long COVID</article-title><source>Nature Reviews. Immunology</source><volume>23</volume><fpage>618</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00904-7</pub-id><pub-id pub-id-type="pmid">37433988</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Pujol</surname><given-names>JC</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Steves</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2</article-title><source>The Lancet</source><volume>399</volume><fpage>2263</fpage><lpage>2264</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00941-2</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apple</surname><given-names>AC</given-names></name><name><surname>Oddi</surname><given-names>A</given-names></name><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Asken</surname><given-names>BM</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Pleasure</surname><given-names>SJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Allen</surname><given-names>IE</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Ndhlovu</surname><given-names>LC</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Stephens</surname><given-names>ML</given-names></name><name><surname>Hellmuth</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19</article-title><source>Annals of Clinical and Translational Neurology</source><volume>9</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1002/acn3.51498</pub-id><pub-id pub-id-type="pmid">35043593</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arastehfar</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>MH</given-names></name><name><surname>Hedayati</surname><given-names>MT</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Perlin</surname><given-names>DS</given-names></name><name><surname>Hoenigl</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>COVID-19-Associated Candidiasis (CAC): an underestimated complication in the absence of immunological predispositions?</article-title><source>Journal of Fungi</source><volume>6</volume><elocation-id>211</elocation-id><pub-id pub-id-type="doi">10.3390/jof6040211</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arastehfar</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Jenks</surname><given-names>JD</given-names></name><name><surname>Koehler</surname><given-names>P</given-names></name><name><surname>Krause</surname><given-names>R</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>S. Perlin</surname><given-names>D</given-names></name><name><surname>Lass-Flörl</surname><given-names>C</given-names></name><name><surname>Hoenigl</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>COVID-19 Associated Pulmonary Aspergillosis (CAPA)—from immunology to treatment</article-title><source>Journal of Fungi</source><volume>6</volume><elocation-id>91</elocation-id><pub-id pub-id-type="doi">10.3390/jof6020091</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augello</surname><given-names>M</given-names></name><name><surname>Bono</surname><given-names>V</given-names></name><name><surname>Rovito</surname><given-names>R</given-names></name><name><surname>Tincati</surname><given-names>C</given-names></name><name><surname>Marchetti</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Immunologic interplay between HIV/AIDS and COVID-19: adding fuel to the flames?</article-title><source>Current HIV/AIDS Reports</source><volume>20</volume><fpage>51</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s11904-023-00647-z</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydillo</surname><given-names>T</given-names></name><name><surname>Rombauts</surname><given-names>A</given-names></name><name><surname>Stadlbauer</surname><given-names>D</given-names></name><name><surname>Aslam</surname><given-names>S</given-names></name><name><surname>Abelenda-Alonso</surname><given-names>G</given-names></name><name><surname>Escalera</surname><given-names>A</given-names></name><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Carratala</surname><given-names>J</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immunological imprinting of the antibody response in COVID-19 patients</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3781</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23977-1</pub-id><pub-id pub-id-type="pmid">34145263</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>NA</given-names></name><name><surname>Richardson</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Posttreatment Lyme disease syndrome and myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and comparison of pathogenesis</article-title><source>Chronic Diseases and Translational Medicine</source><volume>9</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/cdt3.74</pub-id><pub-id pub-id-type="pmid">37711861</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>CE</given-names></name><name><surname>Boshoff</surname><given-names>HI</given-names></name><name><surname>Dartois</surname><given-names>V</given-names></name><name><surname>Dick</surname><given-names>T</given-names></name><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Young</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The spectrum of latent tuberculosis: rethinking the biology and intervention strategies</article-title><source>Nature Reviews. Microbiology</source><volume>7</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2236</pub-id><pub-id pub-id-type="pmid">19855401</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>ES</given-names></name><name><surname>White</surname><given-names>DW</given-names></name><name><surname>Cathelyn</surname><given-names>JS</given-names></name><name><surname>Brett-McClellan</surname><given-names>KA</given-names></name><name><surname>Engle</surname><given-names>M</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Miller</surname><given-names>VL</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Herpesvirus latency confers symbiotic protection from bacterial infection</article-title><source>Nature</source><volume>447</volume><fpage>326</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nature05762</pub-id><pub-id pub-id-type="pmid">17507983</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoszewicz</surname><given-names>M</given-names></name><name><surname>Czaban</surname><given-names>SL</given-names></name><name><surname>Bartoszewicz</surname><given-names>K</given-names></name><name><surname>Kuźmiuk</surname><given-names>D</given-names></name><name><surname>Ładny</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Bacterial bloodstream infection in critically ill patients with COVID-19: a retrospective cohort study</article-title><source>Therapeutic Advances in Infectious Disease</source><volume>10</volume><elocation-id>20499361231207178</elocation-id><pub-id pub-id-type="doi">10.1177/20499361231207178</pub-id><pub-id pub-id-type="pmid">37869469</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binns</surname><given-names>E</given-names></name><name><surname>Koenraads</surname><given-names>M</given-names></name><name><surname>Hristeva</surname><given-names>L</given-names></name><name><surname>Flamant</surname><given-names>A</given-names></name><name><surname>Baier-Grabner</surname><given-names>S</given-names></name><name><surname>Loi</surname><given-names>M</given-names></name><name><surname>Lempainen</surname><given-names>J</given-names></name><name><surname>Osterheld</surname><given-names>E</given-names></name><name><surname>Ramly</surname><given-names>B</given-names></name><name><surname>Chakakala-Chaziya</surname><given-names>J</given-names></name><name><surname>Enaganthi</surname><given-names>N</given-names></name><name><surname>Simó Nebot</surname><given-names>S</given-names></name><name><surname>Buonsenso</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Influenza and respiratory syncytial virus during the COVID-19 pandemic: Time for a new paradigm?</article-title><source>Pediatric Pulmonology</source><volume>57</volume><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/ppul.25719</pub-id><pub-id pub-id-type="pmid">34644459</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Lopez-Collazo</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endotoxin tolerance: new mechanisms, molecules and clinical significance</article-title><source>Trends in Immunology</source><volume>30</volume><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.it.2009.07.009</pub-id><pub-id pub-id-type="pmid">19781994</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Microglia mediated neuroinflammation in neurodegenerative diseases: A review on the cell signaling pathways involved in microglial activation</article-title><source>Journal of Neuroimmunology</source><volume>383</volume><elocation-id>578180</elocation-id><pub-id pub-id-type="doi">10.1016/j.jneuroim.2023.578180</pub-id><pub-id pub-id-type="pmid">37672840</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjornevik</surname><given-names>K</given-names></name><name><surname>Cortese</surname><given-names>M</given-names></name><name><surname>Healy</surname><given-names>BC</given-names></name><name><surname>Kuhle</surname><given-names>J</given-names></name><name><surname>Mina</surname><given-names>MJ</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Niebuhr</surname><given-names>DW</given-names></name><name><surname>Scher</surname><given-names>AI</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis</article-title><source>Science</source><volume>375</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1126/science.abj8222</pub-id><pub-id pub-id-type="pmid">35025605</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>AB</given-names></name><name><surname>Wolfe</surname><given-names>MK</given-names></name><name><surname>White</surname><given-names>BJ</given-names></name><name><surname>Hughes</surname><given-names>B</given-names></name><name><surname>Duong</surname><given-names>D</given-names></name><name><surname>Bidwell</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>More than a Tripledemic: Influenza A virus, respiratory syncytial virus, SARS-CoV-2, and human metapneumovirus in wastewater during winter 2022-2023</article-title><source>Environmental Science &amp; Technology Letters</source><volume>10</volume><fpage>622</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1021/acs.estlett.3c00385</pub-id><pub-id pub-id-type="pmid">37577361</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boras</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name><name><surname>Anson</surname><given-names>BJ</given-names></name><name><surname>Arenson</surname><given-names>D</given-names></name><name><surname>Aschenbrenner</surname><given-names>L</given-names></name><name><surname>Bakowski</surname><given-names>MA</given-names></name><name><surname>Beutler</surname><given-names>N</given-names></name><name><surname>Binder</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Eng</surname><given-names>H</given-names></name><name><surname>Hammond</surname><given-names>H</given-names></name><name><surname>Hammond</surname><given-names>J</given-names></name><name><surname>Haupt</surname><given-names>RE</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Kadar</surname><given-names>EP</given-names></name><name><surname>Kania</surname><given-names>R</given-names></name><name><surname>Kimoto</surname><given-names>E</given-names></name><name><surname>Kirkpatrick</surname><given-names>MG</given-names></name><name><surname>Lanyon</surname><given-names>L</given-names></name><name><surname>Lendy</surname><given-names>EK</given-names></name><name><surname>Lillis</surname><given-names>JR</given-names></name><name><surname>Logue</surname><given-names>J</given-names></name><name><surname>Luthra</surname><given-names>SA</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Mason</surname><given-names>SW</given-names></name><name><surname>McGrath</surname><given-names>ME</given-names></name><name><surname>Noell</surname><given-names>S</given-names></name><name><surname>Obach</surname><given-names>RS</given-names></name><name><surname>O’ Brien</surname><given-names>MN</given-names></name><name><surname>O’Connor</surname><given-names>R</given-names></name><name><surname>Ogilvie</surname><given-names>K</given-names></name><name><surname>Owen</surname><given-names>D</given-names></name><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Reese</surname><given-names>MR</given-names></name><name><surname>Rogers</surname><given-names>TF</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Rossulek</surname><given-names>MI</given-names></name><name><surname>Sathish</surname><given-names>JG</given-names></name><name><surname>Shirai</surname><given-names>N</given-names></name><name><surname>Steppan</surname><given-names>C</given-names></name><name><surname>Ticehurst</surname><given-names>M</given-names></name><name><surname>Updyke</surname><given-names>LW</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>KM</given-names></name><name><surname>García-Sastre</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chatterjee</surname><given-names>AK</given-names></name><name><surname>Mesecar</surname><given-names>AD</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Allerton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>6055</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-26239-2</pub-id><pub-id pub-id-type="pmid">34663813</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>ÁH</given-names></name><name><surname>Silverberg</surname><given-names>MJ</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name><name><surname>Grulich</surname><given-names>AE</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Mitsuyasu</surname><given-names>R</given-names></name><name><surname>Tambussi</surname><given-names>G</given-names></name><name><surname>Sabin</surname><given-names>CA</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Lundgren</surname><given-names>JD</given-names></name><collab>INSIGHT SMART</collab><collab>ESPRIT</collab><collab>SILCAAT Study Groups</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers</article-title><source>AIDS</source><volume>27</volume><fpage>1433</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32835f6b0c</pub-id><pub-id pub-id-type="pmid">23945504</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>JT</given-names></name><name><surname>Leekha</surname><given-names>S</given-names></name><name><surname>Claeys</surname><given-names>K</given-names></name><name><surname>Seung</surname><given-names>H</given-names></name><name><surname>Tripoli</surname><given-names>M</given-names></name><name><surname>Amoroso</surname><given-names>A</given-names></name><name><surname>Heil</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019</article-title><source>Infection Control and Hospital Epidemiology</source><volume>42</volume><fpage>1115</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1017/ice.2020.1360</pub-id><pub-id pub-id-type="pmid">33298211</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulle</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>M-A</given-names></name><name><surname>Hussey</surname><given-names>H</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name><name><surname>Morden</surname><given-names>E</given-names></name><name><surname>Vundle</surname><given-names>Z</given-names></name><name><surname>Zweigenthal</surname><given-names>V</given-names></name><name><surname>Mahomed</surname><given-names>H</given-names></name><name><surname>Paleker</surname><given-names>M</given-names></name><name><surname>Pienaar</surname><given-names>D</given-names></name><name><surname>Tembo</surname><given-names>Y</given-names></name><name><surname>Lawrence</surname><given-names>C</given-names></name><name><surname>Isaacs</surname><given-names>W</given-names></name><name><surname>Mathema</surname><given-names>H</given-names></name><name><surname>Allen</surname><given-names>D</given-names></name><name><surname>Allie</surname><given-names>T</given-names></name><name><surname>Bam</surname><given-names>J-L</given-names></name><name><surname>Buddiga</surname><given-names>K</given-names></name><name><surname>Dane</surname><given-names>P</given-names></name><name><surname>Heekes</surname><given-names>A</given-names></name><name><surname>Matlapeng</surname><given-names>B</given-names></name><name><surname>Mutemaringa</surname><given-names>T</given-names></name><name><surname>Muzarabani</surname><given-names>L</given-names></name><name><surname>Phelanyane</surname><given-names>F</given-names></name><name><surname>Pienaar</surname><given-names>R</given-names></name><name><surname>Rode</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Tiffin</surname><given-names>N</given-names></name><name><surname>Zinyakatira</surname><given-names>N</given-names></name><name><surname>Cragg</surname><given-names>C</given-names></name><name><surname>Marais</surname><given-names>F</given-names></name><name><surname>Mudaly</surname><given-names>V</given-names></name><name><surname>Voget</surname><given-names>J</given-names></name><name><surname>Davids</surname><given-names>J</given-names></name><name><surname>Roodt</surname><given-names>F</given-names></name><name><surname>van Zyl Smit</surname><given-names>N</given-names></name><name><surname>Vermeulen</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>K</given-names></name><name><surname>Audley</surname><given-names>G</given-names></name><name><surname>Bateman</surname><given-names>K</given-names></name><name><surname>Beckwith</surname><given-names>P</given-names></name><name><surname>Bernon</surname><given-names>M</given-names></name><name><surname>Blom</surname><given-names>D</given-names></name><name><surname>Boloko</surname><given-names>L</given-names></name><name><surname>Botha</surname><given-names>J</given-names></name><name><surname>Boutall</surname><given-names>A</given-names></name><name><surname>Burmeister</surname><given-names>S</given-names></name><name><surname>Cairncross</surname><given-names>L</given-names></name><name><surname>Calligaro</surname><given-names>G</given-names></name><name><surname>Coccia</surname><given-names>C</given-names></name><name><surname>Corin</surname><given-names>C</given-names></name><name><surname>Daroowala</surname><given-names>R</given-names></name><name><surname>Dave</surname><given-names>JA</given-names></name><name><surname>De Bruyn</surname><given-names>E</given-names></name><name><surname>De Villiers</surname><given-names>M</given-names></name><name><surname>Deetlefs</surname><given-names>M</given-names></name><name><surname>Dlamini</surname><given-names>S</given-names></name><name><surname>Du Toit</surname><given-names>T</given-names></name><name><surname>Endres</surname><given-names>W</given-names></name><name><surname>Europa</surname><given-names>T</given-names></name><name><surname>Fieggan</surname><given-names>G</given-names></name><name><surname>Figaji</surname><given-names>A</given-names></name><name><surname>Frankenfeld</surname><given-names>P</given-names></name><name><surname>Gatley</surname><given-names>E</given-names></name><name><surname>Gina</surname><given-names>P</given-names></name><name><surname>Govender</surname><given-names>E</given-names></name><name><surname>Grobler</surname><given-names>R</given-names></name><name><surname>Gule</surname><given-names>MV</given-names></name><name><surname>Hanekom</surname><given-names>C</given-names></name><name><surname>Held</surname><given-names>M</given-names></name><name><surname>Heynes</surname><given-names>A</given-names></name><name><surname>Hlatswayo</surname><given-names>S</given-names></name><name><surname>Hodkinson</surname><given-names>B</given-names></name><name><surname>Holtzhausen</surname><given-names>J</given-names></name><name><surname>Hoosain</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>A</given-names></name><name><surname>Kahn</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>T</given-names></name><name><surname>Khamajeet</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Khwitshana</surname><given-names>A</given-names></name><name><surname>Knight</surname><given-names>L</given-names></name><name><surname>Kooverjee</surname><given-names>S</given-names></name><name><surname>Krogscheepers</surname><given-names>R</given-names></name><name><surname>Kruger</surname><given-names>JJ</given-names></name><name><surname>Kuhn</surname><given-names>S</given-names></name><name><surname>Laubscher</surname><given-names>K</given-names></name><name><surname>Lazarus</surname><given-names>J</given-names></name><name><surname>Le Roux</surname><given-names>J</given-names></name><name><surname>Lee Jones</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>D</given-names></name><name><surname>Maartens</surname><given-names>G</given-names></name><name><surname>Majola</surname><given-names>T</given-names></name><name><surname>Manganyi</surname><given-names>R</given-names></name><name><surname>Marais</surname><given-names>D</given-names></name><name><surname>Marais</surname><given-names>S</given-names></name><name><surname>Maritz</surname><given-names>F</given-names></name><name><surname>Maughan</surname><given-names>D</given-names></name><name><surname>Mazondwa</surname><given-names>S</given-names></name><name><surname>Mbanga</surname><given-names>L</given-names></name><name><surname>Mbatani</surname><given-names>N</given-names></name><name><surname>Mbena</surname><given-names>B</given-names></name><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Mendelson</surname><given-names>M</given-names></name><name><surname>Möller</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>A</given-names></name><name><surname>Ndebele</surname><given-names>B</given-names></name><name><surname>Nortje</surname><given-names>M</given-names></name><name><surname>Ntusi</surname><given-names>N</given-names></name><name><surname>Nyengane</surname><given-names>F</given-names></name><name><surname>Ofoegbu</surname><given-names>C</given-names></name><name><surname>Papavarnavas</surname><given-names>N</given-names></name><name><surname>Peter</surname><given-names>J</given-names></name><name><surname>Pickard</surname><given-names>H</given-names></name><name><surname>Pluke</surname><given-names>K</given-names></name><name><surname>Raubenheimer</surname><given-names>PJ</given-names></name><name><surname>Robertson</surname><given-names>G</given-names></name><name><surname>Rozmiarek</surname><given-names>J</given-names></name><name><surname>Sayed</surname><given-names>A</given-names></name><name><surname>Scriba</surname><given-names>M</given-names></name><name><surname>Sekhukhune</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Soldati</surname><given-names>V</given-names></name><name><surname>Stek</surname><given-names>C</given-names></name><name><surname>van den berg</surname><given-names>R</given-names></name><name><surname>van der Merwe</surname><given-names>LR</given-names></name><name><surname>Venter</surname><given-names>P</given-names></name><name><surname>Vermooten</surname><given-names>B</given-names></name><name><surname>Viljoen</surname><given-names>G</given-names></name><name><surname>Viranna</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>J</given-names></name><name><surname>Vundla</surname><given-names>N</given-names></name><name><surname>Wasserman</surname><given-names>S</given-names></name><name><surname>Zitha</surname><given-names>E</given-names></name><name><surname>Lomas-Marais</surname><given-names>V</given-names></name><name><surname>Lombard</surname><given-names>A</given-names></name><name><surname>Stuve</surname><given-names>K</given-names></name><name><surname>Viljoen</surname><given-names>W</given-names></name><name><surname>Basson</surname><given-names>DV</given-names></name><name><surname>Le Roux</surname><given-names>S</given-names></name><name><surname>Linden-Mars</surname><given-names>E</given-names></name><name><surname>Victor</surname><given-names>L</given-names></name><name><surname>Wates</surname><given-names>M</given-names></name><name><surname>Zwanepoel</surname><given-names>E</given-names></name><name><surname>Ebrahim</surname><given-names>N</given-names></name><name><surname>Lahri</surname><given-names>S</given-names></name><name><surname>Mnguni</surname><given-names>A</given-names></name><name><surname>Crede</surname><given-names>T</given-names></name><name><surname>de Man</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Hendrikse</surname><given-names>C</given-names></name><name><surname>Naude</surname><given-names>J</given-names></name><name><surname>Parak</surname><given-names>M</given-names></name><name><surname>Szymanski</surname><given-names>P</given-names></name><name><surname>Van Koningsbruggen</surname><given-names>C</given-names></name><name><surname>Abrahams</surname><given-names>R</given-names></name><name><surname>Allwood</surname><given-names>B</given-names></name><name><surname>Botha</surname><given-names>C</given-names></name><name><surname>Botha</surname><given-names>MH</given-names></name><name><surname>Broadhurst</surname><given-names>A</given-names></name><name><surname>Claasen</surname><given-names>D</given-names></name><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>Dawood</surname><given-names>R</given-names></name><name><surname>du Preez</surname><given-names>M</given-names></name><name><surname>Du Toit</surname><given-names>N</given-names></name><name><surname>Erasmus</surname><given-names>K</given-names></name><name><surname>Koegelenberg</surname><given-names>CFN</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Hugo</surname><given-names>S</given-names></name><name><surname>Jardine</surname><given-names>T</given-names></name><name><surname>Johannes</surname><given-names>C</given-names></name><name><surname>Karamchand</surname><given-names>S</given-names></name><name><surname>Lalla</surname><given-names>U</given-names></name><name><surname>Langenegger</surname><given-names>E</given-names></name><name><surname>Louw</surname><given-names>E</given-names></name><name><surname>Mashigo</surname><given-names>B</given-names></name><name><surname>Mhlana</surname><given-names>N</given-names></name><name><surname>Mnqwazi</surname><given-names>C</given-names></name><name><surname>Moodley</surname><given-names>A</given-names></name><name><surname>Moodley</surname><given-names>D</given-names></name><name><surname>Moolla</surname><given-names>S</given-names></name><name><surname>Mowlana</surname><given-names>A</given-names></name><name><surname>Nortje</surname><given-names>A</given-names></name><name><surname>Olivier</surname><given-names>E</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Paulsen</surname><given-names>C</given-names></name><name><surname>Prozesky</surname><given-names>H</given-names></name><name><surname>Rood</surname><given-names>J</given-names></name><name><surname>Sabela</surname><given-names>T</given-names></name><name><surname>Schrueder</surname><given-names>N</given-names></name><name><surname>Sithole</surname><given-names>N</given-names></name><name><surname>Sithole</surname><given-names>S</given-names></name><name><surname>Taljaard</surname><given-names>JJ</given-names></name><name><surname>Titus</surname><given-names>G</given-names></name><name><surname>Van Der Merwe</surname><given-names>T</given-names></name><name><surname>van Schalkwyk</surname><given-names>M</given-names></name><name><surname>Vazi</surname><given-names>L</given-names></name><name><surname>Viljoen</surname><given-names>AJ</given-names></name><name><surname>Yazied Chothia</surname><given-names>M</given-names></name><name><surname>Naidoo</surname><given-names>V</given-names></name><name><surname>Wallis</surname><given-names>LA</given-names></name><name><surname>Abbass</surname><given-names>M</given-names></name><name><surname>Arendse</surname><given-names>J</given-names></name><name><surname>Armien</surname><given-names>R</given-names></name><name><surname>Bailey</surname><given-names>R</given-names></name><name><surname>Bello</surname><given-names>M</given-names></name><name><surname>Carelse</surname><given-names>R</given-names></name><name><surname>Forgus</surname><given-names>S</given-names></name><name><surname>Kalawe</surname><given-names>N</given-names></name><name><surname>Kariem</surname><given-names>S</given-names></name><name><surname>Kotze</surname><given-names>M</given-names></name><name><surname>Lucas</surname><given-names>J</given-names></name><name><surname>McClaughlin</surname><given-names>J</given-names></name><name><surname>Murie</surname><given-names>K</given-names></name><name><surname>Najjaar</surname><given-names>L</given-names></name><name><surname>Petersen</surname><given-names>L</given-names></name><name><surname>Porter</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Stapar</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Aldum</surname><given-names>L</given-names></name><name><surname>Berkowitz</surname><given-names>N</given-names></name><name><surname>Girran</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Naidoo</surname><given-names>L</given-names></name><name><surname>Neumuller</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Begg</surname><given-names>K</given-names></name><name><surname>Boerlage</surname><given-names>L</given-names></name><name><surname>Cornell</surname><given-names>M</given-names></name><name><surname>de Waal</surname><given-names>R</given-names></name><name><surname>Dudley</surname><given-names>L</given-names></name><name><surname>English</surname><given-names>R</given-names></name><name><surname>Euvrard</surname><given-names>J</given-names></name><name><surname>Groenewald</surname><given-names>P</given-names></name><name><surname>Jacob</surname><given-names>N</given-names></name><name><surname>Jaspan</surname><given-names>H</given-names></name><name><surname>Kalk</surname><given-names>E</given-names></name><name><surname>Levitt</surname><given-names>N</given-names></name><name><surname>Malaba</surname><given-names>T</given-names></name><name><surname>Nyakato</surname><given-names>P</given-names></name><name><surname>Patten</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Shung King</surname><given-names>M</given-names></name><name><surname>Tsondai</surname><given-names>P</given-names></name><name><surname>Van Duuren</surname><given-names>J</given-names></name><name><surname>van Schaik</surname><given-names>N</given-names></name><name><surname>Blumberg</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Govender</surname><given-names>N</given-names></name><name><surname>Jassat</surname><given-names>W</given-names></name><name><surname>Kufa</surname><given-names>T</given-names></name><name><surname>McCarthy</surname><given-names>K</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Hsiao</surname><given-names>N</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Ambler</surname><given-names>J</given-names></name><name><surname>Ngwenya</surname><given-names>O</given-names></name><name><surname>Osei-Yeboah</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Kassanjee</surname><given-names>R</given-names></name><name><surname>Tamuhla</surname><given-names>T</given-names></name><collab>Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Risk Factors for Coronavirus Disease 2019 (COVID-19) death in a population cohort study from the western cape province, South Africa</article-title><source>Clinical Infectious Diseases</source><volume>73</volume><fpage>e2005</fpage><lpage>e2015</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1198</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budhiraja</surname><given-names>S</given-names></name><name><surname>Tarai</surname><given-names>B</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Aggarwal</surname><given-names>M</given-names></name><name><surname>Indrayan</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Mishra</surname><given-names>RS</given-names></name><name><surname>Bali</surname><given-names>S</given-names></name><name><surname>Mahajan</surname><given-names>M</given-names></name><name><surname>Kirtani</surname><given-names>J</given-names></name><name><surname>Tickoo</surname><given-names>R</given-names></name><name><surname>Soni</surname><given-names>P</given-names></name><name><surname>Nangia</surname><given-names>V</given-names></name><name><surname>Lall</surname><given-names>A</given-names></name><name><surname>Kishore</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>O</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Dewan</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Mehra</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Nakra</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>BD</given-names></name><name><surname>Pandey</surname><given-names>PK</given-names></name><name><surname>Singh</surname><given-names>YP</given-names></name><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Chhabra</surname><given-names>R</given-names></name><name><surname>Tuli</surname><given-names>P</given-names></name><name><surname>Boobna</surname><given-names>V</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Aneja</surname><given-names>P</given-names></name><name><surname>Dhall</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Chugh</surname><given-names>IM</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Mittal</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Jyoti</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Bhasin</surname><given-names>P</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Singhal</surname><given-names>RK</given-names></name><name><surname>Bhasin</surname><given-names>A</given-names></name><name><surname>Vardani</surname><given-names>A</given-names></name><name><surname>Pal</surname><given-names>V</given-names></name><name><surname>Pande</surname><given-names>DG</given-names></name><name><surname>Gulati</surname><given-names>T</given-names></name><name><surname>Nayar</surname><given-names>S</given-names></name><name><surname>Kalra</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>M</given-names></name><name><surname>Pande</surname><given-names>R</given-names></name><name><surname>Bag</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>J</given-names></name><name><surname>Handoo</surname><given-names>A</given-names></name><name><surname>Burman</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Choudhary</surname><given-names>PN</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Tayal</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Khanna</surname><given-names>A</given-names></name><name><surname>Kishore</surname><given-names>S</given-names></name><name><surname>Sahay</surname><given-names>S</given-names></name><name><surname>Dang</surname><given-names>R</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Sekhri</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>RC</given-names></name><name><surname>Agrawal</surname><given-names>MB</given-names></name><name><surname>Mathur</surname><given-names>M</given-names></name><name><surname>Banwari</surname><given-names>A</given-names></name><name><surname>Khetarpal</surname><given-names>S</given-names></name><name><surname>Pandove</surname><given-names>S</given-names></name><name><surname>Bhasin</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Midha</surname><given-names>D</given-names></name><name><surname>Bhutani</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Singla</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Sagar</surname><given-names>V</given-names></name><name><surname>Dixit</surname><given-names>A</given-names></name><name><surname>Bajpai</surname><given-names>R</given-names></name><name><surname>Chachra</surname><given-names>V</given-names></name><name><surname>Tyagi</surname><given-names>P</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Uniyal</surname><given-names>B</given-names></name><name><surname>Belwal</surname><given-names>S</given-names></name><name><surname>Aier</surname><given-names>I</given-names></name><name><surname>Singhal</surname><given-names>M</given-names></name><name><surname>Khaduri</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Secondary infections modify the overall course of hospitalized patients with COVID-19: a retrospective study from a network of hospitals across North India</article-title><source>IJID Regions</source><volume>3</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ijregi.2022.02.008</pub-id><pub-id pub-id-type="pmid">35720143</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buehler</surname><given-names>PK</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><name><surname>Hofmaenner</surname><given-names>DA</given-names></name><name><surname>Wendel Garcia</surname><given-names>PD</given-names></name><name><surname>Acevedo</surname><given-names>CT</given-names></name><name><surname>Gómez-Mejia</surname><given-names>A</given-names></name><name><surname>Mairpady Shambat</surname><given-names>S</given-names></name><name><surname>Andreoni</surname><given-names>F</given-names></name><name><surname>Maibach</surname><given-names>MA</given-names></name><name><surname>Bartussek</surname><given-names>J</given-names></name><name><surname>Hilty</surname><given-names>MP</given-names></name><name><surname>Frey</surname><given-names>PM</given-names></name><name><surname>Schuepbach</surname><given-names>RA</given-names></name><name><surname>Brugger</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients</article-title><source>Cell Reports. Medicine</source><volume>2</volume><elocation-id>100229</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100229</pub-id><pub-id pub-id-type="pmid">33748789</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>AA</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Chotani</surname><given-names>RA</given-names></name><name><surname>Shaikh</surname><given-names>OS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection</article-title><source>Liver International</source><volume>41</volume><fpage>1824</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1111/liv.14804</pub-id><pub-id pub-id-type="pmid">33534931</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calcagno</surname><given-names>A</given-names></name><name><surname>Ghisetti</surname><given-names>V</given-names></name><name><surname>Burdino</surname><given-names>E</given-names></name><name><surname>Trunfio</surname><given-names>M</given-names></name><name><surname>Allice</surname><given-names>T</given-names></name><name><surname>Boglione</surname><given-names>L</given-names></name><name><surname>Bonora</surname><given-names>S</given-names></name><name><surname>Di Perri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Co-infection with other respiratory pathogens in COVID-19 patients</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>297</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.08.012</pub-id><pub-id pub-id-type="pmid">32822882</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callard</surname><given-names>F</given-names></name><name><surname>Perego</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>How and why patients made long covid</article-title><source>Social Science &amp; Medicine</source><volume>268</volume><elocation-id>113426</elocation-id><pub-id pub-id-type="doi">10.1016/j.socscimed.2020.113426</pub-id><pub-id pub-id-type="pmid">33199035</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>SARS-CoV-2: The interplay between evolution and host immunity</article-title><source>Annual Review of Immunology</source><volume>43</volume><fpage>29</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-083122-043054</pub-id><pub-id pub-id-type="pmid">39705164</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanares-Zapatero</surname><given-names>D</given-names></name><name><surname>Chalon</surname><given-names>P</given-names></name><name><surname>Kohn</surname><given-names>L</given-names></name><name><surname>Dauvrin</surname><given-names>M</given-names></name><name><surname>Detollenaere</surname><given-names>J</given-names></name><name><surname>Maertens de Noordhout</surname><given-names>C</given-names></name><name><surname>Primus-de Jong</surname><given-names>C</given-names></name><name><surname>Cleemput</surname><given-names>I</given-names></name><name><surname>Van den Heede</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pathophysiology and mechanism of long COVID: a comprehensive review</article-title><source>Annals of Medicine</source><volume>54</volume><fpage>1473</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1080/07853890.2022.2076901</pub-id><pub-id pub-id-type="pmid">35594336</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceballos</surname><given-names>ME</given-names></name><name><surname>Nuñez</surname><given-names>C</given-names></name><name><surname>Uribe</surname><given-names>J</given-names></name><name><surname>Vera</surname><given-names>MM</given-names></name><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>García</surname><given-names>P</given-names></name><name><surname>Arriata</surname><given-names>G</given-names></name><name><surname>Gándara</surname><given-names>V</given-names></name><name><surname>Vargas</surname><given-names>C</given-names></name><name><surname>Dominguez</surname><given-names>A</given-names></name><name><surname>Cerón</surname><given-names>I</given-names></name><name><surname>Born</surname><given-names>P</given-names></name><name><surname>Espíndola</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Secondary respiratory early and late infections in mechanically ventilated patients with COVID-19</article-title><source>BMC Infectious Diseases</source><volume>22</volume><elocation-id>760</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-022-07743-2</pub-id><pub-id pub-id-type="pmid">36175841</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Secondary infection surveillance with metagenomic next-generation sequencing in COVID-19 patients: a cross-sectional study</article-title><source>Infection and Drug Resistance</source><volume>16</volume><fpage>6463</fpage><lpage>6472</lpage><pub-id pub-id-type="doi">10.2147/IDR.S424061</pub-id><pub-id pub-id-type="pmid">37795203</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Pekosz</surname><given-names>A</given-names></name><name><surname>Villano</surname><given-names>JS</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Kulaga</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Gurung</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>SE</given-names></name><name><surname>Witwer</surname><given-names>KW</given-names></name><name><surname>Mankowski</surname><given-names>JL</given-names></name><name><surname>Ramanathan</surname><given-names>M</given-names></name><name><surname>Rowan</surname><given-names>NR</given-names></name><name><surname>Lane</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants</article-title><source>The Journal of Clinical Investigation</source><volume>134</volume><elocation-id>e174439</elocation-id><pub-id pub-id-type="doi">10.1172/JCI174439</pub-id><pub-id pub-id-type="pmid">38483537</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>LSK</given-names></name><name><surname>Chau</surname><given-names>SKY</given-names></name><name><surname>Tso</surname><given-names>EYK</given-names></name><name><surname>Tsang</surname><given-names>SWC</given-names></name><name><surname>Li</surname><given-names>IYF</given-names></name><name><surname>Wong</surname><given-names>BKC</given-names></name><name><surname>Fung</surname><given-names>KSC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster</article-title><source>Therapeutic Advances in Infectious Disease</source><volume>7</volume><elocation-id>2049936120978095</elocation-id><pub-id pub-id-type="doi">10.1177/2049936120978095</pub-id><pub-id pub-id-type="pmid">33335724</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>CCL</given-names></name><name><surname>Goh</surname><given-names>D</given-names></name><name><surname>Lim</surname><given-names>X</given-names></name><name><surname>Tien</surname><given-names>TZ</given-names></name><name><surname>Lim</surname><given-names>JCT</given-names></name><name><surname>Lee</surname><given-names>JN</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Tay</surname><given-names>ZEA</given-names></name><name><surname>Wan</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>EX</given-names></name><name><surname>Nerurkar</surname><given-names>SN</given-names></name><name><surname>Loong</surname><given-names>S</given-names></name><name><surname>Cheow</surname><given-names>PC</given-names></name><name><surname>Chan</surname><given-names>CY</given-names></name><name><surname>Koh</surname><given-names>YX</given-names></name><name><surname>Tan</surname><given-names>TT</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>WMD</given-names></name><name><surname>Ng</surname><given-names>JL</given-names></name><name><surname>Low</surname><given-names>JG-H</given-names></name><name><surname>Yeong</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19</article-title><source>Gut</source><volume>71</volume><fpage>226</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-324280</pub-id><pub-id pub-id-type="pmid">34083386</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>EJ</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The effects of the COVID-19 pandemic on community respiratory virus activity</article-title><source>Nature Reviews. Microbiology</source><volume>21</volume><fpage>195</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00807-9</pub-id><pub-id pub-id-type="pmid">36253478</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Pierce</surname><given-names>J</given-names></name><name><surname>Franklin</surname><given-names>C</given-names></name><name><surname>Olson</surname><given-names>RM</given-names></name><name><surname>Morrison</surname><given-names>AR</given-names></name><name><surname>Amos-Landgraf</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Translating animal models of SARS-CoV-2 infection to vascular, neurological and gastrointestinal manifestations of COVID-19</article-title><source>Disease Models &amp; Mechanisms</source><volume>18</volume><elocation-id>dmm052086</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.052086</pub-id><pub-id pub-id-type="pmid">40195851</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Mathiasen</surname><given-names>VD</given-names></name><name><surname>Schön</surname><given-names>T</given-names></name><name><surname>Wejse</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The global prevalence of latent tuberculosis: a systematic review and meta-analysis</article-title><source>The European Respiratory Journal</source><volume>54</volume><elocation-id>1900655</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.00655-2019</pub-id><pub-id pub-id-type="pmid">31221810</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>W</given-names></name><name><surname>Stuart</surname><given-names>B</given-names></name><name><surname>AIhusein</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Manchundiya</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Antibiotic use and bacterial infection in COVID-19 patients in the second phase of the SARS-CoV-2 Pandemic: A scoping review</article-title><source>Antibiotics</source><volume>11</volume><elocation-id>991</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11080991</pub-id><pub-id pub-id-type="pmid">35892381</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Edwards</surname><given-names>DK</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Abiona</surname><given-names>OM</given-names></name><name><surname>Boyoglu-Barnum</surname><given-names>S</given-names></name><name><surname>Gillespie</surname><given-names>RA</given-names></name><name><surname>Himansu</surname><given-names>S</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Ziwawo</surname><given-names>CT</given-names></name><name><surname>DiPiazza</surname><given-names>AT</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Elbashir</surname><given-names>SM</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Woods</surname><given-names>A</given-names></name><name><surname>Fritch</surname><given-names>EJ</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Bock</surname><given-names>KW</given-names></name><name><surname>Minai</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>BM</given-names></name><name><surname>Hutchinson</surname><given-names>GB</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Bahl</surname><given-names>K</given-names></name><name><surname>Garcia-Dominguez</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Renzi</surname><given-names>I</given-names></name><name><surname>Kong</surname><given-names>WP</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Phung</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>LA</given-names></name><name><surname>Loomis</surname><given-names>RJ</given-names></name><name><surname>Altaras</surname><given-names>NE</given-names></name><name><surname>Narayanan</surname><given-names>E</given-names></name><name><surname>Metkar</surname><given-names>M</given-names></name><name><surname>Presnyak</surname><given-names>V</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>Stevens</surname><given-names>LJ</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Stewart-Jones</surname><given-names>G</given-names></name><name><surname>Bennett</surname><given-names>H</given-names></name><name><surname>Alvarado</surname><given-names>GS</given-names></name><name><surname>Nason</surname><given-names>MC</given-names></name><name><surname>Ruckwardt</surname><given-names>TJ</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Moore</surname><given-names>IN</given-names></name><name><surname>Morabito</surname><given-names>KM</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Carfi</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title><source>Nature</source><volume>586</volume><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmid">32756549</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortellini</surname><given-names>A</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Mukherjee</surname><given-names>U</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Sureda</surname><given-names>A</given-names></name><name><surname>Maluquer</surname><given-names>C</given-names></name><name><surname>Ferrante</surname><given-names>D</given-names></name><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Sharkey</surname><given-names>R</given-names></name><name><surname>Mirallas</surname><given-names>O</given-names></name><name><surname>Plaja</surname><given-names>A</given-names></name><name><surname>Cucurull</surname><given-names>M</given-names></name><name><surname>Mesia</surname><given-names>R</given-names></name><name><surname>Dalla Pria</surname><given-names>A</given-names></name><name><surname>Newsom-Davis</surname><given-names>T</given-names></name><name><surname>Van Hemelrijck</surname><given-names>M</given-names></name><name><surname>Sita-Lumsden</surname><given-names>A</given-names></name><name><surname>Apthorp</surname><given-names>E</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Di Fazio</surname><given-names>GR</given-names></name><name><surname>Tonini</surname><given-names>G</given-names></name><name><surname>Pantano</surname><given-names>F</given-names></name><name><surname>Bertuzzi</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Brunet</surname><given-names>J</given-names></name><name><surname>Lambertini</surname><given-names>M</given-names></name><name><surname>Pedrazzoli</surname><given-names>P</given-names></name><name><surname>Biello</surname><given-names>F</given-names></name><name><surname>D’Avanzo</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>AJX</given-names></name><name><surname>Shawe-Taylor</surname><given-names>M</given-names></name><name><surname>Rogers</surname><given-names>L</given-names></name><name><surname>Murphy</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>L</given-names></name><name><surname>Andaleeb</surname><given-names>R</given-names></name><name><surname>Khalique</surname><given-names>S</given-names></name><name><surname>Bawany</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Carmona-García</surname><given-names>MC</given-names></name><name><surname>Fort-Culillas</surname><given-names>R</given-names></name><name><surname>Liñan</surname><given-names>R</given-names></name><name><surname>Zoratto</surname><given-names>F</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Perachino</surname><given-names>M</given-names></name><name><surname>Doonga</surname><given-names>K</given-names></name><name><surname>Gaidano</surname><given-names>G</given-names></name><name><surname>Bruna</surname><given-names>R</given-names></name><name><surname>Patriarca</surname><given-names>A</given-names></name><name><surname>Martinez-Vila</surname><given-names>C</given-names></name><name><surname>Pérez Criado</surname><given-names>I</given-names></name><name><surname>Giusti</surname><given-names>R</given-names></name><name><surname>Mazzoni</surname><given-names>F</given-names></name><name><surname>Antonuzzo</surname><given-names>L</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Parisi</surname><given-names>A</given-names></name><name><surname>Queirolo</surname><given-names>P</given-names></name><name><surname>Aujayeb</surname><given-names>A</given-names></name><name><surname>Rimassa</surname><given-names>L</given-names></name><name><surname>Diamantis</surname><given-names>N</given-names></name><name><surname>Bertulli</surname><given-names>R</given-names></name><name><surname>Fulgenzi</surname><given-names>CAM</given-names></name><name><surname>D’Alessio</surname><given-names>A</given-names></name><name><surname>Ruiz-Camps</surname><given-names>I</given-names></name><name><surname>Saoudi-Gonzalez</surname><given-names>N</given-names></name><name><surname>Garcia Illescas</surname><given-names>D</given-names></name><name><surname>Medina</surname><given-names>I</given-names></name><name><surname>Fox</surname><given-names>L</given-names></name><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Aguilar-Company</surname><given-names>J</given-names></name><name><surname>Pinato</surname><given-names>DJ</given-names></name><collab>OnCovid study group</collab></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry</article-title><source>The Lancet. Oncology</source><volume>24</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(23)00056-6</pub-id><pub-id pub-id-type="pmid">36898391</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nature Reviews. Microbiology</source><volume>17</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Animal models of post-acute COVID-19 syndrome: a call for longitudinal animal studies</article-title><source>Frontiers in Immunology</source><volume>16</volume><elocation-id>1521029</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2025.1521029</pub-id><pub-id pub-id-type="pmid">40079013</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damania</surname><given-names>B</given-names></name><name><surname>Kenney</surname><given-names>SC</given-names></name><name><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Epstein-Barr virus: Biology and clinical disease</article-title><source>Cell</source><volume>185</volume><fpage>3652</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.08.026</pub-id><pub-id pub-id-type="pmid">36113467</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>HE</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Vogel</surname><given-names>JM</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nature Reviews. Microbiology</source><volume>21</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deinhardt-Emmer</surname><given-names>S</given-names></name><name><surname>Wittschieber</surname><given-names>D</given-names></name><name><surname>Sanft</surname><given-names>J</given-names></name><name><surname>Kleemann</surname><given-names>S</given-names></name><name><surname>Elschner</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>KF</given-names></name><name><surname>Vau</surname><given-names>V</given-names></name><name><surname>Häring</surname><given-names>C</given-names></name><name><surname>Rödel</surname><given-names>J</given-names></name><name><surname>Henke</surname><given-names>A</given-names></name><name><surname>Ehrhardt</surname><given-names>C</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Philipp</surname><given-names>M</given-names></name><name><surname>Gaßler</surname><given-names>N</given-names></name><name><surname>Nietzsche</surname><given-names>S</given-names></name><name><surname>Löffler</surname><given-names>B</given-names></name><name><surname>Mall</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage</article-title><source>eLife</source><volume>10</volume><elocation-id>e60361</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60361</pub-id><pub-id pub-id-type="pmid">33781385</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Michele</surname><given-names>M</given-names></name><name><surname>d’Amati</surname><given-names>G</given-names></name><name><surname>Leopizzi</surname><given-names>M</given-names></name><name><surname>Iacobucci</surname><given-names>M</given-names></name><name><surname>Berto</surname><given-names>I</given-names></name><name><surname>Lorenzano</surname><given-names>S</given-names></name><name><surname>Mazzuti</surname><given-names>L</given-names></name><name><surname>Turriziani</surname><given-names>O</given-names></name><name><surname>Schiavo</surname><given-names>OG</given-names></name><name><surname>Toni</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients</article-title><source>Journal of Hematology &amp; Oncology</source><volume>15</volume><elocation-id>e01329-w</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-022-01329-w</pub-id><pub-id pub-id-type="pmid">35974404</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Nainu</surname><given-names>F</given-names></name><name><surname>Frediansyah</surname><given-names>A</given-names></name><name><surname>Yatoo</surname><given-names>MI</given-names></name><name><surname>Mohapatra</surname><given-names>RK</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Islam</surname><given-names>MR</given-names></name><name><surname>Mamada</surname><given-names>SS</given-names></name><name><surname>Kusuma</surname><given-names>HI</given-names></name><name><surname>Rabaan</surname><given-names>AA</given-names></name><name><surname>Alhumaid</surname><given-names>S</given-names></name><name><surname>Mutair</surname><given-names>AA</given-names></name><name><surname>Iqhrammullah</surname><given-names>M</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Mohaini</surname><given-names>MA</given-names></name><name><surname>Alsalman</surname><given-names>AJ</given-names></name><name><surname>Tuli</surname><given-names>HS</given-names></name><name><surname>Chakraborty</surname><given-names>C</given-names></name><name><surname>Harapan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies</article-title><source>Journal of Infection and Public Health</source><volume>16</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2022.11.024</pub-id><pub-id pub-id-type="pmid">36446204</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Perumal</surname><given-names>T</given-names></name><name><surname>Moultrie</surname><given-names>H</given-names></name><name><surname>Perumal</surname><given-names>R</given-names></name><name><surname>Esmail</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>AJ</given-names></name><name><surname>Udwadia</surname><given-names>Z</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Peter</surname><given-names>J</given-names></name><name><surname>Pooran</surname><given-names>A</given-names></name><name><surname>von Delft</surname><given-names>A</given-names></name><name><surname>von Delft</surname><given-names>D</given-names></name><name><surname>Martinson</surname><given-names>N</given-names></name><name><surname>Loveday</surname><given-names>M</given-names></name><name><surname>Charalambous</surname><given-names>S</given-names></name><name><surname>Kachingwe</surname><given-names>E</given-names></name><name><surname>Jassat</surname><given-names>W</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Tempia</surname><given-names>S</given-names></name><name><surname>Fennelly</surname><given-names>K</given-names></name><name><surname>Pai</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions</article-title><source>The Lancet. Respiratory Medicine</source><volume>10</volume><fpage>603</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(22)00092-3</pub-id><pub-id pub-id-type="pmid">35338841</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Dang</surname><given-names>H</given-names></name><name><surname>Fritch</surname><given-names>EJ</given-names></name><name><surname>Gully</surname><given-names>KL</given-names></name><name><surname>De la Cruz</surname><given-names>G</given-names></name><name><surname>Evangelista</surname><given-names>MD</given-names></name><name><surname>Asakura</surname><given-names>T</given-names></name><name><surname>Gilmore</surname><given-names>RC</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Everman</surname><given-names>JL</given-names></name><name><surname>Sajuthi</surname><given-names>SP</given-names></name><name><surname>Zweigart</surname><given-names>MR</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>McBride</surname><given-names>J</given-names></name><name><surname>Cooley</surname><given-names>MR</given-names></name><name><surname>Hines</surname><given-names>JB</given-names></name><name><surname>Love</surname><given-names>MK</given-names></name><name><surname>Groshong</surname><given-names>SD</given-names></name><name><surname>VanSchoiack</surname><given-names>A</given-names></name><name><surname>Phelan</surname><given-names>SJ</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Hether</surname><given-names>T</given-names></name><name><surname>Leon</surname><given-names>M</given-names></name><name><surname>Zumwalt</surname><given-names>RE</given-names></name><name><surname>Barton</surname><given-names>LM</given-names></name><name><surname>Duval</surname><given-names>EJ</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Stroberg</surname><given-names>E</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Thorne</surname><given-names>LB</given-names></name><name><surname>Sakthivel</surname><given-names>MK</given-names></name><name><surname>Lee</surname><given-names>YZ</given-names></name><name><surname>Hagood</surname><given-names>JS</given-names></name><name><surname>Mock</surname><given-names>JR</given-names></name><name><surname>Seibold</surname><given-names>MA</given-names></name><name><surname>O’Neal</surname><given-names>WK</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabo5070</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abo5070</pub-id><pub-id pub-id-type="pmid">35857635</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domovitz</surname><given-names>T</given-names></name><name><surname>Ayoub</surname><given-names>S</given-names></name><name><surname>Werbner</surname><given-names>M</given-names></name><name><surname>Alter</surname><given-names>J</given-names></name><name><surname>Izhaki Tavor</surname><given-names>L</given-names></name><name><surname>Yahalom-Ronen</surname><given-names>Y</given-names></name><name><surname>Tikhonov</surname><given-names>E</given-names></name><name><surname>Meirson</surname><given-names>T</given-names></name><name><surname>Maman</surname><given-names>Y</given-names></name><name><surname>Paran</surname><given-names>N</given-names></name><name><surname>Israely</surname><given-names>T</given-names></name><name><surname>Dessau</surname><given-names>M</given-names></name><name><surname>Gal-Tanamy</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HCV infection increases the expression of ACE2 receptor, leading to enhanced entry of both HCV and SARS-CoV-2 into Hepatocytes and a coinfection state</article-title><source>Microbiology Spectrum</source><volume>10</volume><elocation-id>e0115022</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.01150-22</pub-id><pub-id pub-id-type="pmid">36314945</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doroshenko</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>MacDonald</surname><given-names>C</given-names></name><name><surname>Zelyas</surname><given-names>N</given-names></name><name><surname>Asadi</surname><given-names>L</given-names></name><name><surname>Kanji</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Decline of influenza and respiratory viruses with COVID-19 public health measures: Alberta, Canada</article-title><source>Mayo Clinic Proceedings</source><volume>96</volume><fpage>3042</fpage><lpage>3052</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2021.09.004</pub-id><pub-id pub-id-type="pmid">34863395</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drago</surname><given-names>F</given-names></name><name><surname>Ciccarese</surname><given-names>G</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19</article-title><source>Journal of Medical Virology</source><volume>93</volume><fpage>1850</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1002/jmv.26549</pub-id><pub-id pub-id-type="pmid">32970319</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>R</given-names></name><name><surname>Aguiar</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>M</given-names></name><name><surname>Furtado</surname><given-names>I</given-names></name><name><surname>Tiberi</surname><given-names>S</given-names></name><name><surname>Lönnroth</surname><given-names>K</given-names></name><name><surname>Migliori</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Different disease, same challenges: Social determinants of tuberculosis and COVID-19</article-title><source>Pulmonology</source><volume>27</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.pulmoe.2021.02.002</pub-id><pub-id pub-id-type="pmid">33648891</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunmire</surname><given-names>SK</given-names></name><name><surname>Verghese</surname><given-names>PS</given-names></name><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2018">2018</year><article-title>Primary Epstein-Barr virus infection</article-title><source>Journal of Clinical Virology</source><volume>102</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2018.03.001</pub-id><pub-id pub-id-type="pmid">29525635</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Win</surname><given-names>S</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Arechiga</surname><given-names>VM</given-names></name><name><surname>Zepeda</surname><given-names>V</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Arreguin</surname><given-names>MI</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Kornak</surname><given-names>J</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e157053</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.157053</pub-id><pub-id pub-id-type="pmid">35389890</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinmann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Analysis reveals global post-covid surge in infectious diseases</article-title><source>BMJ</source><volume>385</volume><elocation-id>q1348</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.q1348</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The role of co-infections and secondary infections in patients with COVID-19</article-title><source>Pneumonia</source><volume>13</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/s41479-021-00083-w</pub-id><pub-id pub-id-type="pmid">33894790</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa Castro</surname><given-names>CE</given-names></name><name><surname>Hersh</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>1409. Pulmonary Non-tuberculous <italic>Mycobacterium</italic> Infection (PNTMI) and COVID-19: Characterization of the National COVID Collaborative Cohort (N3C)</article-title><source>Open Forum Infectious Diseases</source><volume>8</volume><fpage>S788</fpage><lpage>S789</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofab466.1601</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Immune cell interactions in tuberculosis</article-title><source>Cell</source><volume>185</volume><fpage>4682</fpage><lpage>4702</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.10.025</pub-id><pub-id pub-id-type="pmid">36493751</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>JD</given-names></name><name><surname>Zavaleta-Cortijo</surname><given-names>C</given-names></name><name><surname>Ainembabazi</surname><given-names>T</given-names></name><name><surname>Anza-Ramirez</surname><given-names>C</given-names></name><name><surname>Arotoma-Rojas</surname><given-names>I</given-names></name><name><surname>Bezerra</surname><given-names>J</given-names></name><name><surname>Chicmana-Zapata</surname><given-names>V</given-names></name><name><surname>Galappaththi</surname><given-names>EK</given-names></name><name><surname>Hangula</surname><given-names>M</given-names></name><name><surname>Kazaana</surname><given-names>C</given-names></name><name><surname>Lwasa</surname><given-names>S</given-names></name><name><surname>Namanya</surname><given-names>D</given-names></name><name><surname>Nkwinti</surname><given-names>N</given-names></name><name><surname>Nuwagira</surname><given-names>R</given-names></name><name><surname>Okware</surname><given-names>S</given-names></name><name><surname>Osipova</surname><given-names>M</given-names></name><name><surname>Pickering</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>C</given-names></name><name><surname>Berrang-Ford</surname><given-names>L</given-names></name><name><surname>Hyams</surname><given-names>K</given-names></name><name><surname>Miranda</surname><given-names>JJ</given-names></name><name><surname>Naylor</surname><given-names>A</given-names></name><name><surname>New</surname><given-names>M</given-names></name><name><surname>van Bavel</surname><given-names>B</given-names></name><collab>COVID Observatory</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Interactions between climate and COVID-19</article-title><source>The Lancet. Planetary Health</source><volume>6</volume><fpage>e825</fpage><lpage>e833</lpage><pub-id pub-id-type="doi">10.1016/S2542-5196(22)00174-7</pub-id><pub-id pub-id-type="pmid">36208645</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>R</given-names></name><name><surname>Orta-Resendiz</surname><given-names>A</given-names></name><name><surname>Mazein</surname><given-names>A</given-names></name><name><surname>Dockrell</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines</article-title><source>Trends in Molecular Medicine</source><volume>29</volume><fpage>255</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2023.01.003</pub-id><pub-id pub-id-type="pmid">36764906</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>A</given-names></name><name><surname>DeGeorge</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reactivation of latent tuberculosis in a COVID-19 patient on corticosteroid treatment</article-title><source>BMJ Case Reports</source><volume>15</volume><elocation-id>e247562</elocation-id><pub-id pub-id-type="doi">10.1136/bcr-2021-247562</pub-id><pub-id pub-id-type="pmid">35545310</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>D</given-names></name><name><surname>Jojic</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Shen-Orr</surname><given-names>SS</given-names></name><name><surname>Angel</surname><given-names>CJL</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Kidd</surname><given-names>BA</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cytomegalovirus infection enhances the immune response to influenza</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>281ra43</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa2293</pub-id><pub-id pub-id-type="pmid">25834109</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannakopoulos</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Pak</surname><given-names>J</given-names></name><name><surname>Tallquist</surname><given-names>MD</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Post-COVID pulmonary injury in K18-hACE2 mice shows persistent neutrophils and neutrophil extracellular trap formation</article-title><source>Immunity, Inflammation and Disease</source><volume>12</volume><elocation-id>e1343</elocation-id><pub-id pub-id-type="doi">10.1002/iid3.1343</pub-id><pub-id pub-id-type="pmid">39092750</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giron</surname><given-names>LB</given-names></name><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Kenny</surname><given-names>G</given-names></name><name><surname>Zilberstein</surname><given-names>NF</given-names></name><name><surname>Koshy</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>KY</given-names></name><name><surname>Rasmussen</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>GE</given-names></name><name><surname>Bishehsari</surname><given-names>F</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Moy</surname><given-names>JN</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldman</surname><given-names>AR</given-names></name><name><surname>Tang</surname><given-names>HY</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Wasse</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name><name><surname>Landay</surname><given-names>A</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Abdel-Mohsen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e160989</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.160989</pub-id><pub-id pub-id-type="pmid">35727635</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>JE</given-names></name><name><surname>Okyay</surname><given-names>RA</given-names></name><name><surname>Licht</surname><given-names>WE</given-names></name><name><surname>Hurley</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation</article-title><source>Pathogens</source><volume>10</volume><elocation-id>763</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10060763</pub-id><pub-id pub-id-type="pmid">34204243</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Cattaneo</surname><given-names>E</given-names></name><name><surname>Florio</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Secondary infections in critically ill patients with COVID-19</article-title><source>Critical Care</source><volume>25</volume><elocation-id>317</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-021-03672-9</pub-id><pub-id pub-id-type="pmid">34461962</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Scaravilli</surname><given-names>V</given-names></name><name><surname>Mangioni</surname><given-names>D</given-names></name><name><surname>Scudeller</surname><given-names>L</given-names></name><name><surname>Alagna</surname><given-names>L</given-names></name><name><surname>Bartoletti</surname><given-names>M</given-names></name><name><surname>Bellani</surname><given-names>G</given-names></name><name><surname>Biagioni</surname><given-names>E</given-names></name><name><surname>Bonfanti</surname><given-names>P</given-names></name><name><surname>Bottino</surname><given-names>N</given-names></name><name><surname>Coloretti</surname><given-names>I</given-names></name><name><surname>Cutuli</surname><given-names>SL</given-names></name><name><surname>De Pascale</surname><given-names>G</given-names></name><name><surname>Ferlicca</surname><given-names>D</given-names></name><name><surname>Fior</surname><given-names>G</given-names></name><name><surname>Forastieri</surname><given-names>A</given-names></name><name><surname>Franzetti</surname><given-names>M</given-names></name><name><surname>Greco</surname><given-names>M</given-names></name><name><surname>Guzzardella</surname><given-names>A</given-names></name><name><surname>Linguadoca</surname><given-names>S</given-names></name><name><surname>Meschiari</surname><given-names>M</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Monti</surname><given-names>G</given-names></name><name><surname>Morelli</surname><given-names>P</given-names></name><name><surname>Muscatello</surname><given-names>A</given-names></name><name><surname>Redaelli</surname><given-names>S</given-names></name><name><surname>Stefanini</surname><given-names>F</given-names></name><name><surname>Tonetti</surname><given-names>T</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Foti</surname><given-names>G</given-names></name><name><surname>Fumagalli</surname><given-names>R</given-names></name><name><surname>Girardis</surname><given-names>M</given-names></name><name><surname>Ranieri</surname><given-names>M</given-names></name><name><surname>Viale</surname><given-names>P</given-names></name><name><surname>Raviglione</surname><given-names>M</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Gori</surname><given-names>A</given-names></name><name><surname>Bandera</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Hospital-acquired infections in critically Ill patients with COVID-19</article-title><source>Chest</source><volume>160</volume><fpage>454</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2021.04.002</pub-id><pub-id pub-id-type="pmid">33857475</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grobbelaar</surname><given-names>LM</given-names></name><name><surname>Venter</surname><given-names>C</given-names></name><name><surname>Vlok</surname><given-names>M</given-names></name><name><surname>Ngoepe</surname><given-names>M</given-names></name><name><surname>Laubscher</surname><given-names>GJ</given-names></name><name><surname>Lourens</surname><given-names>PJ</given-names></name><name><surname>Steenkamp</surname><given-names>J</given-names></name><name><surname>Kell</surname><given-names>DB</given-names></name><name><surname>Pretorius</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19</article-title><source>Bioscience Reports</source><volume>41</volume><elocation-id>BSR20210611</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20210611</pub-id><pub-id pub-id-type="pmid">34328172</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Group</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tuberculosis and COVID-19 co-infection: description of the global cohort</article-title><source>European Respiratory Journal</source><volume>59</volume><elocation-id>2102538</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.02538-2021</pub-id><pub-id pub-id-type="pmid">34764184</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guebre-Xabier</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Tian</surname><given-names>JH</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Maciejewski</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>K</given-names></name><name><surname>Portnoff</surname><given-names>AD</given-names></name><name><surname>Massare</surname><given-names>MJ</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Piedra</surname><given-names>PA</given-names></name><name><surname>Ellingsworth</surname><given-names>L</given-names></name><name><surname>Glenn</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge</article-title><source>Vaccine</source><volume>38</volume><fpage>7892</fpage><lpage>7896</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.10.064</pub-id><pub-id pub-id-type="pmid">33139139</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>Ge</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels</article-title><source>Oral Oncology</source><volume>93</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.04.024</pub-id><pub-id pub-id-type="pmid">31109701</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The microbiome in post-acute infection syndrome (PAIS)</article-title><source>Computational and Structural Biotechnology Journal</source><volume>21</volume><fpage>3904</fpage><lpage>3911</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.08.002</pub-id><pub-id pub-id-type="pmid">37602232</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Perils at mucosal front lines for HIV and SIV and their hosts</article-title><source>Nature Reviews. Immunology</source><volume>5</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1038/nri1706</pub-id><pub-id pub-id-type="pmid">16200081</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>MLC</given-names></name><name><surname>Lely</surname><given-names>AT</given-names></name><name><surname>Navis</surname><given-names>GJ</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis</article-title><source>The Journal of Pathology</source><volume>203</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/path.1570</pub-id><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Baum</surname><given-names>A</given-names></name><name><surname>Pascal</surname><given-names>KE</given-names></name><name><surname>Russo</surname><given-names>V</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Wloga</surname><given-names>E</given-names></name><name><surname>Fulton</surname><given-names>BO</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Koon</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>KM</given-names></name><name><surname>Hermann</surname><given-names>A</given-names></name><name><surname>Ullman</surname><given-names>E</given-names></name><name><surname>Cruz</surname><given-names>J</given-names></name><name><surname>Rafique</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Fairhurst</surname><given-names>J</given-names></name><name><surname>Libertiny</surname><given-names>C</given-names></name><name><surname>Malbec</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>Welsh</surname><given-names>R</given-names></name><name><surname>Farr</surname><given-names>G</given-names></name><name><surname>Pennington</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Watty</surname><given-names>A</given-names></name><name><surname>Bouffard</surname><given-names>P</given-names></name><name><surname>Babb</surname><given-names>R</given-names></name><name><surname>Levenkova</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Romero Hernandez</surname><given-names>A</given-names></name><name><surname>Saotome</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Franklin</surname><given-names>M</given-names></name><name><surname>Sivapalasingam</surname><given-names>S</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Logue</surname><given-names>J</given-names></name><name><surname>Haupt</surname><given-names>R</given-names></name><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Olson</surname><given-names>W</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Stahl</surname><given-names>N</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Kyratsous</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title><source>Science</source><volume>369</volume><fpage>1010</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1126/science.abd0827</pub-id><pub-id pub-id-type="pmid">32540901</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Pujato</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Maddox</surname><given-names>A</given-names></name><name><surname>Forney</surname><given-names>C</given-names></name><name><surname>Magnusen</surname><given-names>AF</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Yukawa</surname><given-names>M</given-names></name><name><surname>Barski</surname><given-names>A</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Kaufman</surname><given-names>KM</given-names></name><name><surname>Kottyan</surname><given-names>LC</given-names></name><name><surname>Weirauch</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity</article-title><source>Nature Genetics</source><volume>50</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0102-3</pub-id><pub-id pub-id-type="pmid">29662164</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harne</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Abdelal</surname><given-names>HFM</given-names></name><name><surname>Baldwin</surname><given-names>SL</given-names></name><name><surname>Coler</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 infection and immune responses</article-title><source>AIMS Microbiology</source><volume>9</volume><fpage>245</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2023015</pub-id><pub-id pub-id-type="pmid">37091818</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Chandrashekar</surname><given-names>A</given-names></name><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Wegmann</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Mercado</surname><given-names>NB</given-names></name><name><surname>McMahan</surname><given-names>K</given-names></name><name><surname>Martinot</surname><given-names>AJ</given-names></name><name><surname>Piedra-Mora</surname><given-names>C</given-names></name><name><surname>Beecy</surname><given-names>S</given-names></name><name><surname>Ducat</surname><given-names>S</given-names></name><name><surname>Chamanza</surname><given-names>R</given-names></name><name><surname>Huber</surname><given-names>SR</given-names></name><name><surname>van Heerden</surname><given-names>M</given-names></name><name><surname>van der Fits</surname><given-names>L</given-names></name><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Lifton</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Nampanya</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Peter</surname><given-names>L</given-names></name><name><surname>Tostanoski</surname><given-names>LH</given-names></name><name><surname>Pessaint</surname><given-names>L</given-names></name><name><surname>Van Ry</surname><given-names>A</given-names></name><name><surname>Finneyfrock</surname><given-names>B</given-names></name><name><surname>Velasco</surname><given-names>J</given-names></name><name><surname>Teow</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Schuitemaker</surname><given-names>H</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques</article-title><source>Cell</source><volume>184</volume><fpage>3467</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.05.040</pub-id><pub-id pub-id-type="pmid">34133941</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedberg</surname><given-names>P</given-names></name><name><surname>Ternhag</surname><given-names>A</given-names></name><name><surname>Giske</surname><given-names>CG</given-names></name><name><surname>Strålin</surname><given-names>K</given-names></name><name><surname>Özenci</surname><given-names>V</given-names></name><name><surname>Johansson</surname><given-names>N</given-names></name><name><surname>Spindler</surname><given-names>C</given-names></name><name><surname>Hedlund</surname><given-names>J</given-names></name><name><surname>Mårtensson</surname><given-names>J</given-names></name><name><surname>Nauclér</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ventilator-associated lower respiratory tract bacterial infections in COVID-19 compared with non-COVID-19 patients</article-title><source>Critical Care Medicine</source><volume>50</volume><fpage>825</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000005462</pub-id><pub-id pub-id-type="pmid">35148524</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JD</given-names></name><name><surname>Atyeo</surname><given-names>C</given-names></name><name><surname>Zur</surname><given-names>Y</given-names></name><name><surname>Cook</surname><given-names>CE</given-names></name><name><surname>Patel</surname><given-names>NJ</given-names></name><name><surname>Vanni</surname><given-names>KM</given-names></name><name><surname>Kowalski</surname><given-names>EN</given-names></name><name><surname>Qian</surname><given-names>G</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Shadick</surname><given-names>NA</given-names></name><name><surname>Rao</surname><given-names>DA</given-names></name><name><surname>Kellman</surname><given-names>B</given-names></name><name><surname>Mann</surname><given-names>CJ</given-names></name><name><surname>Lauffenburger</surname><given-names>D</given-names></name><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Sparks</surname><given-names>JA</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases</article-title><source>Science Translational Medicine</source><volume>15</volume><elocation-id>eadf6598</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.adf6598</pub-id><pub-id pub-id-type="pmid">37672567</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Orton</surname><given-names>R</given-names></name><name><surname>Tayler</surname><given-names>R</given-names></name><name><surname>Asamaphan</surname><given-names>P</given-names></name><name><surname>Herder</surname><given-names>V</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Smollett</surname><given-names>K</given-names></name><name><surname>Manali</surname><given-names>M</given-names></name><name><surname>Allan</surname><given-names>J</given-names></name><name><surname>Rawlik</surname><given-names>K</given-names></name><name><surname>McDonald</surname><given-names>SE</given-names></name><name><surname>Vink</surname><given-names>E</given-names></name><name><surname>Pollock</surname><given-names>L</given-names></name><name><surname>Gannon</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>C</given-names></name><name><surname>McMenamin</surname><given-names>J</given-names></name><name><surname>Roy</surname><given-names>K</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Divala</surname><given-names>T</given-names></name><name><surname>Holden</surname><given-names>MTG</given-names></name><name><surname>Lockhart</surname><given-names>M</given-names></name><name><surname>Yirrell</surname><given-names>D</given-names></name><name><surname>Currie</surname><given-names>S</given-names></name><name><surname>O’Leary</surname><given-names>M</given-names></name><name><surname>Henderson</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>SJ</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Gunson</surname><given-names>R</given-names></name><name><surname>MacLean</surname><given-names>A</given-names></name><name><surname>McInnes</surname><given-names>N</given-names></name><name><surname>Bradley-Stewart</surname><given-names>A</given-names></name><name><surname>Battle</surname><given-names>R</given-names></name><name><surname>Hollenbach</surname><given-names>JA</given-names></name><name><surname>Henderson</surname><given-names>P</given-names></name><name><surname>Odam</surname><given-names>M</given-names></name><name><surname>Chikowore</surname><given-names>P</given-names></name><name><surname>Oosthuyzen</surname><given-names>W</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>MS</given-names></name><name><surname>Estrada-Rivadeneyra</surname><given-names>D</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Avramidis</surname><given-names>N</given-names></name><name><surname>Pairo-Castineira</surname><given-names>E</given-names></name><name><surname>Vitart</surname><given-names>V</given-names></name><name><surname>Wilkie</surname><given-names>C</given-names></name><name><surname>Palmarini</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>da Silva Filipe</surname><given-names>A</given-names></name><name><surname>Willett</surname><given-names>BJ</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><collab>DIAMONDS Consortium</collab><collab>ISARIC4C Investigators</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Adeno-associated virus 2 infection in children with non-A-E hepatitis</article-title><source>Nature</source><volume>617</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05948-2</pub-id><pub-id pub-id-type="pmid">36996873</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoenigl</surname><given-names>M</given-names></name><name><surname>Seidel</surname><given-names>D</given-names></name><name><surname>Carvalho</surname><given-names>A</given-names></name><name><surname>Rudramurthy</surname><given-names>SM</given-names></name><name><surname>Arastehfar</surname><given-names>A</given-names></name><name><surname>Gangneux</surname><given-names>J-P</given-names></name><name><surname>Nasir</surname><given-names>N</given-names></name><name><surname>Bonifaz</surname><given-names>A</given-names></name><name><surname>Araiza</surname><given-names>J</given-names></name><name><surname>Klimko</surname><given-names>N</given-names></name><name><surname>Serris</surname><given-names>A</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Perfect</surname><given-names>JR</given-names></name><name><surname>White</surname><given-names>PL</given-names></name><name><surname>Chakrabarti</surname><given-names>A</given-names></name><collab>ECMM and ISHAM collaborators</collab></person-group><year iso-8601-date="2022">2022</year><article-title>The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries</article-title><source>The Lancet. Microbe</source><volume>3</volume><fpage>e543</fpage><lpage>e552</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00237-8</pub-id><pub-id pub-id-type="pmid">35098179</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Okuda</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>CE</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Asakura</surname><given-names>T</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>RE</given-names></name><name><surname>Yount</surname><given-names>BL</given-names></name><name><surname>Mascenik</surname><given-names>TM</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Olivier</surname><given-names>KN</given-names></name><name><surname>Ghio</surname><given-names>A</given-names></name><name><surname>Tse</surname><given-names>LV</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>H</given-names></name><name><surname>Gilmore</surname><given-names>R</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Fulcher</surname><given-names>ML</given-names></name><name><surname>Livraghi-Butrico</surname><given-names>A</given-names></name><name><surname>Nicely</surname><given-names>NI</given-names></name><name><surname>Cameron</surname><given-names>M</given-names></name><name><surname>Cameron</surname><given-names>C</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name><name><surname>Markmann</surname><given-names>A</given-names></name><name><surname>Bartelt</surname><given-names>L</given-names></name><name><surname>Zumwalt</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Salvatore</surname><given-names>SP</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Sontake</surname><given-names>V</given-names></name><name><surname>Kimple</surname><given-names>A</given-names></name><name><surname>Jaspers</surname><given-names>I</given-names></name><name><surname>O’Neal</surname><given-names>WK</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract</article-title><source>Cell</source><volume>182</volume><fpage>429</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.042</pub-id><pub-id pub-id-type="pmid">32526206</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houen</surname><given-names>G</given-names></name><name><surname>Trier</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epstein-Barr virus and systemic autoimmune diseases</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>587380</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.587078</pub-id><pub-id pub-id-type="pmid">33391262</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huot</surname><given-names>N</given-names></name><name><surname>Planchais</surname><given-names>C</given-names></name><name><surname>Rosenbaum</surname><given-names>P</given-names></name><name><surname>Contreras</surname><given-names>V</given-names></name><name><surname>Jacquelin</surname><given-names>B</given-names></name><name><surname>Petitdemange</surname><given-names>C</given-names></name><name><surname>Lazzerini</surname><given-names>M</given-names></name><name><surname>Beaumont</surname><given-names>E</given-names></name><name><surname>Orta-Resendiz</surname><given-names>A</given-names></name><name><surname>Rey</surname><given-names>FA</given-names></name><name><surname>Reeves</surname><given-names>RK</given-names></name><name><surname>Le Grand</surname><given-names>R</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Müller-Trutwin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells</article-title><source>Nature Immunology</source><volume>24</volume><fpage>2068</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01661-4</pub-id><pub-id pub-id-type="pmid">37919524</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>23</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubec</surname><given-names>P</given-names></name><name><surname>Genzor</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pulmonary complications following COVID-19 infection</article-title><source>Klinicka Mikrobiologie a Infekcni Lekarstvi</source><volume>28</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3390/life12030357</pub-id><pub-id pub-id-type="pmid">36183412</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>NAF</given-names></name><name><surname>Nyga</surname><given-names>R</given-names></name><name><surname>Vanderbeke</surname><given-names>L</given-names></name><name><surname>Jacobs</surname><given-names>C</given-names></name><name><surname>Ergün</surname><given-names>M</given-names></name><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>van Dijk</surname><given-names>K</given-names></name><name><surname>Altenburg</surname><given-names>J</given-names></name><name><surname>Bouman</surname><given-names>CSC</given-names></name><name><surname>van der Spoel</surname><given-names>HI</given-names></name><name><surname>Rijnders</surname><given-names>BJA</given-names></name><name><surname>Dunbar</surname><given-names>A</given-names></name><name><surname>Schouten</surname><given-names>JA</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Bourgeois</surname><given-names>M</given-names></name><name><surname>Reynders</surname><given-names>M</given-names></name><name><surname>van Regenmortel</surname><given-names>N</given-names></name><name><surname>Rutsaert</surname><given-names>L</given-names></name><name><surname>Lormans</surname><given-names>P</given-names></name><name><surname>Feys</surname><given-names>S</given-names></name><name><surname>Debavaye</surname><given-names>Y</given-names></name><name><surname>Tamion</surname><given-names>F</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Maizel</surname><given-names>J</given-names></name><name><surname>Dupont</surname><given-names>H</given-names></name><name><surname>Chouaki</surname><given-names>T</given-names></name><name><surname>Nseir</surname><given-names>S</given-names></name><name><surname>Sendid</surname><given-names>B</given-names></name><name><surname>Brüggemann</surname><given-names>RJM</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Wauters</surname><given-names>J</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multinational observational cohort study of COVID-19–Associated Pulmonary Aspergillosis1</article-title><source>Emerging Infectious Diseases</source><volume>27</volume><fpage>2892</fpage><lpage>2898</lpage><pub-id pub-id-type="doi">10.3201/eid2711.211174</pub-id><pub-id pub-id-type="pmid">34519638</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaweera</surname><given-names>M</given-names></name><name><surname>Perera</surname><given-names>H</given-names></name><name><surname>Gunawardana</surname><given-names>B</given-names></name><name><surname>Manatunge</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy</article-title><source>Environmental Research</source><volume>188</volume><elocation-id>109819</elocation-id><pub-id pub-id-type="doi">10.1016/j.envres.2020.109819</pub-id><pub-id pub-id-type="pmid">32569870</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffery-Smith</surname><given-names>A</given-names></name><name><surname>Taori</surname><given-names>SK</given-names></name><name><surname>Schelenz</surname><given-names>S</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>EM</given-names></name><name><surname>Borman</surname><given-names>A</given-names></name><name><surname>Incident Management</surname><given-names>T</given-names></name><name><surname>Manuel</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Candida auris: a review of the literature</article-title><source>Clinical Microbiology Reviews</source><volume>31</volume><elocation-id>e00029-17</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00029-17</pub-id><pub-id pub-id-type="pmid">29142078</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>MD</given-names></name><name><surname>Herrmann</surname><given-names>JL</given-names></name><name><surname>Kremer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus</article-title><source>Nature Reviews. Microbiology</source><volume>18</volume><fpage>392</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0331-1</pub-id><pub-id pub-id-type="pmid">32086501</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>KEE</given-names></name><name><surname>Vanderheiden</surname><given-names>A</given-names></name><name><surname>Elrod</surname><given-names>EJ</given-names></name><name><surname>Floyd</surname><given-names>K</given-names></name><name><surname>Geerling</surname><given-names>E</given-names></name><name><surname>Stone</surname><given-names>ET</given-names></name><name><surname>Salinas</surname><given-names>E</given-names></name><name><surname>Banakis</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sathish</surname><given-names>S</given-names></name><name><surname>Shrihari</surname><given-names>S</given-names></name><name><surname>Davis-Gardner</surname><given-names>ME</given-names></name><name><surname>Kohlmeier</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Grakoui</surname><given-names>A</given-names></name><name><surname>Ghedin</surname><given-names>E</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>CD4(+) and CD8(+) T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment</article-title><source>Science Advances</source><volume>10</volume><elocation-id>eadp2636</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adp2636</pub-id><pub-id pub-id-type="pmid">39178263</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaba</surname><given-names>SM</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Helsel</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>LL</given-names></name><name><surname>Avery</surname><given-names>R</given-names></name><name><surname>Dzintars</surname><given-names>K</given-names></name><name><surname>Salinas</surname><given-names>AB</given-names></name><name><surname>Keller</surname><given-names>SC</given-names></name><name><surname>Townsend</surname><given-names>JL</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Amoah</surname><given-names>J</given-names></name><name><surname>Garibaldi</surname><given-names>BT</given-names></name><name><surname>Cosgrove</surname><given-names>SE</given-names></name><name><surname>Fabre</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study</article-title><source>Open Forum Infectious Diseases</source><volume>8</volume><elocation-id>ofaa578</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofaa578</pub-id><pub-id pub-id-type="pmid">33447639</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karami</surname><given-names>Z</given-names></name><name><surname>Knoop</surname><given-names>BT</given-names></name><name><surname>Dofferhoff</surname><given-names>ASM</given-names></name><name><surname>Blaauw</surname><given-names>MJT</given-names></name><name><surname>Janssen</surname><given-names>NA</given-names></name><name><surname>van Apeldoorn</surname><given-names>M</given-names></name><name><surname>Kerckhoffs</surname><given-names>APM</given-names></name><name><surname>van de Maat</surname><given-names>JS</given-names></name><name><surname>Hoogerwerf</surname><given-names>JJ</given-names></name><name><surname>ten Oever</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands</article-title><source>Infectious Diseases</source><volume>53</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1080/23744235.2020.1839672</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsten</surname><given-names>CB</given-names></name><name><surname>Bartsch</surname><given-names>YC</given-names></name><name><surname>Shin</surname><given-names>SA</given-names></name><name><surname>Slein</surname><given-names>MD</given-names></name><name><surname>Heller</surname><given-names>HM</given-names></name><name><surname>Kolandaivelu</surname><given-names>K</given-names></name><name><surname>Middeldorp</surname><given-names>JM</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Julg</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evolution of functional antibodies following acute Epstein-Barr virus infection</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010738</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010738</pub-id><pub-id pub-id-type="pmid">36067220</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthik</surname><given-names>K</given-names></name><name><surname>Senthilkumar</surname><given-names>TMA</given-names></name><name><surname>Udhayavel</surname><given-names>S</given-names></name><name><surname>Raj</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19</article-title><source>Human Vaccines &amp; Immunotherapeutics</source><volume>16</volume><fpage>3055</fpage><lpage>3060</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1796425</pub-id><pub-id pub-id-type="pmid">32845733</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzelnick</surname><given-names>LC</given-names></name><name><surname>Gresh</surname><given-names>L</given-names></name><name><surname>Halloran</surname><given-names>ME</given-names></name><name><surname>Mercado</surname><given-names>JC</given-names></name><name><surname>Kuan</surname><given-names>G</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Balmaseda</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antibody-dependent enhancement of severe dengue disease in humans</article-title><source>Science</source><volume>358</volume><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1126/science.aan6836</pub-id><pub-id pub-id-type="pmid">29097492</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Yoo</surname><given-names>S-J</given-names></name><name><surname>Clijsters</surname><given-names>M</given-names></name><name><surname>Backaert</surname><given-names>W</given-names></name><name><surname>Vanstapel</surname><given-names>A</given-names></name><name><surname>Speleman</surname><given-names>K</given-names></name><name><surname>Lietaer</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Hether</surname><given-names>TD</given-names></name><name><surname>Marcelis</surname><given-names>L</given-names></name><name><surname>Nam</surname><given-names>A</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Reeves</surname><given-names>JW</given-names></name><name><surname>Van Bulck</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Bourgeois</surname><given-names>M</given-names></name><name><surname>Debaveye</surname><given-names>Y</given-names></name><name><surname>De Munter</surname><given-names>P</given-names></name><name><surname>Gunst</surname><given-names>J</given-names></name><name><surname>Jorissen</surname><given-names>M</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Lorent</surname><given-names>N</given-names></name><name><surname>Neyrinck</surname><given-names>A</given-names></name><name><surname>Peetermans</surname><given-names>M</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Vandenbriele</surname><given-names>C</given-names></name><name><surname>Wauters</surname><given-names>J</given-names></name><name><surname>Mombaerts</surname><given-names>P</given-names></name><name><surname>Van Gerven</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb</article-title><source>Cell</source><volume>184</volume><fpage>5932</fpage><lpage>5949</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.10.027</pub-id><pub-id pub-id-type="pmid">34798069</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Guzman Rivera</surname><given-names>J</given-names></name><name><surname>Madhvi</surname><given-names>A</given-names></name><name><surname>Andrews</surname><given-names>T</given-names></name><name><surname>Richlin</surname><given-names>B</given-names></name><name><surname>Suarez</surname><given-names>C</given-names></name><name><surname>Gaur</surname><given-names>S</given-names></name><name><surname>Hasan</surname><given-names>UN</given-names></name><name><surname>Cuddy</surname><given-names>W</given-names></name><name><surname>Singh</surname><given-names>AR</given-names></name><name><surname>Bukulmez</surname><given-names>H</given-names></name><name><surname>Kaelber</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Ganapathi</surname><given-names>U</given-names></name><name><surname>Michailidis</surname><given-names>IE</given-names></name><name><surname>Ukey</surname><given-names>R</given-names></name><name><surname>Moroso-Fela</surname><given-names>S</given-names></name><name><surname>Kuster</surname><given-names>JK</given-names></name><name><surname>Casseus</surname><given-names>M</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Burns</surname><given-names>JC</given-names></name><name><surname>Kleinman</surname><given-names>LC</given-names></name><name><surname>Horton</surname><given-names>DB</given-names></name><name><surname>Lakhani</surname><given-names>SA</given-names></name><name><surname>Gennaro</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>A genetically modulated Toll-like receptor-tolerant phenotype in peripheral blood cells of children with multisystem inflammatory syndrome</article-title><source>Journal of Immunology</source><volume>214</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1093/jimmun/vkaf006</pub-id><pub-id pub-id-type="pmid">40101747</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatri</surname><given-names>A</given-names></name><name><surname>Malhotra</surname><given-names>P</given-names></name><name><surname>Izard</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Oppenheim</surname><given-names>M</given-names></name><name><surname>Gautam-Goyal</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Doan</surname><given-names>T-L</given-names></name><name><surname>Berlinrut</surname><given-names>I</given-names></name><name><surname>Niknam</surname><given-names>N</given-names></name><name><surname>Flannery</surname><given-names>S</given-names></name><name><surname>Hirschwerk</surname><given-names>D</given-names></name><name><surname>Epstein</surname><given-names>M</given-names></name><name><surname>Farber</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hospital-Acquired bloodstream infections in patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection (Coronavirus Disease 2019): Association with immunosuppressive therapies</article-title><source>Open Forum Infectious Diseases</source><volume>8</volume><elocation-id>ofab339</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofab339</pub-id><pub-id pub-id-type="pmid">34337096</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khayat</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Vali</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report</article-title><source>Respiratory Medicine Case Reports</source><volume>32</volume><elocation-id>101344</elocation-id><pub-id pub-id-type="doi">10.1016/j.rmcr.2021.101344</pub-id><pub-id pub-id-type="pmid">33495728</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Jhun</surname><given-names>BW</given-names></name><name><surname>Jeong</surname><given-names>BH</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kwon</surname><given-names>OJ</given-names></name><name><surname>Shin</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The higher incidence of COVID-19 in patients with non-tuberculous mycobacterial pulmonary disease: a single center experience in Korea</article-title><source>Journal of Korean Medical Science</source><volume>37</volume><elocation-id>e250</elocation-id><pub-id pub-id-type="doi">10.3346/jkms.2022.37.e250</pub-id><pub-id pub-id-type="pmid">35971764</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Jaycox</surname><given-names>JR</given-names></name><name><surname>Dhodapkar</surname><given-names>RM</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Gehlhausen</surname><given-names>JR</given-names></name><name><surname>Tabachnikova</surname><given-names>A</given-names></name><name><surname>Greene</surname><given-names>K</given-names></name><name><surname>Tabacof</surname><given-names>L</given-names></name><name><surname>Malik</surname><given-names>AA</given-names></name><name><surname>Silva Monteiro</surname><given-names>V</given-names></name><name><surname>Silva</surname><given-names>J</given-names></name><name><surname>Kamath</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Dhal</surname><given-names>A</given-names></name><name><surname>Ott</surname><given-names>IM</given-names></name><name><surname>Valle</surname><given-names>G</given-names></name><name><surname>Peña-Hernández</surname><given-names>M</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Bhattacharjee</surname><given-names>B</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Lucas</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>McCarthy</surname><given-names>D</given-names></name><name><surname>Breyman</surname><given-names>E</given-names></name><name><surname>Tosto-Mancuso</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Perotti</surname><given-names>E</given-names></name><name><surname>Akduman</surname><given-names>K</given-names></name><name><surname>Tzeng</surname><given-names>TJ</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Geraghty</surname><given-names>AC</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name><name><surname>Yildirim</surname><given-names>I</given-names></name><name><surname>Shon</surname><given-names>J</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Lutchmansingh</surname><given-names>D</given-names></name><name><surname>Possick</surname><given-names>JD</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name><name><surname>Omer</surname><given-names>SB</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Dela Cruz</surname><given-names>CS</given-names></name><name><surname>van Dijk</surname><given-names>D</given-names></name><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Putrino</surname><given-names>D</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Distinguishing features of long COVID identified through immune profiling</article-title><source>Nature</source><volume>623</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id><pub-id pub-id-type="pmid">37748514</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehler</surname><given-names>P</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Böttiger</surname><given-names>BW</given-names></name><name><surname>Dusse</surname><given-names>F</given-names></name><name><surname>Eichenauer</surname><given-names>DA</given-names></name><name><surname>Fuchs</surname><given-names>F</given-names></name><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>N</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Persigehl</surname><given-names>T</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Böll</surname><given-names>B</given-names></name><name><surname>Shimabukuro-Vornhagen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 associated pulmonary aspergillosis</article-title><source>Mycoses</source><volume>63</volume><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1111/myc.13096</pub-id><pub-id pub-id-type="pmid">32339350</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolenda</surname><given-names>C</given-names></name><name><surname>Ranc</surname><given-names>AG</given-names></name><name><surname>Boisset</surname><given-names>S</given-names></name><name><surname>Caspar</surname><given-names>Y</given-names></name><name><surname>Carricajo</surname><given-names>A</given-names></name><name><surname>Souche</surname><given-names>A</given-names></name><name><surname>Dauwalder</surname><given-names>O</given-names></name><name><surname>Verhoeven</surname><given-names>PO</given-names></name><name><surname>Vandenesch</surname><given-names>F</given-names></name><name><surname>Laurent</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome Coronavirus 2-Positive patients hospitalized in intensive care units using conventional culture and bioFire, filmarray pneumonia panel plus assay</article-title><source>Open Forum Infectious Diseases</source><volume>7</volume><elocation-id>ofaa484</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofaa484</pub-id><pub-id pub-id-type="pmid">33204762</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolloli</surname><given-names>A</given-names></name><name><surname>Ramasamy</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Nisa</surname><given-names>A</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Subbian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1270414</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1270414</pub-id><pub-id pub-id-type="pmid">37854602</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosmidis</surname><given-names>C</given-names></name><name><surname>Denning</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The clinical spectrum of pulmonary aspergillosis</article-title><source>Thorax</source><volume>70</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2014-206291</pub-id><pub-id pub-id-type="pmid">25354514</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Tracy</surname><given-names>R</given-names></name><name><surname>Belloso</surname><given-names>W</given-names></name><name><surname>De Wit</surname><given-names>S</given-names></name><name><surname>Drummond</surname><given-names>F</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Ledergerber</surname><given-names>B</given-names></name><name><surname>Lundgren</surname><given-names>J</given-names></name><name><surname>Neuhaus</surname><given-names>J</given-names></name><name><surname>Nixon</surname><given-names>D</given-names></name><name><surname>Paton</surname><given-names>NI</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><collab>INSIGHT SMART Study Group</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Inflammatory and coagulation biomarkers and mortality in patients with HIV infection</article-title><source>PLOS Medicine</source><volume>5</volume><elocation-id>e203</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0050203</pub-id><pub-id pub-id-type="pmid">18942885</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 pathogenesis</article-title><source>Nature Reviews. Microbiology</source><volume>20</volume><fpage>270</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00713-0</pub-id><pub-id pub-id-type="pmid">35354968</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>BJ</given-names></name><name><surname>So</surname><given-names>M</given-names></name><name><surname>Raybardhan</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>V</given-names></name><name><surname>Westwood</surname><given-names>D</given-names></name><name><surname>MacFadden</surname><given-names>DR</given-names></name><name><surname>Soucy</surname><given-names>JPR</given-names></name><name><surname>Daneman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title><source>Clinical Microbiology and Infection</source><volume>26</volume><fpage>1622</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id><pub-id pub-id-type="pmid">32711058</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantos</surname><given-names>PM</given-names></name><name><surname>Branda</surname><given-names>JA</given-names></name><name><surname>Boggan</surname><given-names>JC</given-names></name><name><surname>Chudgar</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>EA</given-names></name><name><surname>Ruffin</surname><given-names>F</given-names></name><name><surname>Fowler</surname><given-names>V</given-names></name><name><surname>Auwaerter</surname><given-names>PG</given-names></name><name><surname>Nigrovic</surname><given-names>LE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Poor positive predictive value of lyme disease serologic testing in an area of low disease incidence</article-title><source>Clinical Infectious Diseases</source><volume>61</volume><fpage>1374</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1093/cid/civ584</pub-id><pub-id pub-id-type="pmid">26195017</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonso</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Prol</surname><given-names>R</given-names></name><name><surname>Rawat</surname><given-names>S</given-names></name><name><surname>Khunger</surname><given-names>A</given-names></name><name><surname>Bromberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A rare case of latent tuberculosis reactivation secondary to a COVID-19 infection</article-title><source>Infectious Disease Reports</source><volume>14</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.3390/idr14030048</pub-id><pub-id pub-id-type="pmid">35735758</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Libbey</surname><given-names>JE</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2002">2002</year><chapter-title>Virus-induced immunosuppression</chapter-title><person-group person-group-type="editor"><name><surname>Brogden</surname><given-names>KA</given-names></name><name><surname>Guthmiller</surname><given-names>JM</given-names></name></person-group><source>Polymicrobial Diseases</source><publisher-name>ASM Press</publisher-name></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieber</surname><given-names>CM</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Sobolik</surname><given-names>EB</given-names></name><name><surname>Sticher</surname><given-names>ZM</given-names></name><name><surname>Ngo</surname><given-names>VL</given-names></name><name><surname>Gewirtz</surname><given-names>AT</given-names></name><name><surname>Kolykhalov</surname><given-names>AA</given-names></name><name><surname>Natchus</surname><given-names>MG</given-names></name><name><surname>Greninger</surname><given-names>AL</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>Plemper</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection</article-title><source>Journal of Virology</source><volume>98</volume><elocation-id>e0090524</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.00905-24</pub-id><pub-id pub-id-type="pmid">39207133</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>WT</given-names></name><name><surname>Torpy</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><chapter-title>Chronic fatigue syndrome</chapter-title><person-group person-group-type="editor"><name><surname>Feingold</surname><given-names>KR</given-names></name><name><surname>Anawalt</surname><given-names>B</given-names></name><name><surname>Blackman</surname><given-names>MR</given-names></name><name><surname>Boyce</surname><given-names>A</given-names></name><name><surname>Chrousos</surname><given-names>G</given-names></name><name><surname>Corpas</surname><given-names>E</given-names></name><name><surname>de Herder</surname><given-names>WW</given-names></name><name><surname>Dhatariya</surname><given-names>K</given-names></name><name><surname>Dungan</surname><given-names>K</given-names></name><name><surname>Hofland</surname><given-names>J</given-names></name><name><surname>Trence</surname><given-names>DL</given-names></name></person-group><source>Endotext</source><publisher-name>MDText</publisher-name></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limaye</surname><given-names>AP</given-names></name><name><surname>Stapleton</surname><given-names>RD</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Gunn</surname><given-names>SR</given-names></name><name><surname>Kimball</surname><given-names>LE</given-names></name><name><surname>Hyzy</surname><given-names>R</given-names></name><name><surname>Exline</surname><given-names>MC</given-names></name><name><surname>Files</surname><given-names>DC</given-names></name><name><surname>Morris</surname><given-names>PE</given-names></name><name><surname>Frankel</surname><given-names>SK</given-names></name><name><surname>Mikkelsen</surname><given-names>ME</given-names></name><name><surname>Hite</surname><given-names>D</given-names></name><name><surname>Enfield</surname><given-names>KB</given-names></name><name><surname>Steingrub</surname><given-names>J</given-names></name><name><surname>O’Brien</surname><given-names>J</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Cuschieri</surname><given-names>J</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Hotchkin</surname><given-names>DL</given-names></name><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effect of Ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial</article-title><source>JAMA</source><volume>318</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.10569</pub-id><pub-id pub-id-type="pmid">28829877</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Decreased incidence of influenza during the COVID-19 Pandemic</article-title><source>International Journal of General Medicine</source><volume>15</volume><fpage>2957</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S343940</pub-id><pub-id pub-id-type="pmid">35308571</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffia-Bizzozero</surname><given-names>S</given-names></name><name><surname>Cevallos</surname><given-names>C</given-names></name><name><surname>Lenicov</surname><given-names>FR</given-names></name><name><surname>Freiberger</surname><given-names>RN</given-names></name><name><surname>Lopez</surname><given-names>CAM</given-names></name><name><surname>Guano Toaquiza</surname><given-names>A</given-names></name><name><surname>Sviercz</surname><given-names>F</given-names></name><name><surname>Jarmoluk</surname><given-names>P</given-names></name><name><surname>Bustos</surname><given-names>C</given-names></name><name><surname>D’Addario</surname><given-names>AC</given-names></name><name><surname>Quarleri</surname><given-names>J</given-names></name><name><surname>Delpino</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Viable SARS-CoV-2 Omicron sub-variants isolated from autopsy tissues</article-title><source>Frontiers in Microbiology</source><volume>14</volume><elocation-id>1192832</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1192832</pub-id><pub-id pub-id-type="pmid">37283920</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco</surname><given-names>MH</given-names></name><name><surname>Ahmedov</surname><given-names>S</given-names></name><name><surname>Castro</surname><given-names>KG</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The global impact of COVID-19 on tuberculosis: a thematic scoping review, 2020-2023</article-title><source>PLOS Global Public Health</source><volume>4</volume><elocation-id>e0003043</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgph.0003043</pub-id><pub-id pub-id-type="pmid">38959278</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marjot</surname><given-names>T</given-names></name><name><surname>Webb</surname><given-names>GJ</given-names></name><name><surname>Barritt</surname><given-names>AS</given-names></name><name><surname>Moon</surname><given-names>AM</given-names></name><name><surname>Stamataki</surname><given-names>Z</given-names></name><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 and liver disease: mechanistic and clinical perspectives</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>18</volume><fpage>348</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00426-4</pub-id><pub-id pub-id-type="pmid">33692570</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Persistent symptoms after treatment of lyme disease</article-title><source>Infectious Disease Clinics of North America</source><volume>36</volume><fpage>621</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2022.04.004</pub-id><pub-id pub-id-type="pmid">36116839</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masoumi</surname><given-names>M</given-names></name><name><surname>Sakhaee</surname><given-names>F</given-names></name><name><surname>Vaziri</surname><given-names>F</given-names></name><name><surname>Siadat</surname><given-names>SD</given-names></name><name><surname>Fateh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reactivation of <italic>Mycobacterium simiae</italic> after the recovery of COVID-19 infection</article-title><source>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</source><volume>24</volume><elocation-id>100257</elocation-id><pub-id pub-id-type="doi">10.1016/j.jctube.2021.100257</pub-id><pub-id pub-id-type="pmid">34222683</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Burger</surname><given-names>ZC</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Lammers</surname><given-names>M</given-names></name><name><surname>Rubiro</surname><given-names>P</given-names></name><name><surname>Quiambao</surname><given-names>L</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>da Silva Antunes</surname><given-names>R</given-names></name><name><surname>Greenbaum</surname><given-names>J</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Markmann</surname><given-names>AJ</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmid">32753554</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>S</given-names></name><name><surname>Vilensky</surname><given-names>JA</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The relationship between encephalitis lethargica and influenza: a critical analysis</article-title><source>Journal of Neurovirology</source><volume>14</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1080/13550280801995445</pub-id><pub-id pub-id-type="pmid">18569452</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehandru</surname><given-names>S</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pathological sequelae of long-haul COVID</article-title><source>Nature Immunology</source><volume>23</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01104-y</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middeldorp</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epstein-Barr virus-specific humoral immune responses in health and disease</article-title><source>Current Topics in Microbiology and Immunology</source><volume>391</volume><fpage>289</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-22834-1_10</pub-id><pub-id pub-id-type="pmid">26428379</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mina</surname><given-names>MJ</given-names></name><name><surname>Kula</surname><given-names>T</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>de Vries</surname><given-names>RD</given-names></name><name><surname>Knip</surname><given-names>M</given-names></name><name><surname>Siljander</surname><given-names>H</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Choy</surname><given-names>DF</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name><name><surname>Larman</surname><given-names>HB</given-names></name><name><surname>Nelson</surname><given-names>AN</given-names></name><name><surname>Griffin</surname><given-names>DE</given-names></name><name><surname>de Swart</surname><given-names>RL</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens</article-title><source>Science</source><volume>366</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1126/science.aay6485</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollayeva</surname><given-names>T</given-names></name><name><surname>Kendzerska</surname><given-names>T</given-names></name><name><surname>Mollayeva</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>CM</given-names></name><name><surname>Colantonio</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A systematic review of fatigue in patients with traumatic brain injury: the course, predictors and consequences</article-title><source>Neuroscience and Biobehavioral Reviews</source><volume>47</volume><fpage>684</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.10.024</pub-id><pub-id pub-id-type="pmid">25451201</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-García</surname><given-names>E</given-names></name><name><surname>Puerta-Alcalde</surname><given-names>P</given-names></name><name><surname>Letona</surname><given-names>L</given-names></name><name><surname>Meira</surname><given-names>F</given-names></name><name><surname>Dueñas</surname><given-names>G</given-names></name><name><surname>Chumbita</surname><given-names>M</given-names></name><name><surname>Garcia-Pouton</surname><given-names>N</given-names></name><name><surname>Monzó</surname><given-names>P</given-names></name><name><surname>Lopera</surname><given-names>C</given-names></name><name><surname>Serra</surname><given-names>L</given-names></name><name><surname>Cardozo</surname><given-names>C</given-names></name><name><surname>Hernandez-Meneses</surname><given-names>M</given-names></name><name><surname>Rico</surname><given-names>V</given-names></name><name><surname>Bodro</surname><given-names>M</given-names></name><name><surname>Morata</surname><given-names>L</given-names></name><name><surname>Fernandez-Pittol</surname><given-names>M</given-names></name><name><surname>Grafia</surname><given-names>I</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Martínez</surname><given-names>JA</given-names></name><name><surname>Sanjuan</surname><given-names>G</given-names></name><name><surname>Marcos</surname><given-names>MA</given-names></name><name><surname>Soriano</surname><given-names>A</given-names></name><name><surname>Garcia-Vidal</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Bacterial co-infection at hospital admission in patients with COVID-19</article-title><source>International Journal of Infectious Diseases</source><volume>118</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2022.03.003</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murgia</surname><given-names>F</given-names></name><name><surname>Fiamma</surname><given-names>M</given-names></name><name><surname>Serra</surname><given-names>S</given-names></name><name><surname>Marras</surname><given-names>G</given-names></name><name><surname>Argiolas</surname><given-names>R</given-names></name><name><surname>Mattana</surname><given-names>C</given-names></name><name><surname>Mattu</surname><given-names>MG</given-names></name><name><surname>Garau</surname><given-names>MC</given-names></name><name><surname>Doneddu</surname><given-names>S</given-names></name><name><surname>Olla</surname><given-names>S</given-names></name><name><surname>Cocco</surname><given-names>E</given-names></name><name><surname>Lorefice</surname><given-names>L</given-names></name><name><surname>Muntoni</surname><given-names>S</given-names></name><name><surname>Paffi</surname><given-names>P</given-names></name><name><surname>Porru</surname><given-names>S</given-names></name><name><surname>Abis</surname><given-names>M</given-names></name><name><surname>Bellizzi</surname><given-names>S</given-names></name><name><surname>Pani</surname><given-names>A</given-names></name><name><surname>Angioi</surname><given-names>A</given-names></name><name><surname>Simbula</surname><given-names>G</given-names></name><name><surname>Mussap</surname><given-names>M</given-names></name><name><surname>Massidda</surname><given-names>O</given-names></name><name><surname>Carta</surname><given-names>F</given-names></name><name><surname>Atzori</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The impact of the secondary infections in ICU patients affected by COVID-19 during three different phases of the SARS-CoV-2 pandemic</article-title><source>Clinical and Experimental Medicine</source><volume>23</volume><fpage>1251</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1007/s10238-022-00959-1</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musuuza</surname><given-names>JS</given-names></name><name><surname>Watson</surname><given-names>L</given-names></name><name><surname>Parmasad</surname><given-names>V</given-names></name><name><surname>Putman-Buehler</surname><given-names>N</given-names></name><name><surname>Christensen</surname><given-names>L</given-names></name><name><surname>Safdar</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0251170</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0251170</pub-id><pub-id pub-id-type="pmid">33956882</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narasimhan</surname><given-names>H</given-names></name><name><surname>Cheon</surname><given-names>IS</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>SS</given-names></name><name><surname>Parimon</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Goplen</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Son</surname><given-names>YM</given-names></name><name><surname>Fink</surname><given-names>E</given-names></name><name><surname>de Almeida Santos</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>C</given-names></name><name><surname>Muehling</surname><given-names>L</given-names></name><name><surname>Canderan</surname><given-names>G</given-names></name><name><surname>Kadl</surname><given-names>A</given-names></name><name><surname>Cannon</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>S</given-names></name><name><surname>Hannan</surname><given-names>R</given-names></name><name><surname>Bingham</surname><given-names>G</given-names></name><name><surname>Arish</surname><given-names>M</given-names></name><name><surname>Sen Chaudhari</surname><given-names>A</given-names></name><name><surname>Im</surname><given-names>JS</given-names></name><name><surname>Mattingly</surname><given-names>CLR</given-names></name><name><surname>Pramoonjago</surname><given-names>P</given-names></name><name><surname>Marchesvsky</surname><given-names>A</given-names></name><name><surname>Sturek</surname><given-names>J</given-names></name><name><surname>Kohlmeier</surname><given-names>JE</given-names></name><name><surname>Shim</surname><given-names>YM</given-names></name><name><surname>Woodfolk</surname><given-names>J</given-names></name><name><surname>Zang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>An aberrant immune-epithelial progenitor niche drives viral lung sequelae</article-title><source>Nature</source><volume>634</volume><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07926-8</pub-id><pub-id pub-id-type="pmid">39232171</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>JSF</given-names></name><name><surname>Castro</surname><given-names>RRT</given-names></name><name><surname>Nascimento</surname><given-names>JKF</given-names></name><name><surname>Knoploch</surname><given-names>BB</given-names></name><name><surname>Duque</surname><given-names>PMCO</given-names></name><name><surname>Neves</surname><given-names>MAO</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Coinfection of SARS-CoV-2 and Measles morbillivirus in a front-line health worker in Rio de Janeiro, Brasil</article-title><source>Revista Da Associacao Medica Brasileira</source><volume>66</volume><fpage>1027</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1590/1806-9282.66.8.1027</pub-id><pub-id pub-id-type="pmid">32935793</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasrullah</surname><given-names>A</given-names></name><name><surname>Gangu</surname><given-names>K</given-names></name><name><surname>Garg</surname><given-names>I</given-names></name><name><surname>Javed</surname><given-names>A</given-names></name><name><surname>Shuja</surname><given-names>H</given-names></name><name><surname>Chourasia</surname><given-names>P</given-names></name><name><surname>Shekhar</surname><given-names>R</given-names></name><name><surname>Sheikh</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Trends in hospitalization and mortality for influenza and other respiratory viruses during the COVID-19 Pandemic in the United States</article-title><source>Vaccines</source><volume>11</volume><elocation-id>412</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11020412</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>A</given-names></name><name><surname>Zlitni</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>EF</given-names></name><name><surname>Vance</surname><given-names>SE</given-names></name><name><surname>Dahlen</surname><given-names>A</given-names></name><name><surname>Hedlin</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>RM</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Schmidtke</surname><given-names>DT</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Jacobson</surname><given-names>KB</given-names></name><name><surname>Parsonnet</surname><given-names>J</given-names></name><name><surname>Bonilla</surname><given-names>HF</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Pinsky</surname><given-names>BA</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Jagannathan</surname><given-names>P</given-names></name><name><surname>Bhatt</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection</article-title><source>Med</source><volume>3</volume><fpage>371</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.medj.2022.04.001</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Academies of Sciences E, and Medicine</collab><collab>Health and Medicine Division</collab><collab>Board on Health Care Services</collab></person-group><year iso-8601-date="2024">2024</year><chapter-title>Board on health care services; committee on the long-term health effects stemming from COVID-19 and implications for the social security administration. 2024</chapter-title><person-group person-group-type="editor"><name><surname>Spicer</surname><given-names>CM</given-names></name><name><surname>Chu</surname><given-names>BX</given-names></name><name><surname>Volberding</surname><given-names>PA</given-names></name></person-group><source>Long-Term Health Effects of COVID-19: Disability and Function Following SARS-CoV-2 Infection</source><publisher-name>The National Academies Press</publisher-name><fpage>1</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.17226/27756</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Needle</surname><given-names>RF</given-names></name><name><surname>Russell</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Immunity debt, a gap in learning, or immune dysfunction?</article-title><source>Viral Immunology</source><volume>36</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1089/vim.2022.0204</pub-id><pub-id pub-id-type="pmid">36648772</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Ziogas</surname><given-names>A</given-names></name><name><surname>Benn</surname><given-names>CS</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Chumakov</surname><given-names>K</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Gallo</surname><given-names>R</given-names></name><name><surname>Aaby</surname><given-names>P</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The role of trained immunity in COVID-19: Lessons for the next pandemic</article-title><source>Cell Host &amp; Microbe</source><volume>31</volume><fpage>890</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.05.004</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nhamoyebonde</surname><given-names>S</given-names></name><name><surname>Leslie</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Biological differences between the sexes and susceptibility to tuberculosis</article-title><source>The Journal of Infectious Diseases</source><volume>209 Suppl 3</volume><fpage>S100</fpage><lpage>S106</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu147</pub-id><pub-id pub-id-type="pmid">24966189</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicoli</surname><given-names>F</given-names></name><name><surname>Clave</surname><given-names>E</given-names></name><name><surname>Wanke</surname><given-names>K</given-names></name><name><surname>von Braun</surname><given-names>A</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Douay</surname><given-names>C</given-names></name><name><surname>Baque</surname><given-names>M</given-names></name><name><surname>Lependu</surname><given-names>C</given-names></name><name><surname>Marconi</surname><given-names>P</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Heinz</surname><given-names>FX</given-names></name><name><surname>Muetsch</surname><given-names>M</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Boddaert</surname><given-names>J</given-names></name><name><surname>Sauce</surname><given-names>D</given-names></name><name><surname>Toubert</surname><given-names>A</given-names></name><name><surname>Karrer</surname><given-names>U</given-names></name><name><surname>Appay</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old</article-title><source>EBioMedicine</source><volume>76</volume><elocation-id>103852</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103852</pub-id><pub-id pub-id-type="pmid">35114631</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordell</surname><given-names>AD</given-names></name><name><surname>McKenna</surname><given-names>M</given-names></name><name><surname>Borges</surname><given-names>ÁH</given-names></name><name><surname>Duprez</surname><given-names>D</given-names></name><name><surname>Neuhaus</surname><given-names>J</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><collab>INSIGHT SMART, ESPRIT Study Groups</collab><collab>SILCAAT Scientific Committee</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation</article-title><source>Journal of the American Heart Association</source><volume>3</volume><elocation-id>e000844</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.114.000844</pub-id><pub-id pub-id-type="pmid">24870935</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norouzi Masir</surname><given-names>M</given-names></name><name><surname>Shirvaliloo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Symptomatology and microbiology of the gastrointestinal tract in post-COVID conditions</article-title><source>JGH Open</source><volume>6</volume><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1002/jgh3.12811</pub-id><pub-id pub-id-type="pmid">36247234</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>ME</given-names></name><name><surname>Thurman</surname><given-names>A</given-names></name><name><surname>Pezzulo</surname><given-names>AA</given-names></name><name><surname>Leidinger</surname><given-names>MR</given-names></name><name><surname>Klesney-Tait</surname><given-names>JA</given-names></name><name><surname>Karp</surname><given-names>PH</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C</given-names></name><name><surname>McCray</surname><given-names>PB</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract</article-title><source>EBioMedicine</source><volume>60</volume><elocation-id>102976</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102976</pub-id><pub-id pub-id-type="pmid">32971472</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patton</surname><given-names>MJ</given-names></name><name><surname>Orihuela</surname><given-names>CJ</given-names></name><name><surname>Harrod</surname><given-names>KS</given-names></name><name><surname>Bhuiyan</surname><given-names>MAN</given-names></name><name><surname>Dominic</surname><given-names>P</given-names></name><name><surname>Kevil</surname><given-names>CG</given-names></name><name><surname>Fort</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>VX</given-names></name><name><surname>Farhat</surname><given-names>M</given-names></name><name><surname>Koff</surname><given-names>JL</given-names></name><name><surname>Lal</surname><given-names>CV</given-names></name><name><surname>Gaggar</surname><given-names>A</given-names></name><name><surname>Richter</surname><given-names>RP</given-names></name><name><surname>Erdmann</surname><given-names>N</given-names></name><name><surname>Might</surname><given-names>M</given-names></name><name><surname>Gaggar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation</article-title><source>Critical Care</source><volume>27</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s13054-023-04312-0</pub-id><pub-id pub-id-type="pmid">36691080</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Bakkour</surname><given-names>S</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>A high percentage of people with Human Immunodeficiency Virus (HIV) on antiretroviral therapy experience detectable low-level plasma HIV-1 RNA following Coronavirus Disease 2019 (COVID-19)</article-title><source>Clinical Infectious Diseases</source><volume>73</volume><fpage>e2845</fpage><lpage>e2846</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1754</pub-id><pub-id pub-id-type="pmid">33211091</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>AF</given-names></name><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Ho</surname><given-names>HE</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Forman</surname><given-names>CA</given-names></name><name><surname>Munter</surname><given-names>SE</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Greenhouse</surname><given-names>B</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Daniel Kelly</surname><given-names>J</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>The Journal of Infectious Diseases</source><volume>224</volume><fpage>1839</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab490</pub-id><pub-id pub-id-type="pmid">34677601</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Early clues regarding the pathogenesis of long-COVID</article-title><source>Trends in Immunology</source><volume>43</volume><fpage>268</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.it.2022.02.008</pub-id><pub-id pub-id-type="pmid">35272932</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Mustapic</surname><given-names>M</given-names></name><name><surname>Kapogiannis</surname><given-names>D</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Martinez</surname><given-names>EO</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Goetzl</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>SARS-CoV-2 and Mitochondrial proteins in neural-derived exosomes of COVID-19</article-title><source>Annals of Neurology</source><volume>91</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1002/ana.26350</pub-id><pub-id pub-id-type="pmid">35285072</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Davidson</surname><given-names>MC</given-names></name><name><surname>Mathur</surname><given-names>S</given-names></name><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Spinelli</surname><given-names>MA</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Fehrman</surname><given-names>EA</given-names></name><name><surname>Torres</surname><given-names>L</given-names></name><name><surname>Hernandez</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>MC</given-names></name><name><surname>Arreguin</surname><given-names>MI</given-names></name><name><surname>Ngo</surname><given-names>LH</given-names></name><name><surname>Deswal</surname><given-names>M</given-names></name><name><surname>Munter</surname><given-names>SE</given-names></name><name><surname>Martinez</surname><given-names>EO</given-names></name><name><surname>Anglin</surname><given-names>KA</given-names></name><name><surname>Romero</surname><given-names>MD</given-names></name><name><surname>Tavs</surname><given-names>J</given-names></name><name><surname>Rugart</surname><given-names>PR</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Sans</surname><given-names>HM</given-names></name><name><surname>Murray</surname><given-names>VW</given-names></name><name><surname>Ellis</surname><given-names>PK</given-names></name><name><surname>Donohue</surname><given-names>KC</given-names></name><name><surname>Massachi</surname><given-names>JA</given-names></name><name><surname>Weiss</surname><given-names>JO</given-names></name><name><surname>Mehdi</surname><given-names>I</given-names></name><name><surname>Pineda-Ramirez</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>AF</given-names></name><name><surname>Wenger</surname><given-names>MA</given-names></name><name><surname>Assenzio</surname><given-names>MT</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Krone</surname><given-names>MR</given-names></name><name><surname>Rutishauser</surname><given-names>RL</given-names></name><name><surname>Rodriguez-Barraquer</surname><given-names>I</given-names></name><name><surname>Greenhouse</surname><given-names>B</given-names></name><name><surname>Sauceda</surname><given-names>JA</given-names></name><name><surname>Gandhi</surname><given-names>M</given-names></name><name><surname>Scheffler</surname><given-names>AW</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2022">2022c</year><article-title>Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of sars-cov-2 infection: cohort description and approaches for measurement</article-title><source>Open Forum Infectious Diseases</source><volume>9</volume><elocation-id>ofab640</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofab640</pub-id><pub-id pub-id-type="pmid">35106317</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Sans</surname><given-names>HM</given-names></name><name><surname>Forman</surname><given-names>CA</given-names></name><name><surname>Nylander</surname><given-names>AN</given-names></name><name><surname>Ho</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Munter</surname><given-names>SE</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Greene</surname><given-names>M</given-names></name><name><surname>Chow</surname><given-names>FC</given-names></name><name><surname>Hellmuth</surname><given-names>J</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2022">2022d</year><article-title>Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection</article-title><source>Neurology Neuroimmunology &amp; Neuroinflammation</source><volume>9</volume><elocation-id>e200003</elocation-id><pub-id pub-id-type="doi">10.1212/NXI.0000000000200003</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Spinelli</surname><given-names>MA</given-names></name><name><surname>Deveau</surname><given-names>TM</given-names></name><name><surname>Forman</surname><given-names>CA</given-names></name><name><surname>Munter</surname><given-names>SE</given-names></name><name><surname>Mathur</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>AF</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Arreguin</surname><given-names>MI</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Martinez</surname><given-names>EO</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Lynch</surname><given-names>KL</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Gandhi</surname><given-names>M</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Rutishauser</surname><given-names>RL</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2022">2022e</year><article-title>Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection</article-title><source>AIDS</source><volume>36</volume><fpage>F7</fpage><lpage>F16</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003338</pub-id><pub-id pub-id-type="pmid">35866847</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Deveau</surname><given-names>TM</given-names></name><name><surname>Munter</surname><given-names>SE</given-names></name><name><surname>Ryder</surname><given-names>D</given-names></name><name><surname>Buck</surname><given-names>A</given-names></name><name><surname>Beck-Engeser</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Tai</surname><given-names>V</given-names></name><name><surname>Torres</surname><given-names>L</given-names></name><name><surname>Iyer</surname><given-names>NS</given-names></name><name><surname>Deswal</surname><given-names>M</given-names></name><name><surname>Ngo</surname><given-names>LH</given-names></name><name><surname>Buitrago</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Yee</surname><given-names>BC</given-names></name><name><surname>Chenna</surname><given-names>A</given-names></name><name><surname>Winslow</surname><given-names>JW</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Deitchman</surname><given-names>AN</given-names></name><name><surname>Hellmuth</surname><given-names>J</given-names></name><name><surname>Spinelli</surname><given-names>MA</given-names></name><name><surname>Durstenfeld</surname><given-names>MS</given-names></name><name><surname>Hsue</surname><given-names>PY</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Chronic viral coinfections differentially affect the likelihood of developing long COVID</article-title><source>The Journal of Clinical Investigation</source><volume>133</volume><elocation-id>e163669</elocation-id><pub-id pub-id-type="doi">10.1172/JCI163669</pub-id><pub-id pub-id-type="pmid">36454631</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perico</surname><given-names>L</given-names></name><name><surname>Morigi</surname><given-names>M</given-names></name><name><surname>Pezzotta</surname><given-names>A</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Imberti</surname><given-names>B</given-names></name><name><surname>Corna</surname><given-names>D</given-names></name><name><surname>Cerullo</surname><given-names>D</given-names></name><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling</article-title><source>Scientific Reports</source><volume>13</volume><elocation-id>11392</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-38382-5</pub-id><pub-id pub-id-type="pmid">37452090</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Permpalung</surname><given-names>N</given-names></name><name><surname>Chiang</surname><given-names>TPY</given-names></name><name><surname>Massie</surname><given-names>AB</given-names></name><name><surname>Zhang</surname><given-names>SX</given-names></name><name><surname>Avery</surname><given-names>RK</given-names></name><name><surname>Nematollahi</surname><given-names>S</given-names></name><name><surname>Ostrander</surname><given-names>D</given-names></name><name><surname>Segev</surname><given-names>DL</given-names></name><name><surname>Marr</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Coronavirus disease 2019-associated pulmonary aspergillosis in mechanically ventilated patients</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab223</pub-id><pub-id pub-id-type="pmid">33693551</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pesti</surname><given-names>A</given-names></name><name><surname>Danics</surname><given-names>K</given-names></name><name><surname>Glasz</surname><given-names>T</given-names></name><name><surname>Várkonyi</surname><given-names>T</given-names></name><name><surname>Barbai</surname><given-names>T</given-names></name><name><surname>Reszegi</surname><given-names>A</given-names></name><name><surname>Kovalszky</surname><given-names>I</given-names></name><name><surname>Vályi-Nagy</surname><given-names>I</given-names></name><name><surname>Dobi</surname><given-names>D</given-names></name><name><surname>Lotz</surname><given-names>G</given-names></name><name><surname>Schaff</surname><given-names>Z</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Liver alterations and detection of SARS-CoV-2 RNA and proteins in COVID-19 autopsies</article-title><source>GeroScience</source><volume>45</volume><fpage>1015</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1007/s11357-022-00700-6</pub-id><pub-id pub-id-type="pmid">36527584</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>VN</given-names></name><name><surname>Sawatsky</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>AX</given-names></name><name><surname>Laksono</surname><given-names>BM</given-names></name><name><surname>Walz</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>E</given-names></name><name><surname>Pieper</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>CA</given-names></name><name><surname>de Vries</surname><given-names>RD</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Kellam</surname><given-names>P</given-names></name><name><surname>von Messling</surname><given-names>V</given-names></name><name><surname>de Swart</surname><given-names>RL</given-names></name><name><surname>Russell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles</article-title><source>Science Immunology</source><volume>4</volume><elocation-id>eaay6125</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aay6125</pub-id><pub-id pub-id-type="pmid">31672862</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petty</surname><given-names>LA</given-names></name><name><surname>Flanders</surname><given-names>SA</given-names></name><name><surname>Vaughn</surname><given-names>VM</given-names></name><name><surname>Ratz</surname><given-names>D</given-names></name><name><surname>O’Malley</surname><given-names>M</given-names></name><name><surname>Malani</surname><given-names>AN</given-names></name><name><surname>Washer</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Kocher</surname><given-names>KE</given-names></name><name><surname>Kaatz</surname><given-names>S</given-names></name><name><surname>Czilok</surname><given-names>T</given-names></name><name><surname>McLaughlin</surname><given-names>E</given-names></name><name><surname>Prescott</surname><given-names>HC</given-names></name><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Gandhi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study</article-title><source>Infection Control &amp; Hospital Epidemiology</source><volume>43</volume><fpage>1184</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1017/ice.2021.341</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phetsouphanh</surname><given-names>C</given-names></name><name><surname>Darley</surname><given-names>DR</given-names></name><name><surname>Wilson</surname><given-names>DB</given-names></name><name><surname>Howe</surname><given-names>A</given-names></name><name><surname>Munier</surname><given-names>CML</given-names></name><name><surname>Patel</surname><given-names>SK</given-names></name><name><surname>Juno</surname><given-names>JA</given-names></name><name><surname>Burrell</surname><given-names>LM</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>Kelleher</surname><given-names>AD</given-names></name><name><surname>Matthews</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection</article-title><source>Nature Immunology</source><volume>23</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01113-x</pub-id><pub-id pub-id-type="pmid">35027728</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prattes</surname><given-names>J</given-names></name><name><surname>Wauters</surname><given-names>J</given-names></name><name><surname>Giacobbe</surname><given-names>DR</given-names></name><name><surname>Salmanton-García</surname><given-names>J</given-names></name><name><surname>Maertens</surname><given-names>J</given-names></name><name><surname>Bourgeois</surname><given-names>M</given-names></name><name><surname>Reynders</surname><given-names>M</given-names></name><name><surname>Rutsaert</surname><given-names>L</given-names></name><name><surname>Van Regenmortel</surname><given-names>N</given-names></name><name><surname>Lormans</surname><given-names>P</given-names></name><name><surname>Feys</surname><given-names>S</given-names></name><name><surname>Reisinger</surname><given-names>AC</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Lahmer</surname><given-names>T</given-names></name><name><surname>Valerio</surname><given-names>M</given-names></name><name><surname>Delhaes</surname><given-names>L</given-names></name><name><surname>Jabeen</surname><given-names>K</given-names></name><name><surname>Steinmann</surname><given-names>J</given-names></name><name><surname>Chamula</surname><given-names>M</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Hatzl</surname><given-names>S</given-names></name><name><surname>Rautemaa-Richardson</surname><given-names>R</given-names></name><name><surname>Koehler</surname><given-names>P</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Hoenigl</surname><given-names>M</given-names></name><collab>ECMM-CAPA Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology</article-title><source>Clinical Microbiology and Infection</source><volume>28</volume><fpage>580</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.08.014</pub-id><pub-id pub-id-type="pmid">34454093</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruijssers</surname><given-names>AJ</given-names></name><name><surname>George</surname><given-names>AS</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Gralinksi</surname><given-names>LE</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names><suffix>III</suffix></name><name><surname>Yount</surname><given-names>BL</given-names></name><name><surname>Agostini</surname><given-names>ML</given-names></name><name><surname>Stevens</surname><given-names>LJ</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Hughes</surname><given-names>TM</given-names></name><name><surname>Gully</surname><given-names>K</given-names></name><name><surname>Martinez</surname><given-names>DR</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Perry</surname><given-names>JK</given-names></name><name><surname>Du Pont</surname><given-names>V</given-names></name><name><surname>Pitts</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Babusis</surname><given-names>D</given-names></name><name><surname>Murakami</surname><given-names>E</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Bilello</surname><given-names>JP</given-names></name><name><surname>Porter</surname><given-names>DP</given-names></name><name><surname>Cihlar</surname><given-names>T</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>107940</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107940</pub-id><pub-id pub-id-type="pmid">32668216</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Breese</surname><given-names>GR</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name><name><surname>Knapp</surname><given-names>DJ</given-names></name><name><surname>Crews</surname><given-names>FT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration</article-title><source>Glia</source><volume>55</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1002/glia.20467</pub-id><pub-id pub-id-type="pmid">17203472</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>ST</given-names></name><name><surname>Bruce</surname><given-names>AW</given-names></name><name><surname>Anbalagan</surname><given-names>M</given-names></name><name><surname>Srinivasan</surname><given-names>H</given-names></name><name><surname>Chinnappan</surname><given-names>S</given-names></name><name><surname>Rajagopal</surname><given-names>M</given-names></name><name><surname>Khanna</surname><given-names>K</given-names></name><name><surname>Chandramoorthy</surname><given-names>HC</given-names></name><name><surname>Mani</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>14</volume><elocation-id>1384939</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1384939</pub-id><pub-id pub-id-type="pmid">38863829</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Armistead</surname><given-names>I</given-names></name><name><surname>Tyler</surname><given-names>A</given-names></name><name><surname>Lensing</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>SR</given-names></name><name><surname>Alden</surname><given-names>NB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Respiratory syncytial virus, influenza, and coronavirus disease 2019 hospitalizations in children in colorado during the 2021-2022 respiratory virus season</article-title><source>The Journal of Pediatrics</source><volume>260</volume><elocation-id>113491</elocation-id><pub-id pub-id-type="doi">10.1016/j.jpeds.2023.113491</pub-id><pub-id pub-id-type="pmid">37201680</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raut</surname><given-names>A</given-names></name><name><surname>Huy</surname><given-names>NT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?</article-title><source>The Lancet. Respiratory Medicine</source><volume>9</volume><elocation-id>e77</elocation-id><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00265-4</pub-id><pub-id pub-id-type="pmid">34090607</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravani</surname><given-names>SA</given-names></name><name><surname>Agrawal</surname><given-names>GA</given-names></name><name><surname>Leuva</surname><given-names>PA</given-names></name><name><surname>Modi</surname><given-names>PH</given-names></name><name><surname>Amin</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rise of the phoenix: Mucormycosis in COVID-19 times</article-title><source>Indian Journal of Ophthalmology</source><volume>69</volume><fpage>1563</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.4103/ijo.IJO_310_21</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravimohan</surname><given-names>S</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Bisson</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tuberculosis and lung damage: from epidemiology to pathophysiology</article-title><source>European Respiratory Review</source><volume>27</volume><elocation-id>e2017</elocation-id><pub-id pub-id-type="doi">10.1183/16000617.0077-2017</pub-id><pub-id pub-id-type="pmid">29491034</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riou</surname><given-names>C</given-names></name><name><surname>du Bruyn</surname><given-names>E</given-names></name><name><surname>Stek</surname><given-names>C</given-names></name><name><surname>Daroowala</surname><given-names>R</given-names></name><name><surname>Goliath</surname><given-names>RT</given-names></name><name><surname>Abrahams</surname><given-names>F</given-names></name><name><surname>Said-Hartley</surname><given-names>Q</given-names></name><name><surname>Allwood</surname><given-names>BW</given-names></name><name><surname>Hsiao</surname><given-names>N-Y</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Arlehamn</surname><given-names>CSL</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Wasserman</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><collab>HIATUS consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e149125</elocation-id><pub-id pub-id-type="doi">10.1172/JCI149125</pub-id><pub-id pub-id-type="pmid">33945513</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripa</surname><given-names>M</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>Poli</surname><given-names>A</given-names></name><name><surname>Oltolini</surname><given-names>C</given-names></name><name><surname>Spagnuolo</surname><given-names>V</given-names></name><name><surname>Mastrangelo</surname><given-names>A</given-names></name><name><surname>Muccini</surname><given-names>C</given-names></name><name><surname>Monti</surname><given-names>G</given-names></name><name><surname>De Luca</surname><given-names>G</given-names></name><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Clementi</surname><given-names>M</given-names></name><name><surname>Rovere Querini</surname><given-names>P</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name><name><surname>Lazzarin</surname><given-names>A</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Scarpellini</surname><given-names>P</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><collab>COVID-BioB study group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors</article-title><source>Clinical Microbiology and Infection</source><volume>27</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.10.021</pub-id><pub-id pub-id-type="pmid">33223114</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripa</surname><given-names>M</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>D’Angelo</surname><given-names>A</given-names></name><name><surname>Apruzzi</surname><given-names>L</given-names></name><name><surname>Palumbo</surname><given-names>D</given-names></name><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Tassan Din</surname><given-names>C</given-names></name><name><surname>Danise</surname><given-names>A</given-names></name><name><surname>Da Prat</surname><given-names>V</given-names></name><name><surname>Vitali</surname><given-names>G</given-names></name><name><surname>Brugliera</surname><given-names>L</given-names></name><name><surname>Poli</surname><given-names>A</given-names></name><name><surname>Monardo</surname><given-names>R</given-names></name><name><surname>Monti</surname><given-names>G</given-names></name><name><surname>Baccellieri</surname><given-names>D</given-names></name><name><surname>De Cobelli</surname><given-names>F</given-names></name><name><surname>Clementi</surname><given-names>M</given-names></name><name><surname>Iannaccone</surname><given-names>S</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Rovere-Querini</surname><given-names>P</given-names></name><name><surname>Ciceri</surname><given-names>F</given-names></name><name><surname>Tresoldi</surname><given-names>M</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Scarpellini</surname><given-names>P</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><collab>COVID-BioB Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>High risk of secondary infections following thrombotic complications in patients with COVID-19</article-title><source>Open Forum Infectious Diseases</source><volume>9</volume><elocation-id>ofac454</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofac454</pub-id><pub-id pub-id-type="pmid">36168552</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>JA</given-names></name><name><surname>Bonnano</surname><given-names>C</given-names></name><name><surname>Khatiwada</surname><given-names>P</given-names></name><name><surname>Roa</surname><given-names>AA</given-names></name><name><surname>Mayer</surname><given-names>D</given-names></name><name><surname>Eckardt</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 coinfection with <italic>Mycobacterium abscessus</italic> in a Patient with Multiple Myeloma</article-title><source>Case Reports in Infectious Diseases</source><volume>2021</volume><elocation-id>8840536</elocation-id><pub-id pub-id-type="doi">10.1155/2021/8840536</pub-id><pub-id pub-id-type="pmid">33505740</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Z</given-names></name><name><surname>Mai</surname><given-names>H</given-names></name><name><surname>Ebert</surname><given-names>G</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Puelles</surname><given-names>VG</given-names></name><name><surname>Czogalla</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Prtvar</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Schädler</surname><given-names>J</given-names></name><name><surname>Delbridge</surname><given-names>C</given-names></name><name><surname>Steinke</surname><given-names>H</given-names></name><name><surname>Frenzel</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>C</given-names></name><name><surname>Bruch</surname><given-names>G</given-names></name><name><surname>Ruf</surname><given-names>V</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Sühs</surname><given-names>K-W</given-names></name><name><surname>Nemati</surname><given-names>M</given-names></name><name><surname>Hopfner</surname><given-names>F</given-names></name><name><surname>Ulukaya</surname><given-names>S</given-names></name><name><surname>Jeridi</surname><given-names>D</given-names></name><name><surname>Mistretta</surname><given-names>D</given-names></name><name><surname>Caliskan</surname><given-names>ÖS</given-names></name><name><surname>Wettengel</surname><given-names>JM</given-names></name><name><surname>Cherif</surname><given-names>F</given-names></name><name><surname>Kolabas</surname><given-names>ZI</given-names></name><name><surname>Molbay</surname><given-names>M</given-names></name><name><surname>Horvath</surname><given-names>I</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Krahmer</surname><given-names>N</given-names></name><name><surname>Yildirim</surname><given-names>AÖ</given-names></name><name><surname>Ussar</surname><given-names>S</given-names></name><name><surname>Herms</surname><given-names>J</given-names></name><name><surname>Huber</surname><given-names>TB</given-names></name><name><surname>Tahirovic</surname><given-names>S</given-names></name><name><surname>Schwarzmaier</surname><given-names>SM</given-names></name><name><surname>Plesnila</surname><given-names>N</given-names></name><name><surname>Höglinger</surname><given-names>G</given-names></name><name><surname>Ondruschka</surname><given-names>B</given-names></name><name><surname>Bechmann</surname><given-names>I</given-names></name><name><surname>Protzer</surname><given-names>U</given-names></name><name><surname>Elsner</surname><given-names>M</given-names></name><name><surname>Bhatia</surname><given-names>HS</given-names></name><name><surname>Hellal</surname><given-names>F</given-names></name><name><surname>Ertürk</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19</article-title><source>Cell Host &amp; Microbe</source><volume>32</volume><fpage>2112</fpage><lpage>2130</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2024.11.007</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>K</given-names></name><name><surname>Lahmer</surname><given-names>T</given-names></name><name><surname>Rasch</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Spinner</surname><given-names>CD</given-names></name><name><surname>Wallnöfer</surname><given-names>F</given-names></name><name><surname>Wurst</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>RM</given-names></name><name><surname>Waschulzik</surname><given-names>B</given-names></name><name><surname>Fuest</surname><given-names>K</given-names></name><name><surname>Kriescher</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name><name><surname>Feihl</surname><given-names>S</given-names></name><name><surname>Heim</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dexamethasone therapy and rates of secondary pulmonary and bloodstream infections in critically ill COVID-19 patients</article-title><source>Multidisciplinary Respiratory Medicine</source><volume>16</volume><elocation-id>793</elocation-id><pub-id pub-id-type="doi">10.4081/mrm.2021.793</pub-id><pub-id pub-id-type="pmid">34760275</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>From “Immunity Debt” to “Immunity Theft”—How COVID-19 might be tied to recent respiratory disease surges</article-title><source>JAMA</source><volume>331</volume><elocation-id>e26608</elocation-id><pub-id pub-id-type="doi">10.1001/jama.2023.26608</pub-id><pub-id pub-id-type="pmid">38198193</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Fairfield</surname><given-names>CJ</given-names></name><name><surname>Drake</surname><given-names>TM</given-names></name><name><surname>Turtle</surname><given-names>L</given-names></name><name><surname>Seaton</surname><given-names>RA</given-names></name><name><surname>Wootton</surname><given-names>DG</given-names></name><name><surname>Sigfrid</surname><given-names>L</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>Egan</surname><given-names>C</given-names></name><name><surname>Pius</surname><given-names>R</given-names></name><name><surname>Hardwick</surname><given-names>HE</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Girvan</surname><given-names>M</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>JS</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Openshaw</surname><given-names>PJ</given-names></name><name><surname>Carson</surname><given-names>G</given-names></name><name><surname>Alex</surname><given-names>B</given-names></name><name><surname>Bach</surname><given-names>B</given-names></name><name><surname>Barclay</surname><given-names>WS</given-names></name><name><surname>Bogaert</surname><given-names>D</given-names></name><name><surname>Chand</surname><given-names>M</given-names></name><name><surname>Cooke</surname><given-names>GS</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>Dunning</surname><given-names>J</given-names></name><name><surname>da Silva Filipe</surname><given-names>A</given-names></name><name><surname>Fletcher</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>CA</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Hiscox</surname><given-names>JA</given-names></name><name><surname>Ho</surname><given-names>AY</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Khoo</surname><given-names>S</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Law</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Merson</surname><given-names>L</given-names></name><name><surname>Meynert</surname><given-names>AM</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>SC</given-names></name><name><surname>Palmarini</surname><given-names>M</given-names></name><name><surname>Paxton</surname><given-names>WA</given-names></name><name><surname>Pollakis</surname><given-names>G</given-names></name><name><surname>Price</surname><given-names>N</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Sancho-Shimizu</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>JT</given-names></name><name><surname>de Silva</surname><given-names>T</given-names></name><name><surname>Sigfrid</surname><given-names>L</given-names></name><name><surname>Solomon</surname><given-names>T</given-names></name><name><surname>Sriskandan</surname><given-names>S</given-names></name><name><surname>Stuart</surname><given-names>D</given-names></name><name><surname>Summers</surname><given-names>C</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Thompson</surname><given-names>AR</given-names></name><name><surname>Thwaites</surname><given-names>RS</given-names></name><name><surname>Turtle</surname><given-names>LC</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Palmieri</surname><given-names>C</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Hardwick</surname><given-names>H</given-names></name><name><surname>Donohue</surname><given-names>C</given-names></name><name><surname>Lyons</surname><given-names>R</given-names></name><name><surname>Griffiths</surname><given-names>F</given-names></name><name><surname>Oosthuyzen</surname><given-names>W</given-names></name><name><surname>Norman</surname><given-names>L</given-names></name><name><surname>Pius</surname><given-names>R</given-names></name><name><surname>Drake</surname><given-names>TM</given-names></name><name><surname>Fairfield</surname><given-names>CJ</given-names></name><name><surname>Knight</surname><given-names>SR</given-names></name><name><surname>Mclean</surname><given-names>KA</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Dalton</surname><given-names>J</given-names></name><name><surname>Girvan</surname><given-names>M</given-names></name><name><surname>Saviciute</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Harrison</surname><given-names>J</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Connor</surname><given-names>M</given-names></name><name><surname>Halpin</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Gamble</surname><given-names>C</given-names></name><name><surname>Leeming</surname><given-names>G</given-names></name><name><surname>Law</surname><given-names>A</given-names></name><name><surname>Wham</surname><given-names>M</given-names></name><name><surname>Clohisey</surname><given-names>S</given-names></name><name><surname>Hendry</surname><given-names>R</given-names></name><name><surname>Scott-Brown</surname><given-names>J</given-names></name><name><surname>Greenhalf</surname><given-names>W</given-names></name><name><surname>Shaw</surname><given-names>V</given-names></name><name><surname>McDonald</surname><given-names>SE</given-names></name><name><surname>Keating</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>KA</given-names></name><name><surname>Armstrong</surname><given-names>JA</given-names></name><name><surname>Ashworth</surname><given-names>M</given-names></name><name><surname>Asiimwe</surname><given-names>IG</given-names></name><name><surname>Bakshi</surname><given-names>S</given-names></name><name><surname>Barlow</surname><given-names>SL</given-names></name><name><surname>Booth</surname><given-names>L</given-names></name><name><surname>Brennan</surname><given-names>B</given-names></name><name><surname>Bullock</surname><given-names>K</given-names></name><name><surname>Catterall</surname><given-names>BW</given-names></name><name><surname>Clark</surname><given-names>JJ</given-names></name><name><surname>Clarke</surname><given-names>EA</given-names></name><name><surname>Cole</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>L</given-names></name><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Dincarslan</surname><given-names>O</given-names></name><name><surname>Dunn</surname><given-names>C</given-names></name><name><surname>Dyer</surname><given-names>P</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Finch</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>LW</given-names></name><name><surname>Foster</surname><given-names>T</given-names></name><name><surname>Garcia-Dorival</surname><given-names>I</given-names></name><name><surname>Greenhalf</surname><given-names>W</given-names></name><name><surname>Gunning</surname><given-names>P</given-names></name><name><surname>Hartley</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Jones</surname><given-names>CB</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Khandaker</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>K</given-names></name><name><surname>Kiy</surname><given-names>RT</given-names></name><name><surname>Koukorava</surname><given-names>C</given-names></name><name><surname>Lake</surname><given-names>A</given-names></name><name><surname>Lant</surname><given-names>S</given-names></name><name><surname>Latawiec</surname><given-names>D</given-names></name><name><surname>Lavelle-Langham</surname><given-names>L</given-names></name><name><surname>Lefteri</surname><given-names>D</given-names></name><name><surname>Lett</surname><given-names>L</given-names></name><name><surname>Livoti</surname><given-names>LA</given-names></name><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>McEvoy</surname><given-names>L</given-names></name><name><surname>McLauchlan</surname><given-names>J</given-names></name><name><surname>Metelmann</surname><given-names>S</given-names></name><name><surname>Miah</surname><given-names>NS</given-names></name><name><surname>Middleton</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>SC</given-names></name><name><surname>Murphy</surname><given-names>EG</given-names></name><name><surname>Penrice-Randal</surname><given-names>R</given-names></name><name><surname>Pilgrim</surname><given-names>J</given-names></name><name><surname>Prince</surname><given-names>T</given-names></name><name><surname>Reynolds</surname><given-names>W</given-names></name><name><surname>Ridley</surname><given-names>PM</given-names></name><name><surname>Sales</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>VE</given-names></name><name><surname>Shears</surname><given-names>RK</given-names></name><name><surname>Small</surname><given-names>B</given-names></name><name><surname>Subramaniam</surname><given-names>KS</given-names></name><name><surname>Szemiel</surname><given-names>A</given-names></name><name><surname>Taggart</surname><given-names>A</given-names></name><name><surname>Tanianis-Hughes</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Trochu</surname><given-names>E</given-names></name><name><surname>van Tonder</surname><given-names>L</given-names></name><name><surname>Wilcock</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>JE</given-names></name><name><surname>Flaherty</surname><given-names>L</given-names></name><name><surname>Maziere</surname><given-names>N</given-names></name><name><surname>Cass</surname><given-names>E</given-names></name><name><surname>Doce Carracedo</surname><given-names>A</given-names></name><name><surname>Carlucci</surname><given-names>N</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name><name><surname>Massey</surname><given-names>H</given-names></name><name><surname>Murphy</surname><given-names>L</given-names></name><name><surname>Wrobel</surname><given-names>N</given-names></name><name><surname>McCafferty</surname><given-names>S</given-names></name><name><surname>Morrice</surname><given-names>K</given-names></name><name><surname>MacLean</surname><given-names>A</given-names></name><name><surname>Adeniji</surname><given-names>K</given-names></name><name><surname>Agranoff</surname><given-names>D</given-names></name><name><surname>Agwuh</surname><given-names>K</given-names></name><name><surname>Ail</surname><given-names>D</given-names></name><name><surname>Aldera</surname><given-names>EL</given-names></name><name><surname>Alegria</surname><given-names>A</given-names></name><name><surname>Angus</surname><given-names>B</given-names></name><name><surname>Ashish</surname><given-names>A</given-names></name><name><surname>Atkinson</surname><given-names>D</given-names></name><name><surname>Bari</surname><given-names>S</given-names></name><name><surname>Barlow</surname><given-names>G</given-names></name><name><surname>Barnass</surname><given-names>S</given-names></name><name><surname>Barrett</surname><given-names>N</given-names></name><name><surname>Bassford</surname><given-names>C</given-names></name><name><surname>Basude</surname><given-names>S</given-names></name><name><surname>Baxter</surname><given-names>D</given-names></name><name><surname>Beadsworth</surname><given-names>M</given-names></name><name><surname>Bernatoniene</surname><given-names>J</given-names></name><name><surname>Berridge</surname><given-names>J</given-names></name><name><surname>Best</surname><given-names>N</given-names></name><name><surname>Bothma</surname><given-names>P</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><name><surname>Brittain-Long</surname><given-names>R</given-names></name><name><surname>Bulteel</surname><given-names>N</given-names></name><name><surname>Burden</surname><given-names>T</given-names></name><name><surname>Burtenshaw</surname><given-names>A</given-names></name><name><surname>Caruth</surname><given-names>V</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><name><surname>Chambler</surname><given-names>D</given-names></name><name><surname>Chee</surname><given-names>N</given-names></name><name><surname>Child</surname><given-names>J</given-names></name><name><surname>Chukkambotla</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Collini</surname><given-names>P</given-names></name><name><surname>Cosgrove</surname><given-names>C</given-names></name><name><surname>Cupitt</surname><given-names>J</given-names></name><name><surname>Cutino-Moguel</surname><given-names>MT</given-names></name><name><surname>Dark</surname><given-names>P</given-names></name><name><surname>Dawson</surname><given-names>C</given-names></name><name><surname>Dervisevic</surname><given-names>S</given-names></name><name><surname>Donnison</surname><given-names>P</given-names></name><name><surname>Douthwaite</surname><given-names>S</given-names></name><name><surname>DuRand</surname><given-names>I</given-names></name><name><surname>Dushianthan</surname><given-names>A</given-names></name><name><surname>Dyer</surname><given-names>T</given-names></name><name><surname>Evans</surname><given-names>C</given-names></name><name><surname>Eziefula</surname><given-names>C</given-names></name><name><surname>Fegan</surname><given-names>C</given-names></name><name><surname>Finn</surname><given-names>A</given-names></name><name><surname>Fullerton</surname><given-names>D</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name><name><surname>Gkrania-Klotsas</surname><given-names>E</given-names></name><name><surname>Godden</surname><given-names>J</given-names></name><name><surname>Goldsmith</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Hardy</surname><given-names>E</given-names></name><name><surname>Hartshorn</surname><given-names>S</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Havalda</surname><given-names>P</given-names></name><name><surname>Hawcutt</surname><given-names>DB</given-names></name><name><surname>Hobrok</surname><given-names>M</given-names></name><name><surname>Hodgson</surname><given-names>L</given-names></name><name><surname>Hormis</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Jennings</surname><given-names>P</given-names></name><name><surname>Kaliappan</surname><given-names>A</given-names></name><name><surname>Kasipandian</surname><given-names>V</given-names></name><name><surname>Kegg</surname><given-names>S</given-names></name><name><surname>Kelsey</surname><given-names>M</given-names></name><name><surname>Kendall</surname><given-names>J</given-names></name><name><surname>Kerrison</surname><given-names>C</given-names></name><name><surname>Kerslake</surname><given-names>I</given-names></name><name><surname>Koch</surname><given-names>O</given-names></name><name><surname>Koduri</surname><given-names>G</given-names></name><name><surname>Koshy</surname><given-names>G</given-names></name><name><surname>Laha</surname><given-names>S</given-names></name><name><surname>Laird</surname><given-names>S</given-names></name><name><surname>Larkin</surname><given-names>S</given-names></name><name><surname>Leiner</surname><given-names>T</given-names></name><name><surname>Lillie</surname><given-names>P</given-names></name><name><surname>Limb</surname><given-names>J</given-names></name><name><surname>Linnett</surname><given-names>V</given-names></name><name><surname>Little</surname><given-names>J</given-names></name><name><surname>Lyttle</surname><given-names>M</given-names></name><name><surname>MacMahon</surname><given-names>M</given-names></name><name><surname>MacNaughton</surname><given-names>E</given-names></name><name><surname>Mankregod</surname><given-names>R</given-names></name><name><surname>Masson</surname><given-names>H</given-names></name><name><surname>Matovu</surname><given-names>E</given-names></name><name><surname>McCullough</surname><given-names>K</given-names></name><name><surname>McEwen</surname><given-names>R</given-names></name><name><surname>Meda</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>G</given-names></name><name><surname>Minton</surname><given-names>J</given-names></name><name><surname>Mirfenderesky</surname><given-names>M</given-names></name><name><surname>Mohandas</surname><given-names>K</given-names></name><name><surname>Mok</surname><given-names>Q</given-names></name><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Mortimore</surname><given-names>K</given-names></name><name><surname>Moses</surname><given-names>S</given-names></name><name><surname>Mpenge</surname><given-names>M</given-names></name><name><surname>Mulla</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Nagel</surname><given-names>M</given-names></name><name><surname>Nagarajan</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>M</given-names></name><name><surname>O’Shea</surname><given-names>MK</given-names></name><name><surname>Otahal</surname><given-names>I</given-names></name><name><surname>Ostermann</surname><given-names>M</given-names></name><name><surname>Pais</surname><given-names>M</given-names></name><name><surname>Panchatsharam</surname><given-names>S</given-names></name><name><surname>Papakonstantino</surname><given-names>D</given-names></name><name><surname>Paraiso</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Pattison</surname><given-names>N</given-names></name><name><surname>Pepperell</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Phull</surname><given-names>M</given-names></name><name><surname>Pintus</surname><given-names>S</given-names></name><name><surname>Singh Pooni</surname><given-names>J</given-names></name><name><surname>Post</surname><given-names>F</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Prout</surname><given-names>R</given-names></name><name><surname>Rae</surname><given-names>N</given-names></name><name><surname>Reschreiter</surname><given-names>H</given-names></name><name><surname>Reynolds</surname><given-names>T</given-names></name><name><surname>Richardson</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Rose</surname><given-names>A</given-names></name><name><surname>Rousseau</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>B</given-names></name><name><surname>Saluja</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Shanmuga</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Shawcross</surname><given-names>A</given-names></name><name><surname>Sizer</surname><given-names>J</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Snelson</surname><given-names>C</given-names></name><name><surname>Spittle</surname><given-names>N</given-names></name><name><surname>Staines</surname><given-names>N</given-names></name><name><surname>Stambach</surname><given-names>T</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Subudhi</surname><given-names>P</given-names></name><name><surname>Szakmany</surname><given-names>T</given-names></name><name><surname>Tatham</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Tridente</surname><given-names>A</given-names></name><name><surname>Tupper-Carey</surname><given-names>D</given-names></name><name><surname>Twagira</surname><given-names>M</given-names></name><name><surname>Ustianowski</surname><given-names>A</given-names></name><name><surname>Vallotton</surname><given-names>N</given-names></name><name><surname>Vincent-Smith</surname><given-names>L</given-names></name><name><surname>Visuvanathan</surname><given-names>S</given-names></name><name><surname>Vuylsteke</surname><given-names>A</given-names></name><name><surname>Waddy</surname><given-names>S</given-names></name><name><surname>Wake</surname><given-names>R</given-names></name><name><surname>Walden</surname><given-names>A</given-names></name><name><surname>Welters</surname><given-names>I</given-names></name><name><surname>Whitehouse</surname><given-names>T</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name><name><surname>Whittington</surname><given-names>A</given-names></name><name><surname>Papineni</surname><given-names>P</given-names></name><name><surname>Wijesinghe</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>L</given-names></name><name><surname>Sarah</surname><given-names>S</given-names></name><name><surname>Winchester</surname><given-names>S</given-names></name><name><surname>Wiselka</surname><given-names>M</given-names></name><name><surname>Wolverson</surname><given-names>A</given-names></name><name><surname>Wootton</surname><given-names>DG</given-names></name><name><surname>Workman</surname><given-names>A</given-names></name><name><surname>Yates</surname><given-names>B</given-names></name><name><surname>Young</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study</article-title><source>The Lancet. Microbe</source><volume>2</volume><fpage>e354</fpage><lpage>e365</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00090-2</pub-id><pub-id pub-id-type="pmid">34100002</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmanton-García</surname><given-names>J</given-names></name><name><surname>Sprute</surname><given-names>R</given-names></name><name><surname>Stemler</surname><given-names>J</given-names></name><name><surname>Bartoletti</surname><given-names>M</given-names></name><name><surname>Dupont</surname><given-names>D</given-names></name><name><surname>Valerio</surname><given-names>M</given-names></name><name><surname>Garcia-Vidal</surname><given-names>C</given-names></name><name><surname>Falces-Romero</surname><given-names>I</given-names></name><name><surname>Machado</surname><given-names>M</given-names></name><name><surname>de la Villa</surname><given-names>S</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Hoyo</surname><given-names>I</given-names></name><name><surname>Hanses</surname><given-names>F</given-names></name><name><surname>Ferreira-Paim</surname><given-names>K</given-names></name><name><surname>Giacobbe</surname><given-names>DR</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Gangneux</surname><given-names>J-P</given-names></name><name><surname>Rodríguez-Guardado</surname><given-names>A</given-names></name><name><surname>Antinori</surname><given-names>S</given-names></name><name><surname>Sal</surname><given-names>E</given-names></name><name><surname>Malaj</surname><given-names>X</given-names></name><name><surname>Seidel</surname><given-names>D</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Koehler</surname><given-names>P</given-names></name><collab>FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19-associated pulmonary aspergillosis, March-August 2020</article-title><source>Emerging Infectious Diseases</source><volume>27</volume><fpage>1077</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.3201/eid2704.204895</pub-id><pub-id pub-id-type="pmid">33539721</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>A</given-names></name><name><surname>Deleage</surname><given-names>C</given-names></name><name><surname>Sereti</surname><given-names>I</given-names></name><name><surname>Rerknimitr</surname><given-names>R</given-names></name><name><surname>Phanuphak</surname><given-names>N</given-names></name><name><surname>Phuang-Ngern</surname><given-names>Y</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Sandler</surname><given-names>NG</given-names></name><name><surname>Sukhumvittaya</surname><given-names>S</given-names></name><name><surname>Marovich</surname><given-names>M</given-names></name><name><surname>Jongrakthaitae</surname><given-names>S</given-names></name><name><surname>Akapirat</surname><given-names>S</given-names></name><name><surname>Fletscher</surname><given-names>JLK</given-names></name><name><surname>Kroon</surname><given-names>E</given-names></name><name><surname>Dewar</surname><given-names>R</given-names></name><name><surname>Trichavaroj</surname><given-names>R</given-names></name><name><surname>Chomchey</surname><given-names>N</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>O Connell</surname><given-names>RJ</given-names></name><name><surname>Ngauy</surname><given-names>V</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Phanuphak</surname><given-names>P</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Excler</surname><given-names>J-L</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>de Souza</surname><given-names>MS</given-names></name><name><surname>Ananworanich</surname><given-names>J</given-names></name><collab>RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004543</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004543</pub-id><pub-id pub-id-type="pmid">25503054</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seagle</surname><given-names>EE</given-names></name><name><surname>Jackson</surname><given-names>BR</given-names></name><name><surname>Lockhart</surname><given-names>SR</given-names></name><name><surname>Georgacopoulos</surname><given-names>O</given-names></name><name><surname>Nunnally</surname><given-names>NS</given-names></name><name><surname>Roland</surname><given-names>J</given-names></name><name><surname>Barter</surname><given-names>DM</given-names></name><name><surname>Johnston</surname><given-names>HL</given-names></name><name><surname>Czaja</surname><given-names>CA</given-names></name><name><surname>Kayalioglu</surname><given-names>H</given-names></name><name><surname>Clogher</surname><given-names>P</given-names></name><name><surname>Revis</surname><given-names>A</given-names></name><name><surname>Farley</surname><given-names>MM</given-names></name><name><surname>Harrison</surname><given-names>LH</given-names></name><name><surname>Davis</surname><given-names>SS</given-names></name><name><surname>Phipps</surname><given-names>EC</given-names></name><name><surname>Tesini</surname><given-names>BL</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name><name><surname>Markus</surname><given-names>TM</given-names></name><name><surname>Lyman</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The landscape of candidemia during the coronavirus disease 2019 (COVID-19) Pandemic</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab562</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeßle</surname><given-names>J</given-names></name><name><surname>Waterboer</surname><given-names>T</given-names></name><name><surname>Hippchen</surname><given-names>T</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>B</given-names></name><name><surname>Merle</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study</article-title><source>Clinical Infectious Diseases</source><volume>74</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab611</pub-id><pub-id pub-id-type="pmid">34223884</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda</surname><given-names>J</given-names></name><name><surname>Westblade</surname><given-names>LF</given-names></name><name><surname>Whittier</surname><given-names>S</given-names></name><name><surname>Satlin</surname><given-names>MJ</given-names></name><name><surname>Greendyke</surname><given-names>WG</given-names></name><name><surname>Aaron</surname><given-names>JG</given-names></name><name><surname>Zucker</surname><given-names>J</given-names></name><name><surname>Dietz</surname><given-names>D</given-names></name><name><surname>Sobieszczyk</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Russell</surname><given-names>S</given-names></name><name><surname>Connelly</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Bacteremia and blood culture utilization during COVID-19 Surge in New York City</article-title><source>Journal of Clinical Microbiology</source><volume>58</volume><elocation-id>e00875-20</elocation-id><pub-id pub-id-type="doi">10.1128/JCM.00875-20</pub-id><pub-id pub-id-type="pmid">32404482</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sereti</surname><given-names>I</given-names></name><name><surname>Krebs</surname><given-names>SJ</given-names></name><name><surname>Phanuphak</surname><given-names>N</given-names></name><name><surname>Fletcher</surname><given-names>JL</given-names></name><name><surname>Slike</surname><given-names>B</given-names></name><name><surname>Pinyakorn</surname><given-names>S</given-names></name><name><surname>O’Connell</surname><given-names>RJ</given-names></name><name><surname>Rupert</surname><given-names>A</given-names></name><name><surname>Chomont</surname><given-names>N</given-names></name><name><surname>Valcour</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Ananworanich</surname><given-names>J</given-names></name><name><surname>Utay</surname><given-names>NS</given-names></name><collab>RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 protocol teams</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Persistent, Albeit Reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection</article-title><source>Clinical Infectious Diseases</source><volume>64</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw683</pub-id><pub-id pub-id-type="pmid">27737952</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Servellita</surname><given-names>V</given-names></name><name><surname>Sotomayor Gonzalez</surname><given-names>A</given-names></name><name><surname>Lamson</surname><given-names>DM</given-names></name><name><surname>Foresythe</surname><given-names>A</given-names></name><name><surname>Huh</surname><given-names>HJ</given-names></name><name><surname>Bazinet</surname><given-names>AL</given-names></name><name><surname>Bergman</surname><given-names>NH</given-names></name><name><surname>Bull</surname><given-names>RL</given-names></name><name><surname>Garcia</surname><given-names>KY</given-names></name><name><surname>Goodrich</surname><given-names>JS</given-names></name><name><surname>Lovett</surname><given-names>SP</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><name><surname>Radune</surname><given-names>D</given-names></name><name><surname>Hatada</surname><given-names>A</given-names></name><name><surname>Pan</surname><given-names>CY</given-names></name><name><surname>Rizzo</surname><given-names>K</given-names></name><name><surname>Bertumen</surname><given-names>JB</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name><name><surname>Oluniyi</surname><given-names>PE</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Stryke</surname><given-names>D</given-names></name><name><surname>Jaber</surname><given-names>R</given-names></name><name><surname>Leslie</surname><given-names>MT</given-names></name><name><surname>Lyons</surname><given-names>Z</given-names></name><name><surname>Hedman</surname><given-names>HD</given-names></name><name><surname>Parashar</surname><given-names>U</given-names></name><name><surname>Sullivan</surname><given-names>M</given-names></name><name><surname>Wroblewski</surname><given-names>K</given-names></name><name><surname>Oberste</surname><given-names>MS</given-names></name><name><surname>Tate</surname><given-names>JE</given-names></name><name><surname>Baker</surname><given-names>JM</given-names></name><name><surname>Sugerman</surname><given-names>D</given-names></name><name><surname>Potts</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Chhabra</surname><given-names>P</given-names></name><name><surname>Ingram</surname><given-names>LA</given-names></name><name><surname>Shiau</surname><given-names>H</given-names></name><name><surname>Britt</surname><given-names>W</given-names></name><name><surname>Gutierrez Sanchez</surname><given-names>LH</given-names></name><name><surname>Ciric</surname><given-names>C</given-names></name><name><surname>Rostad</surname><given-names>CA</given-names></name><name><surname>Vinjé</surname><given-names>J</given-names></name><name><surname>Kirking</surname><given-names>HL</given-names></name><name><surname>Wadford</surname><given-names>DA</given-names></name><name><surname>Raborn</surname><given-names>RT</given-names></name><name><surname>St George</surname><given-names>K</given-names></name><name><surname>Chiu</surname><given-names>CY</given-names></name><collab>Pediatric Hepatitis of Unknown Etiology Working Group</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Adeno-associated virus type 2 in US children with acute severe hepatitis</article-title><source>Nature</source><volume>617</volume><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05949-1</pub-id><pub-id pub-id-type="pmid">36996871</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifipour</surname><given-names>E</given-names></name><name><surname>Shams</surname><given-names>S</given-names></name><name><surname>Esmkhani</surname><given-names>M</given-names></name><name><surname>Khodadadi</surname><given-names>J</given-names></name><name><surname>Fotouhi-Ardakani</surname><given-names>R</given-names></name><name><surname>Koohpaei</surname><given-names>A</given-names></name><name><surname>Doosti</surname><given-names>Z</given-names></name><name><surname>Ej Golzari</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU</article-title><source>BMC Infectious Diseases</source><volume>20</volume><elocation-id>646</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05374-z</pub-id><pub-id pub-id-type="pmid">32873235</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shariq</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>JA</given-names></name><name><surname>Quadir</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Hasnain</surname><given-names>SE</given-names></name><name><surname>Ehtesham</surname><given-names>NZ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>COVID-19 and tuberculosis: the double whammy of respiratory pathogens</article-title><source>European Respiratory Review</source><volume>31</volume><elocation-id>210264</elocation-id><pub-id pub-id-type="doi">10.1183/16000617.0264-2021</pub-id><pub-id pub-id-type="pmid">35418488</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>PM</given-names></name><name><surname>Chege</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>LYY</given-names></name><name><surname>Huibner</surname><given-names>S</given-names></name><name><surname>Yue</surname><given-names>FY</given-names></name><name><surname>Loutfy</surname><given-names>M</given-names></name><name><surname>Halpenny</surname><given-names>R</given-names></name><name><surname>Persad</surname><given-names>D</given-names></name><name><surname>Kovacs</surname><given-names>C</given-names></name><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Kandel</surname><given-names>G</given-names></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Immune reconstitution in the sigmoid colon after long-term HIV therapy</article-title><source>Mucosal Immunology</source><volume>1</volume><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/mi.2008.23</pub-id><pub-id pub-id-type="pmid">19079202</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sievers</surname><given-names>BL</given-names></name><name><surname>Cheng</surname><given-names>MTK</given-names></name><name><surname>Csiba</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>SARS-CoV-2 and innate immunity: the good, the bad, and the &quot;goldilocks</article-title><source>Cellular &amp; Molecular Immunology</source><volume>21</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01104-y</pub-id><pub-id pub-id-type="pmid">37985854</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spatola</surname><given-names>M</given-names></name><name><surname>Nziza</surname><given-names>N</given-names></name><name><surname>Jung</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Dinoto</surname><given-names>A</given-names></name><name><surname>Bozzetti</surname><given-names>S</given-names></name><name><surname>Chiodega</surname><given-names>V</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Mariotto</surname><given-names>S</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses</article-title><source>Brain</source><volume>146</volume><fpage>4292</fpage><lpage>4305</lpage><pub-id pub-id-type="doi">10.1093/brain/awad155</pub-id><pub-id pub-id-type="pmid">37161609</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreenath</surname><given-names>K</given-names></name><name><surname>Batra</surname><given-names>P</given-names></name><name><surname>Vinayaraj</surname><given-names>EV</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>SaiKiran</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>UB</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Trikha</surname><given-names>A</given-names></name><name><surname>Guleria</surname><given-names>R</given-names></name><name><surname>Chaudhry</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Coinfections with other respiratory pathogens among patients with COVID-19</article-title><source>Microbiology Spectrum</source><volume>9</volume><elocation-id>e0016321</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.00163-21</pub-id><pub-id pub-id-type="pmid">34287033</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>SR</given-names></name><name><surname>Ramelli</surname><given-names>SC</given-names></name><name><surname>Grazioli</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>J-Y</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Yinda</surname><given-names>CK</given-names></name><name><surname>Winkler</surname><given-names>CW</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Dickey</surname><given-names>JM</given-names></name><name><surname>Ylaya</surname><given-names>K</given-names></name><name><surname>Ko</surname><given-names>SH</given-names></name><name><surname>Platt</surname><given-names>AP</given-names></name><name><surname>Burbelo</surname><given-names>PD</given-names></name><name><surname>Quezado</surname><given-names>M</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Purcell</surname><given-names>M</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>Belinky</surname><given-names>F</given-names></name><name><surname>Ramos-Benitez</surname><given-names>MJ</given-names></name><name><surname>Boritz</surname><given-names>EA</given-names></name><name><surname>Lach</surname><given-names>IA</given-names></name><name><surname>Herr</surname><given-names>DL</given-names></name><name><surname>Rabin</surname><given-names>J</given-names></name><name><surname>Saharia</surname><given-names>KK</given-names></name><name><surname>Madathil</surname><given-names>RJ</given-names></name><name><surname>Tabatabai</surname><given-names>A</given-names></name><name><surname>Soherwardi</surname><given-names>S</given-names></name><name><surname>McCurdy</surname><given-names>MT</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Vannella</surname><given-names>KM</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Chertow</surname><given-names>DS</given-names></name><collab>NIH COVID-19 Autopsy Consortium</collab></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infection and persistence in the human body and brain at autopsy</article-title><source>Nature</source><volume>612</volume><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05542-y</pub-id><pub-id pub-id-type="pmid">36517603</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>DG</given-names></name><name><surname>Ng</surname><given-names>RH</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Kornilov</surname><given-names>SA</given-names></name><name><surname>Scherler</surname><given-names>K</given-names></name><name><surname>Pavlovitch-Bedzyk</surname><given-names>AJ</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Lausted</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Fallen</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>CL</given-names></name><name><surname>Baloni</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Duvvuri</surname><given-names>VR</given-names></name><name><surname>Anderson</surname><given-names>KG</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Duncombe</surname><given-names>CJ</given-names></name><name><surname>McCulloch</surname><given-names>DJ</given-names></name><name><surname>Rostomily</surname><given-names>C</given-names></name><name><surname>Troisch</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Mackay</surname><given-names>S</given-names></name><name><surname>DeGottardi</surname><given-names>Q</given-names></name><name><surname>May</surname><given-names>DH</given-names></name><name><surname>Taniguchi</surname><given-names>R</given-names></name><name><surname>Gittelman</surname><given-names>RM</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Roper</surname><given-names>R</given-names></name><name><surname>Wojciechowska</surname><given-names>G</given-names></name><name><surname>Murray</surname><given-names>K</given-names></name><name><surname>Edmark</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Rowen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Chour</surname><given-names>W</given-names></name><name><surname>Algren</surname><given-names>HA</given-names></name><name><surname>Berrington</surname><given-names>WR</given-names></name><name><surname>Wallick</surname><given-names>JA</given-names></name><name><surname>Cochran</surname><given-names>RA</given-names></name><name><surname>Micikas</surname><given-names>ME</given-names></name><name><surname>Wrin</surname><given-names>T</given-names></name><name><surname>Petropoulos</surname><given-names>CJ</given-names></name><name><surname>Cole</surname><given-names>HR</given-names></name><name><surname>Fischer</surname><given-names>TD</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Hoon</surname><given-names>DSB</given-names></name><name><surname>Price</surname><given-names>ND</given-names></name><name><surname>Subramanian</surname><given-names>N</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Hadlock</surname><given-names>J</given-names></name><name><surname>Magis</surname><given-names>AT</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Hood</surname><given-names>L</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>Goldman</surname><given-names>JD</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name><collab>ISB-Swedish COVID-19 Biobanking Unit</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Multiple early factors anticipate post-acute COVID-19 sequelae</article-title><source>Cell</source><volume>185</volume><fpage>881</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.014</pub-id><pub-id pub-id-type="pmid">35216672</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swank</surname><given-names>Z</given-names></name><name><surname>Senussi</surname><given-names>Y</given-names></name><name><surname>Manickas-Hill</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Walt</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae</article-title><source>Clinical Infectious Diseases</source><volume>76</volume><fpage>e487</fpage><lpage>e490</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac722</pub-id><pub-id pub-id-type="pmid">36052466</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swank</surname><given-names>Z</given-names></name><name><surname>Borberg</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Senussi</surname><given-names>Y</given-names></name><name><surname>Chalise</surname><given-names>S</given-names></name><name><surname>Manickas-Hill</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Hoh</surname><given-names>R</given-names></name><name><surname>Goldberg</surname><given-names>SA</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Martin</surname><given-names>JN</given-names></name><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Talla</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Skene</surname><given-names>P</given-names></name><name><surname>Bumol</surname><given-names>TF</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name><name><surname>Czartoski</surname><given-names>JL</given-names></name><name><surname>McElrath</surname><given-names>MJ</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Walt</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study</article-title><source>Clinical Microbiology and Infection</source><volume>30</volume><fpage>1599</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2024.09.001</pub-id><pub-id pub-id-type="pmid">39389851</pub-id></element-citation></ref><ref id="bib198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szewczyk-Dąbrowska</surname><given-names>A</given-names></name><name><surname>Budziar</surname><given-names>W</given-names></name><name><surname>Harhala</surname><given-names>M</given-names></name><name><surname>Baniecki</surname><given-names>K</given-names></name><name><surname>Pikies</surname><given-names>A</given-names></name><name><surname>Jędruchniewicz</surname><given-names>N</given-names></name><name><surname>Kaźmierczak</surname><given-names>Z</given-names></name><name><surname>Gembara</surname><given-names>K</given-names></name><name><surname>Klimek</surname><given-names>T</given-names></name><name><surname>Witkiewicz</surname><given-names>W</given-names></name><name><surname>Nahorecki</surname><given-names>A</given-names></name><name><surname>Barczyk</surname><given-names>K</given-names></name><name><surname>Kłak</surname><given-names>M</given-names></name><name><surname>Grata-Borkowska</surname><given-names>U</given-names></name><name><surname>Dąbrowska</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>15944</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-20202-x</pub-id><pub-id pub-id-type="pmid">36153350</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talla</surname><given-names>A</given-names></name><name><surname>Vasaikar</surname><given-names>SV</given-names></name><name><surname>Szeto</surname><given-names>GL</given-names></name><name><surname>Lemos</surname><given-names>MP</given-names></name><name><surname>Czartoski</surname><given-names>JL</given-names></name><name><surname>MacMillan</surname><given-names>H</given-names></name><name><surname>Moodie</surname><given-names>Z</given-names></name><name><surname>Cohen</surname><given-names>KW</given-names></name><name><surname>Fleming</surname><given-names>LB</given-names></name><name><surname>Thomson</surname><given-names>Z</given-names></name><name><surname>Okada</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>LA</given-names></name><name><surname>Coffey</surname><given-names>EM</given-names></name><name><surname>De Rosa</surname><given-names>SC</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Skene</surname><given-names>PJ</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Bumol</surname><given-names>TF</given-names></name><name><surname>Juliana McElrath</surname><given-names>M</given-names></name><name><surname>Torgerson</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Persistent serum protein signatures define an inflammatory subcategory of long COVID</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>3417</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-38682-4</pub-id><pub-id pub-id-type="pmid">37296110</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamuzi</surname><given-names>JL</given-names></name><name><surname>Ayele</surname><given-names>BT</given-names></name><name><surname>Shumba</surname><given-names>CS</given-names></name><name><surname>Adetokunboh</surname><given-names>OO</given-names></name><name><surname>Uwimana-Nicol</surname><given-names>J</given-names></name><name><surname>Haile</surname><given-names>ZT</given-names></name><name><surname>Inugu</surname><given-names>J</given-names></name><name><surname>Nyasulu</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence</article-title><source>BMC Infectious Diseases</source><volume>20</volume><elocation-id>744</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05450-4</pub-id><pub-id pub-id-type="pmid">33036570</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenorio</surname><given-names>AR</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Bosch</surname><given-names>RJ</given-names></name><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Plants</surname><given-names>J</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>CC</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Lederman</surname><given-names>MM</given-names></name><name><surname>Landay</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment</article-title><source>The Journal of Infectious Diseases</source><volume>210</volume><fpage>1248</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu254</pub-id><pub-id pub-id-type="pmid">24795473</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>KW</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Roland</surname><given-names>D</given-names></name><name><surname>Gaillard</surname><given-names>EA</given-names></name><name><surname>Tang</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Rhinovirus persistence during the COVID-19 pandemic-Impact on pediatric acute wheezing presentations</article-title><source>Journal of Medical Virology</source><volume>94</volume><fpage>5547</fpage><lpage>5552</lpage><pub-id pub-id-type="doi">10.1002/jmv.27986</pub-id><pub-id pub-id-type="pmid">35811371</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa Magar</surname><given-names>S</given-names></name><name><surname>Lokhandwala</surname><given-names>HI</given-names></name><name><surname>Batool</surname><given-names>S</given-names></name><name><surname>Zahoor</surname><given-names>F</given-names></name><name><surname>Zaidi</surname><given-names>SKF</given-names></name><name><surname>Sahtiya</surname><given-names>S</given-names></name><name><surname>Khemani</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Voloshyna</surname><given-names>D</given-names></name><name><surname>Saleem</surname><given-names>F</given-names></name><name><surname>Ghaffari</surname><given-names>MAZ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A systematic review of neurological manifestations of COVID-19</article-title><source>Cureus</source><volume>14</volume><elocation-id>e28309</elocation-id><pub-id pub-id-type="doi">10.7759/cureus.28309</pub-id><pub-id pub-id-type="pmid">36168382</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaweethai</surname><given-names>T</given-names></name><name><surname>Jolley</surname><given-names>SE</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Levitan</surname><given-names>EB</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>McComsey</surname><given-names>GA</given-names></name><name><surname>McCorkell</surname><given-names>L</given-names></name><name><surname>Nadkarni</surname><given-names>GN</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Walker</surname><given-names>TA</given-names></name><name><surname>Selvaggi</surname><given-names>CA</given-names></name><name><surname>Shinnick</surname><given-names>DJ</given-names></name><name><surname>Schulte</surname><given-names>CCM</given-names></name><name><surname>Atchley-Challenner</surname><given-names>R</given-names></name><name><surname>Alba</surname><given-names>GA</given-names></name><name><surname>Alicic</surname><given-names>R</given-names></name><name><surname>Altman</surname><given-names>N</given-names></name><name><surname>Anglin</surname><given-names>K</given-names></name><name><surname>Argueta</surname><given-names>U</given-names></name><name><surname>Ashktorab</surname><given-names>H</given-names></name><name><surname>Baslet</surname><given-names>G</given-names></name><name><surname>Bassett</surname><given-names>IV</given-names></name><name><surname>Bateman</surname><given-names>L</given-names></name><name><surname>Bedi</surname><given-names>B</given-names></name><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><name><surname>Bind</surname><given-names>MA</given-names></name><name><surname>Blomkalns</surname><given-names>AL</given-names></name><name><surname>Bonilla</surname><given-names>H</given-names></name><name><surname>Brim</surname><given-names>H</given-names></name><name><surname>Bush</surname><given-names>PA</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Charney</surname><given-names>AW</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Chibnik</surname><given-names>LB</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Clifton</surname><given-names>RG</given-names></name><name><surname>Costantine</surname><given-names>MM</given-names></name><name><surname>Cribbs</surname><given-names>SK</given-names></name><name><surname>Davila Nieves</surname><given-names>SI</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Duven</surname><given-names>A</given-names></name><name><surname>Emery</surname><given-names>IF</given-names></name><name><surname>Erdmann</surname><given-names>N</given-names></name><name><surname>Erlandson</surname><given-names>KM</given-names></name><name><surname>Ernst</surname><given-names>KC</given-names></name><name><surname>Farah-Abraham</surname><given-names>R</given-names></name><name><surname>Farner</surname><given-names>CE</given-names></name><name><surname>Feuerriegel</surname><given-names>EM</given-names></name><name><surname>Fleurimont</surname><given-names>J</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Franko</surname><given-names>N</given-names></name><name><surname>Gainer</surname><given-names>V</given-names></name><name><surname>Gander</surname><given-names>JC</given-names></name><name><surname>Gardner</surname><given-names>EM</given-names></name><name><surname>Geng</surname><given-names>LN</given-names></name><name><surname>Gibson</surname><given-names>KS</given-names></name><name><surname>Go</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>JD</given-names></name><name><surname>Grebe</surname><given-names>H</given-names></name><name><surname>Greenway</surname><given-names>FL</given-names></name><name><surname>Habli</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>JE</given-names></name><name><surname>Hanson</surname><given-names>KA</given-names></name><name><surname>Heath</surname><given-names>J</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>R</given-names></name><name><surname>Hodder</surname><given-names>SL</given-names></name><name><surname>Hoffman</surname><given-names>MK</given-names></name><name><surname>Hoover</surname><given-names>SE</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Hughes</surname><given-names>BL</given-names></name><name><surname>Jagannathan</surname><given-names>P</given-names></name><name><surname>John</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>MR</given-names></name><name><surname>Katz</surname><given-names>SD</given-names></name><name><surname>Kaufman</surname><given-names>ES</given-names></name><name><surname>Kelly</surname><given-names>JD</given-names></name><name><surname>Kelly</surname><given-names>SW</given-names></name><name><surname>Kemp</surname><given-names>MM</given-names></name><name><surname>Kirwan</surname><given-names>JP</given-names></name><name><surname>Klein</surname><given-names>JD</given-names></name><name><surname>Knox</surname><given-names>KS</given-names></name><name><surname>Krishnan</surname><given-names>JA</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Laiyemo</surname><given-names>AO</given-names></name><name><surname>Lambert</surname><given-names>AA</given-names></name><name><surname>Lanca</surname><given-names>M</given-names></name><name><surname>Lee-Iannotti</surname><given-names>JK</given-names></name><name><surname>Logarbo</surname><given-names>BP</given-names></name><name><surname>Longo</surname><given-names>MT</given-names></name><name><surname>Luciano</surname><given-names>CA</given-names></name><name><surname>Lutrick</surname><given-names>K</given-names></name><name><surname>Maley</surname><given-names>JH</given-names></name><name><surname>Mallett</surname><given-names>G</given-names></name><name><surname>Marathe</surname><given-names>JG</given-names></name><name><surname>Marconi</surname><given-names>V</given-names></name><name><surname>Marshall</surname><given-names>GD</given-names></name><name><surname>Martin</surname><given-names>CF</given-names></name><name><surname>Matusov</surname><given-names>Y</given-names></name><name><surname>Mehari</surname><given-names>A</given-names></name><name><surname>Mendez-Figueroa</surname><given-names>H</given-names></name><name><surname>Mermelstein</surname><given-names>R</given-names></name><name><surname>Metz</surname><given-names>TD</given-names></name><name><surname>Morse</surname><given-names>R</given-names></name><name><surname>Mosier</surname><given-names>J</given-names></name><name><surname>Mouchati</surname><given-names>C</given-names></name><name><surname>Mullington</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>SN</given-names></name><name><surname>Neuman</surname><given-names>RB</given-names></name><name><surname>Nikolich</surname><given-names>JZ</given-names></name><name><surname>Ofotokun</surname><given-names>I</given-names></name><name><surname>Ojemakinde</surname><given-names>E</given-names></name><name><surname>Palatnik</surname><given-names>A</given-names></name><name><surname>Palomares</surname><given-names>K</given-names></name><name><surname>Parimon</surname><given-names>T</given-names></name><name><surname>Parry</surname><given-names>S</given-names></name><name><surname>Patterson</surname><given-names>JE</given-names></name><name><surname>Patterson</surname><given-names>TF</given-names></name><name><surname>Patzer</surname><given-names>RE</given-names></name><name><surname>Peluso</surname><given-names>MJ</given-names></name><name><surname>Pemu</surname><given-names>P</given-names></name><name><surname>Pettker</surname><given-names>CM</given-names></name><name><surname>Plunkett</surname><given-names>BA</given-names></name><name><surname>Pogreba-Brown</surname><given-names>K</given-names></name><name><surname>Poppas</surname><given-names>A</given-names></name><name><surname>Quigley</surname><given-names>JG</given-names></name><name><surname>Reddy</surname><given-names>U</given-names></name><name><surname>Reece</surname><given-names>R</given-names></name><name><surname>Reeder</surname><given-names>H</given-names></name><name><surname>Reeves</surname><given-names>WB</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Rischard</surname><given-names>F</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Rouse</surname><given-names>DJ</given-names></name><name><surname>Ruff</surname><given-names>A</given-names></name><name><surname>Saade</surname><given-names>G</given-names></name><name><surname>Sandoval</surname><given-names>GJ</given-names></name><name><surname>Santana</surname><given-names>JL</given-names></name><name><surname>Schlater</surname><given-names>SM</given-names></name><name><surname>Sciurba</surname><given-names>FC</given-names></name><name><surname>Shepherd</surname><given-names>F</given-names></name><name><surname>Sherif</surname><given-names>ZA</given-names></name><name><surname>Simhan</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>NG</given-names></name><name><surname>Skupski</surname><given-names>DW</given-names></name><name><surname>Sowles</surname><given-names>A</given-names></name><name><surname>Sparks</surname><given-names>JA</given-names></name><name><surname>Sukhera</surname><given-names>FI</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Teunis</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>RJ</given-names></name><name><surname>Thorp</surname><given-names>JM</given-names></name><name><surname>Thuluvath</surname><given-names>P</given-names></name><name><surname>Ticotsky</surname><given-names>A</given-names></name><name><surname>Tita</surname><given-names>AT</given-names></name><name><surname>Tuttle</surname><given-names>KR</given-names></name><name><surname>Urdaneta</surname><given-names>AE</given-names></name><name><surname>Valdivieso</surname><given-names>D</given-names></name><name><surname>VanWagoner</surname><given-names>TM</given-names></name><name><surname>Vasey</surname><given-names>A</given-names></name><name><surname>Verduzco-Gutierrez</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Ward</surname><given-names>HD</given-names></name><name><surname>Warren</surname><given-names>DE</given-names></name><name><surname>Weiner</surname><given-names>SJ</given-names></name><name><surname>Welch</surname><given-names>S</given-names></name><name><surname>Whiteheart</surname><given-names>SW</given-names></name><name><surname>Wiley</surname><given-names>Z</given-names></name><name><surname>Wisnivesky</surname><given-names>JP</given-names></name><name><surname>Yee</surname><given-names>LM</given-names></name><name><surname>Zisis</surname><given-names>S</given-names></name><name><surname>Horwitz</surname><given-names>LI</given-names></name><name><surname>Foulkes</surname><given-names>AS</given-names></name><collab>RECOVER Consortium</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Development of a definition of postacute sequelae of SARS-CoV-2 infection</article-title><source>JAMA</source><volume>329</volume><fpage>1934</fpage><lpage>1946</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.8823</pub-id><pub-id pub-id-type="pmid">37278994</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thelen</surname><given-names>JM</given-names></name><name><surname>Buenen</surname><given-names>AGN</given-names></name><name><surname>van Apeldoorn</surname><given-names>M</given-names></name><name><surname>Wertheim</surname><given-names>HF</given-names></name><name><surname>Hermans</surname><given-names>MHA</given-names></name><name><surname>Wever</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Community-acquired bacteraemia in COVID-19 in comparison to influenza A and influenza B: a retrospective cohort study</article-title><source>BMC Infectious Diseases</source><volume>21</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-05902-5</pub-id><pub-id pub-id-type="pmid">33618663</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>JH</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Haupt</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Weston</surname><given-names>S</given-names></name><name><surname>Hammond</surname><given-names>H</given-names></name><name><surname>Logue</surname><given-names>J</given-names></name><name><surname>Portnoff</surname><given-names>AD</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Guebre-Xabier</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Jacobson</surname><given-names>K</given-names></name><name><surname>Maciejewski</surname><given-names>S</given-names></name><name><surname>Khatoon</surname><given-names>R</given-names></name><name><surname>Wisniewska</surname><given-names>M</given-names></name><name><surname>Moffitt</surname><given-names>W</given-names></name><name><surname>Kluepfel-Stahl</surname><given-names>S</given-names></name><name><surname>Ekechukwu</surname><given-names>B</given-names></name><name><surname>Papin</surname><given-names>J</given-names></name><name><surname>Boddapati</surname><given-names>S</given-names></name><name><surname>Jason Wong</surname><given-names>C</given-names></name><name><surname>Piedra</surname><given-names>PA</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name><name><surname>Massare</surname><given-names>MJ</given-names></name><name><surname>Fries</surname><given-names>L</given-names></name><name><surname>Bengtsson</surname><given-names>KL</given-names></name><name><surname>Stertman</surname><given-names>L</given-names></name><name><surname>Ellingsworth</surname><given-names>L</given-names></name><name><surname>Glenn</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>372</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmid">33446655</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>T</given-names></name><name><surname>Brann</surname><given-names>DH</given-names></name><name><surname>Datta</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mechanisms of SARS-CoV-2-associated anosmia</article-title><source>Physiological Reviews</source><volume>103</volume><fpage>2759</fpage><lpage>2766</lpage><pub-id pub-id-type="doi">10.1152/physrev.00012.2023</pub-id><pub-id pub-id-type="pmid">37342077</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderheiden</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Animal models of non-respiratory, post-acute sequelae of COVID-19</article-title><source>Viruses</source><volume>17</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.3390/v17010098</pub-id><pub-id pub-id-type="pmid">39861887</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Lambe</surname><given-names>T</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name><surname>Purushotham</surname><given-names>JN</given-names></name><name><surname>Port</surname><given-names>JR</given-names></name><name><surname>Avanzato</surname><given-names>VA</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Flaxman</surname><given-names>A</given-names></name><name><surname>Ulaszewska</surname><given-names>M</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Allen</surname><given-names>ER</given-names></name><name><surname>Sharpe</surname><given-names>H</given-names></name><name><surname>Schulz</surname><given-names>J</given-names></name><name><surname>Holbrook</surname><given-names>M</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Meade-White</surname><given-names>K</given-names></name><name><surname>Pérez-Pérez</surname><given-names>L</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Wright</surname><given-names>D</given-names></name><name><surname>Bissett</surname><given-names>C</given-names></name><name><surname>Gilbride</surname><given-names>C</given-names></name><name><surname>Williamson</surname><given-names>BN</given-names></name><name><surname>Rosenke</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>D</given-names></name><name><surname>Ishwarbhai</surname><given-names>A</given-names></name><name><surname>Kailath</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Powers</surname><given-names>C</given-names></name><name><surname>Lovaglio</surname><given-names>J</given-names></name><name><surname>Hanley</surname><given-names>PW</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Saturday</surname><given-names>G</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><volume>586</volume><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gorkom</surname><given-names>T</given-names></name><name><surname>Kremer</surname><given-names>K</given-names></name><name><surname>Voet</surname><given-names>W</given-names></name><name><surname>Notermans</surname><given-names>DW</given-names></name><name><surname>Vlaminckx</surname><given-names>BJM</given-names></name><name><surname>Sankatsing</surname><given-names>SUC</given-names></name><name><surname>Thijsen</surname><given-names>SFT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Disagreement between the results from three commercial tests for the detection of Borrelia-specific serum antibodies in the Netherlands associated with antibiotic treatment for Lyme borreliosis: a retrospective study</article-title><source>European Journal of Clinical Microbiology &amp; Infectious Diseases</source><volume>36</volume><fpage>2137</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1007/s10096-017-3037-1</pub-id></element-citation></ref><ref id="bib211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>VM</given-names></name><name><surname>Gandhi</surname><given-names>TN</given-names></name><name><surname>Petty</surname><given-names>LA</given-names></name><name><surname>Patel</surname><given-names>PK</given-names></name><name><surname>Prescott</surname><given-names>HC</given-names></name><name><surname>Malani</surname><given-names>AN</given-names></name><name><surname>Ratz</surname><given-names>D</given-names></name><name><surname>McLaughlin</surname><given-names>E</given-names></name><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Flanders</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study</article-title><source>Clinical Infectious Diseases</source><volume>72</volume><fpage>e533</fpage><lpage>e541</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1239</pub-id><pub-id pub-id-type="pmid">32820807</pub-id></element-citation></ref><ref id="bib212"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>AK</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e160277</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.160277</pub-id><pub-id pub-id-type="pmid">36378534</pub-id></element-citation></ref><ref id="bib213"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>JO</given-names></name><name><surname>Wohler</surname><given-names>J</given-names></name><name><surname>Fenton</surname><given-names>K</given-names></name><name><surname>Reich</surname><given-names>DS</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings</article-title><source>Multiple Sclerosis</source><volume>20</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1177/1352458513490545</pub-id><pub-id pub-id-type="pmid">23722324</pub-id></element-citation></ref><ref id="bib214"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>AB</given-names></name><name><surname>Kanevsky</surname><given-names>I</given-names></name><name><surname>Che</surname><given-names>Y</given-names></name><name><surname>Swanson</surname><given-names>KA</given-names></name><name><surname>Muik</surname><given-names>A</given-names></name><name><surname>Vormehr</surname><given-names>M</given-names></name><name><surname>Kranz</surname><given-names>LM</given-names></name><name><surname>Walzer</surname><given-names>KC</given-names></name><name><surname>Hein</surname><given-names>S</given-names></name><name><surname>Güler</surname><given-names>A</given-names></name><name><surname>Loschko</surname><given-names>J</given-names></name><name><surname>Maddur</surname><given-names>MS</given-names></name><name><surname>Ota-Setlik</surname><given-names>A</given-names></name><name><surname>Tompkins</surname><given-names>K</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Lui</surname><given-names>BG</given-names></name><name><surname>Ziegenhals</surname><given-names>T</given-names></name><name><surname>Plaschke</surname><given-names>A</given-names></name><name><surname>Eisel</surname><given-names>D</given-names></name><name><surname>Dany</surname><given-names>SC</given-names></name><name><surname>Fesser</surname><given-names>S</given-names></name><name><surname>Erbar</surname><given-names>S</given-names></name><name><surname>Bates</surname><given-names>F</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Jesionek</surname><given-names>B</given-names></name><name><surname>Sänger</surname><given-names>B</given-names></name><name><surname>Wallisch</surname><given-names>A-K</given-names></name><name><surname>Feuchter</surname><given-names>Y</given-names></name><name><surname>Junginger</surname><given-names>H</given-names></name><name><surname>Krumm</surname><given-names>SA</given-names></name><name><surname>Heinen</surname><given-names>AP</given-names></name><name><surname>Adams-Quack</surname><given-names>P</given-names></name><name><surname>Schlereth</surname><given-names>J</given-names></name><name><surname>Schille</surname><given-names>S</given-names></name><name><surname>Kröner</surname><given-names>C</given-names></name><name><surname>de la Caridad Güimil Garcia</surname><given-names>R</given-names></name><name><surname>Hiller</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>L</given-names></name><name><surname>Sellers</surname><given-names>RS</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>O</given-names></name><name><surname>Vascotto</surname><given-names>F</given-names></name><name><surname>Gutman</surname><given-names>MR</given-names></name><name><surname>Fontenot</surname><given-names>JA</given-names></name><name><surname>Hall-Ursone</surname><given-names>S</given-names></name><name><surname>Brasky</surname><given-names>K</given-names></name><name><surname>Griffor</surname><given-names>MC</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>AAH</given-names></name><name><surname>Lees</surname><given-names>JA</given-names></name><name><surname>Nedoma</surname><given-names>NL</given-names></name><name><surname>Mashalidis</surname><given-names>EH</given-names></name><name><surname>Sahasrabudhe</surname><given-names>PV</given-names></name><name><surname>Tan</surname><given-names>CY</given-names></name><name><surname>Pavliakova</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Fontes-Garfias</surname><given-names>C</given-names></name><name><surname>Pride</surname><given-names>M</given-names></name><name><surname>Scully</surname><given-names>IL</given-names></name><name><surname>Ciolino</surname><given-names>T</given-names></name><name><surname>Obregon</surname><given-names>J</given-names></name><name><surname>Gazi</surname><given-names>M</given-names></name><name><surname>Carrion</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Alfson</surname><given-names>KJ</given-names></name><name><surname>Kalina</surname><given-names>WV</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>P-Y</given-names></name><name><surname>Klamp</surname><given-names>T</given-names></name><name><surname>Rosenbaum</surname><given-names>C</given-names></name><name><surname>Kuhn</surname><given-names>AN</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Dormitzer</surname><given-names>PR</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>BNT162b vaccines protect rhesus macaques from SARS-CoV-2</article-title><source>Nature</source><volume>592</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03275-y</pub-id><pub-id pub-id-type="pmid">33524990</pub-id></element-citation></ref><ref id="bib215"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Lao</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increased long noncoding RNA LINK-A contributes to rheumatoid synovial inflammation and aggression</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>e146757</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.146757</pub-id><pub-id pub-id-type="pmid">34877935</pub-id></element-citation></ref><ref id="bib216"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webber</surname><given-names>BJ</given-names></name><name><surname>Burganowski</surname><given-names>RP</given-names></name><name><surname>Colton</surname><given-names>L</given-names></name><name><surname>Escobar</surname><given-names>JD</given-names></name><name><surname>Pathak</surname><given-names>SR</given-names></name><name><surname>Gambino-Shirley</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lyme disease overdiagnosis in a large healthcare system: a population-based, retrospective study</article-title><source>Clinical Microbiology and Infection</source><volume>25</volume><fpage>1233</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.02.020</pub-id><pub-id pub-id-type="pmid">30802651</pub-id></element-citation></ref><ref id="bib217"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Kehl</surname><given-names>V</given-names></name><name><surname>Erber</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>KI</given-names></name><name><surname>Jetzlsperger</surname><given-names>A-M</given-names></name><name><surname>Burrell</surname><given-names>T</given-names></name><name><surname>Schober</surname><given-names>K</given-names></name><name><surname>Schommers</surname><given-names>P</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Crowell</surname><given-names>CS</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Winter</surname><given-names>C</given-names></name><name><surname>Moosmann</surname><given-names>A</given-names></name><name><surname>Spinner</surname><given-names>CD</given-names></name><name><surname>Protzer</surname><given-names>U</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>D’Ippolito</surname><given-names>E</given-names></name><name><surname>Busch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients</article-title><source>PLOS ONE</source><volume>17</volume><elocation-id>e0268530</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0268530</pub-id><pub-id pub-id-type="pmid">35613127</pub-id></element-citation></ref><ref id="bib218"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendisch</surname><given-names>D</given-names></name><name><surname>Dietrich</surname><given-names>O</given-names></name><name><surname>Mari</surname><given-names>T</given-names></name><name><surname>von Stillfried</surname><given-names>S</given-names></name><name><surname>Ibarra</surname><given-names>IL</given-names></name><name><surname>Mittermaier</surname><given-names>M</given-names></name><name><surname>Mache</surname><given-names>C</given-names></name><name><surname>Chua</surname><given-names>RL</given-names></name><name><surname>Knoll</surname><given-names>R</given-names></name><name><surname>Timm</surname><given-names>S</given-names></name><name><surname>Brumhard</surname><given-names>S</given-names></name><name><surname>Krammer</surname><given-names>T</given-names></name><name><surname>Zauber</surname><given-names>H</given-names></name><name><surname>Hiller</surname><given-names>AL</given-names></name><name><surname>Pascual-Reguant</surname><given-names>A</given-names></name><name><surname>Mothes</surname><given-names>R</given-names></name><name><surname>Bülow</surname><given-names>RD</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Leipold</surname><given-names>AM</given-names></name><name><surname>Djudjaj</surname><given-names>S</given-names></name><name><surname>Erhard</surname><given-names>F</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Pott</surname><given-names>F</given-names></name><name><surname>Kazmierski</surname><given-names>J</given-names></name><name><surname>Radke</surname><given-names>J</given-names></name><name><surname>Pergantis</surname><given-names>P</given-names></name><name><surname>Baßler</surname><given-names>K</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Wyler</surname><given-names>E</given-names></name><name><surname>Horst</surname><given-names>D</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Uhrig</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Machleidt</surname><given-names>F</given-names></name><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Elezkurtaj</surname><given-names>S</given-names></name><name><surname>Thibeault</surname><given-names>C</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Cochain</surname><given-names>C</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Goffinet</surname><given-names>C</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Radbruch</surname><given-names>H</given-names></name><name><surname>Ochs</surname><given-names>M</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Müller-Redetzky</surname><given-names>H</given-names></name><name><surname>Hauser</surname><given-names>AE</given-names></name><name><surname>Luecken</surname><given-names>MD</given-names></name><name><surname>Theis</surname><given-names>FJ</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Wolff</surname><given-names>T</given-names></name><name><surname>Boor</surname><given-names>P</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Saliba</surname><given-names>A-E</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><collab>Deutsche COVID-19 OMICS Initiative (DeCOI)</collab></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis</article-title><source>Cell</source><volume>184</volume><fpage>6243</fpage><lpage>6261</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.11.033</pub-id><pub-id pub-id-type="pmid">34914922</pub-id></element-citation></ref><ref id="bib219"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Huo</surname><given-names>F</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>XX</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Bian</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>ZN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis</article-title><source>Signal Transduction and Targeted Therapy</source><volume>7</volume><elocation-id>382</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-022-01230-5</pub-id><pub-id pub-id-type="pmid">36424379</pub-id></element-citation></ref><ref id="bib220"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>TT-H</given-names></name><name><surname>Travaglini</surname><given-names>KJ</given-names></name><name><surname>Rustagi</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Andronov</surname><given-names>L</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Gillich</surname><given-names>A</given-names></name><name><surname>Dehghannasiri</surname><given-names>R</given-names></name><name><surname>Martínez-Colón</surname><given-names>GJ</given-names></name><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>DD</given-names></name><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Morri</surname><given-names>M</given-names></name><name><surname>Trope</surname><given-names>WL</given-names></name><name><surname>Bierman</surname><given-names>R</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Shrager</surname><given-names>JB</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name><name><surname>Kuo</surname><given-names>CS</given-names></name><name><surname>Salzman</surname><given-names>J</given-names></name><name><surname>Moerner</surname><given-names>WE</given-names></name><name><surname>Kim</surname><given-names>PS</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Krasnow</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung</article-title><source>The Journal of Experimental Medicine</source><volume>221</volume><elocation-id>e20232192</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20232192</pub-id><pub-id pub-id-type="pmid">38597954</pub-id></element-citation></ref><ref id="bib221"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19</article-title><source>The British Journal of Dermatology</source><volume>183</volume><fpage>1145</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1111/bjd.19484</pub-id><pub-id pub-id-type="pmid">32790074</pub-id></element-citation></ref><ref id="bib222"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Shannon</surname><given-names>CP</given-names></name><name><surname>Tebbutt</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Omicron variants of SARS-CoV-2 and long COVID</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>1061686</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1061686</pub-id></element-citation></ref><ref id="bib223"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youngs</surname><given-names>J</given-names></name><name><surname>Wyncoll</surname><given-names>D</given-names></name><name><surname>Hopkins</surname><given-names>P</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Ball</surname><given-names>J</given-names></name><name><surname>Bicanic</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza</article-title><source>The Journal of Infection</source><volume>81</volume><fpage>e55</fpage><lpage>e57</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.056</pub-id><pub-id pub-id-type="pmid">32593654</pub-id></element-citation></ref><ref id="bib224"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Xian</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Lan</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development</article-title><source>Emerging Microbes &amp; Infections</source><volume>13</volume><elocation-id>2353302</elocation-id><pub-id pub-id-type="doi">10.1080/22221751.2024.2353302</pub-id><pub-id pub-id-type="pmid">38753462</pub-id></element-citation></ref><ref id="bib225"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bib226"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuhair</surname><given-names>M</given-names></name><name><surname>Smit</surname><given-names>GSA</given-names></name><name><surname>Wallis</surname><given-names>G</given-names></name><name><surname>Jabbar</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Devleesschauwer</surname><given-names>B</given-names></name><name><surname>Griffiths</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis</article-title><source>Reviews in Medical Virology</source><volume>29</volume><elocation-id>e2034</elocation-id><pub-id pub-id-type="doi">10.1002/rmv.2034</pub-id><pub-id pub-id-type="pmid">30706584</pub-id></element-citation></ref><ref id="bib227"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Lui</surname><given-names>GCY</given-names></name><name><surname>Yeoh</surname><given-names>YK</given-names></name><name><surname>Li</surname><given-names>AYL</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>ACK</given-names></name><name><surname>Cheung</surname><given-names>CP</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Lai</surname><given-names>CKC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tso</surname><given-names>EYK</given-names></name><name><surname>Fung</surname><given-names>KSC</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>Joynt</surname><given-names>G</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Chan</surname><given-names>FKL</given-names></name><name><surname>Chan</surname><given-names>PKS</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alterations in gut microbiota of patients with COVID-19 during time of hospitalization</article-title><source>Gastroenterology</source><volume>159</volume><fpage>944</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.048</pub-id><pub-id pub-id-type="pmid">32442562</pub-id></element-citation></ref></ref-list></back></article>